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Abstract 
 Sarcolipin (SLN) and phospholamban (PLN) are two small proteins that physically 
interact with and inhibit the sarco(endo)plasmic reticulum Ca2+-ATPase (SERCA) pump. 
Results from our laboratory and others have shown that, under conditions of high-fat feeding, 
SLN is recruited in skeletal muscles to uncouple SERCA-mediated Ca2+ transport from ATP 
hydrolysis thereby increasing energy expenditure by the SERCA pumps and combating 
obesity.  Since, PLN is considered structurally and functionally homologous with SLN, we 
initially questioned whether PLN could also uncouple the SERCA pump, increase energy 
expenditure, and combat the obesigenic effects of a high-fat diet.  To this end, we purchased 
commercially available mice that overexpressed PLN (PlnOE); however, the surprising 
discovery of pathology within their soleus muscles shifted the focus from metabolism to 
myopathy. 
 In the first study of this thesis, the overall objectives were to characterize the PlnOE 
mouse model with respect to SERCA and muscle function, and to diagnose the disease found 
in their skeletal muscles.  Since the PlnOE mice were designed to overexpress PLN 
specifically in their type I skeletal muscle fibres, the analyses of this study was restricted to 
the postural muscles, soleus and gluteus minimus, that normally contain approximately 55-
65% and 27% type I fibre proportions, respectively.  As a result of the 6-to-7-fold 
upregulation in the inhibitory PLN protein, reductions in SERCA’s apparent affinity for Ca2+ 
(-0.16 KCa in pCa units, P < 0.05), maximal activity (-15-28%, P < 0.05), and Ca2+ uptake (-
20-74%, P < 0.05) in the soleus and gluteus minimus muscles from PlnOE mice were 
observed.  Reductions in the rates of relaxation (-dF/dt, -60%, P < 0.05) in isolated soleus 
muscles assessed in vitro further support the decrements in SERCA function.  With respect to 
	  vii 
the myopathy, the soleus muscles exhibited muscle weakness and progressive atrophy, which 
was associated with an overall enhancement of all the major proteolytic pathways existing in 
skeletal muscle (caspase-3, cathepsin, calpain, and proteasome, P < 0.05) and oxidative stress 
revealed with dichlorofluoroscein fluorescence assays (P < 0.05) and protein nitrosylation (P 
< 0.05).  Moreover, results from histological, histochemical, and immunofluorescent analyses 
of the PlnOE soleus and gluteus minimus muscles revealed greater central nuclei, type I fibre 
predominance and hypotrophy, and central aggregation of oxidative activity, suggesting that 
the myopathy found in these muscles resembled the rare congenital disease centronuclear 
myopathy (CNM).  Interestingly, preliminary findings from muscle biopsies from three CNM 
patients and five healthy controls revealed that, in CNM, SERCA function is significantly 
impaired (-53% maximal activity, P < 0.05) and is associated with a trending increase in 
PLN expression (P = 0.08); however future experiments with more CNM patients that are 
genetically related are required to further examine PLN’s potential role in CNM.  
Nevertheless, the results from study I demonstrate, for the first time, the importance of PLN 
in skeletal muscle health and disease, and have uncovered a novel model for CNM to test 
novel mechanisms and therapeutic strategies.    
 In study II, the diaphragm muscles from PlnOE mice were examined because these 
types of investigations that assess respiratory function in animal models of CNM are limited.  
Since the diaphragm muscles typically comprise of 10% type I fibres, it was hypothesized 
that the diaphragm muscles would also display impaired SERCA function, muscle weakness, 
and CNM pathology.  The results from this study; however, indicate that although SERCA’s 
affinity for Ca2+ was significantly lower in the PlnOE diaphragm compared with wild-type (-
0.07 KCa in pCa units, P < 0.05), SERCA function was not impaired to the extent seen in the 
	  viii 
PlnOE soleus and gluteus minimus muscles with no differences in maximal SERCA activity 
and only a 15% reduction in Ca2+ uptake that did not reach statistical significance (P = 0.08).  
Moreover, there was very little pathology in the PlnOE diaphragm with no impairments in in 
vitro force contractility and only type I fibre hypotrophy being evident with no central nuclei, 
type I fibre predominance, or central aggregation of oxidative activity.  Thus, the diaphragm 
muscles appear to confer resistance to PlnOE-induced myopathy and understanding the 
underlying mechanisms may lead to novel therapeutic strategies.   
 One interesting possibility that was tested in this thesis involved the potential role of 
SLN, which was upregulated according to disease severity in the PlnOE mice as SLN was 
increased 7-9 fold (P < 0.05) in the PlnOE gluteus minimus and soleus muscles; but only 
increased 2.5-fold (P < 0.05) in the PlnOE diaphragm.  Similar patterns of SLN expression 
were previously observed in the dystrophic mdx and mdx/utrophin-null mouse models where 
SLN was found upregulated to a greater extent in the mdx/utrophin-null mouse which 
exhibits far worse dystrophic pathology.  The question of whether this increase in SLN 
represents a maladaptive or adaptive role in myopathy was the focus of study III in this thesis.  
To this end, three separate mouse models of myopathy were tested.   
 First, the role of SLN in the PlnOE-induced myopathy was assessed by generating the 
PlnOE/SlnKO mouse.  The results from these experiments show that in the absence of Sln the 
PlnOE induced myopathy was worsened with greater reductions in in vitro soleus force 
production and muscle mass relative to body weight (P < 0.05).  The exacerbated muscle 
weakness and atrophy could not be attributed to differences in food intake, daily activity, or 
muscle proteolysis, and was instead accounted for by a failure to promote type II fibre 
hypertrophy.  In response to Pln overexpression and the concomitant reduction in type I fibre 
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cross-sectional area, the type II fibres hypertrophy (P < 0.05) and transition towards a slower 
oxidative fibre population (P < 0.05)  – a result due to the increased load bearing activities of 
the type II fibres that subsequently activate the Ca2+-dependent serine/threonine phosphatase 
calcineurin.  Without Sln, the PlnOE/SlnKO mice had lower activation of calcineurin revealed 
by greater levels of phosphorylated nuclear factor of activated T-cells (NFAT, P < 0.05) 
thereby causing a failure in the type II fibres to hypertrophy and transition to a slow fibre 
population.  Interestingly, similar effects were observed in mechanical overload experiments 
where WT plantaris muscles exhibited ectopic SLN expression, myofibre hypertrophy and a 
transition towards a slow-oxidative population (P < 0.05) as a result of calcineurin activation 
(61% lower phosphorylation of NFAT, P < 0.05).  In contrast, SlnKO plantaris muscles failed 
to hypertrophy and transition to a slow-oxidative phenotype as a result of a blunted activation 
of calcineurin (22% lower phosphorylation of NFAT, P = 0.11).  Collectively, the results 
from these experiments suggest that the SLN upregulation in the PlnOE mouse is critical in 
triggering calcineurin and mediating adaptive muscle remodeling.   
 The second mouse model of disease used in study III was the tenotomized soleus, 
which is a model of hindlimb unloading known to cause muscle degeneration.  The results 
from these experiments revealed that in the absence of a 14-fold upregulation of SLN, the 
soleus muscles exhibited greater muscle atrophy (P < 0.05), associated with larger percent 
reductions in myofibre cross-secitonal area (CSA) and an accelerated slow-to-fast fibre type 
transition.  Consistent with SLN’s role in activating calcineurin, tenotomy resulted in a 
significantly lower phophorylation of NFAT in WT soleus (-57%, P < 0.03), which was 
blunted in the SlnKO soleus (-32%, P = 0.06).  Taken together, these results suggests that SLN 
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upregulation, as result of muscle unloading, is required to amplify calcineurin signaling to 
counteract/stabilize the effects of muscle atrophy and slow-to-fast fibre type transitions. 
 Finally, the role of SLN in the mdx mouse was determined by generating mdx/SlnKO 
mice.  Consistent with the findings throughout study III, in the absence of Sln the myofibres 
of the mdx/SlnKO mice exhibited smaller CSA (P < 0.05) and a slow-to-fast fibre type 
transition (P < 0.05).  Since promoting the slow-fibre population is considered a valid 
therapeutic strategy with the leading mechanistic hypothesis being an induction of utrophin, 
the slow-to-fast fibre type shift in the mdx/SlnKO mice is maladaptive.  Indeed, this fibre type 
shift did result in lowered utrophin expression compared with mdx (P < 0.05).  Utrophin is a 
dystrophin homolog that provides compensatory membrane stability in the absence of 
dystrophin, and its expression is largely controlled by calcineurin.  Thus, these results are in 
support of SLN’s role in activating calcineurin and can account for the worsened dystrophic 
pathology with greater myofibre degeneration revealed by an elevated serum creatine kinase 
concentration (P < 0.05) and greater variation in the minimal Feret’s diameter (P < 0.05), an 
indicator of dystrophic pathology.  The increased variability in fibre diameter is likely due to 
the combined effects of increased degeneration, reduced myofibre cross-sectional area, and 
impaired regenerative capacity (P < 0.05) in the absence of Sln.    
 Taken together the results from study III have answered the questioned pertaining to 
SLN’s role in skeletal muscle disease, a question that has remained elusive for many years.  
These findings clearly demonstrate that SLN is vital in activating muscle growth and 
remodeling and counters disease pathology by promoting calcineurin signaling.  Combined 
with the findings in the PlnOE mouse in study I, the results from study III show that although 
PLN and SLN are structurally homologous and are both capable of inhibiting SERCA 
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function, their physiological roles in skeletal muscle may differ.  Specifically, increased PLN 
expression can cause skeletal muscle atrophy and disease whereas increased SLN is required 
to counter it.  Thus, the collective results from this thesis reveal the importance of PLN and 
SLN in skeletal muscle disease. 
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DCF – dichlorofluoroscein 
DHPR – dihidropyridine receptors 
DMD – Duchenne’s muscular dystrophy 
-df/dt – Rate of force decay/relaxation 
+df/dt – Rate of force production 
ECC – excitation-contraction coupling 
ECL – enhanced chemiluminescence 
KCa – concentration of Ca2+ required to elicit half maximal SERCA activity 
MEF2 – myocyte enhancer factor 2 
mdx – mouse model for Duchenne’s muscular dystrophy 
	  xxiii 
mdx/SlnKO – mouse model for Duchenne’s muscular dystrophy 
mdx/Utr-/- – mouse model for Duchenne’s muscular dystrophy without utrophin protein 
MHC – myosin heavy chain 
mMD – multiplie minicores disease 
MTM1 or mtm1 – gene encoding for myotubularin 1 in human or mouse 
M1-M10 – SERCA’s 10 transmembrane helices 
NFAT – nuclear factor of activated T-cells 
NADH-TR – nicotinamide adenine dinucleotide tetrazolium reductase 
NM – nemaline myopathy 
Ny - nitrosylation 
OV – mechanical overload induced by soleus and gastrocnemius tenotomy 
pCa – negative logarithm of the concentration of Ca2+ 
PCR – polymerase chain reaction 
PGC-1α – Peroxisome proliferator-activated receptor gamma coactivator 1-alpha 
PIP3 – phosphoinositide-3 phosphate 
PI3K – phosphoinositide-3 kinase 
PLN – phospholamban 
PLN or Pln – gene encoding phospholamban in human or mouse 
Pln-/- - mouse model with phospholamban genetically removed 
PlnOE – mouse model of PLN overexpression in slow-twitch type I fibres 
PlnOE/SlnKO – mouse model PLN overexpression in slow-twitch type I fibres without SLN 
PVDF – polyvinylidene difluoride 
RyR – ryanodine receptor 
SDH – succinate dehydrogenase 
SDS-PAGE – sodium dodecyl sulfate polyacrylamide gel electrophoresis 
Ser16 – serine residue 16 in phospholamban that is subjected to phosphorylation 
SERCA – sarco(endo)plasmic reticulum Ca2+-ATPase 
	  xxiv 
SERCA1a – the SERCA isoform found predominantly in fast muscle 
SERCA2a – the SERCA isoform found predominantly in slow muscle 
SLN – sarcolipin 
SLN or Sln – gene encoding sarcolipin in human or mouse 
SlnKO or Sln-/- - mouse model with sarcolipin genetically removed 
SR – sarcoplasmic reticulum 
SREBP1 – sterol regulatory binding protein 1 
Thr5 – threonine residue 5 in sarcolipin that is subjected to phosphorylation 
Thr17 – threonine residue 17 in phospholamban that is subjected to phosphorylation 
Tny - tenotomy 
t-tubule – transverse tubule 
TTN – gene encoding for titin in human 
Tukey HSD – Tukey honest significant difference test 
Ub - ubiquitin 
Vmax – in this context, maximal rates of SERCA activity 
WT – wild-type mice 
	  1 
Chapter 1 – Introduction, review of the literature and statement of the problem 
 
Introduction and review of the literature 
Ca2+ ions in skeletal muscle govern many physiological processes including 
excitation-contraction coupling (ECC) (1), energy expenditure (2-4), second messenger 
signaling (5), and apoptosis (6).  Therefore, it is easy to understand that the concentration of 
intracellular free Ca2+ ([Ca2+]i) needs to be controlled precisely.  The sarcoplasmic reticulum 
(SR) is largely responsible for the control of [Ca2+]i, although there are important 
contributions from cytoplasmic buffers, mitochondria, and sarcolemmal proteins (7, 8).  The 
SR tightly regulates resting [Ca2+]i to a concentration of 30-100 nM while maintaining a 
lumenal concentration in the millimolar range (8) thereby creating a large intra-extracellular 
ion gradient (1:10,000) (9, 10).  This task is accomplished by the activities of the 
sarco(endo)plasmic reticulum Ca2+-ATPases (SERCAs or SERCA pumps) and Ca2+ release 
channels (ryanodine receptors; RyRs) both of which are integral SR membrane proteins (1).  
The reciprocal action of RyRs and SERCA pumps allows for the SR to exert its 
control of [Ca2+]i.  For example, during ECC in skeletal muscle, an action potential 
depolarizes the transverse-tubule membrane leading to SR Ca2+ release through RyRs by 
virtue of their direct connection with voltage sensitive dihydropiridine receptors (DHPRs) at 
the terminal cisternae of the triad (transverse-tubule flanked by two junctional SR 
membranes).  The increased [Ca2+]i, binds to troponin C removing the inhibitory actions of 
tropomyosin on actin and allowing for the formation of cross bridges and muscle contraction.  
Conversely, SERCA pumps catalyze the active transport of Ca2+ back into the SR, using 
energy from ATP hydrolysis, thereby returning [Ca2+]i back to resting level and eliciting 
muscle relaxation.  Even at rest, SERCA pumps act to maintain [Ca2+]i as they counteract the 
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natural leak of Ca2+ that occurs through RyRs and SERCA pumps themselves.  Experiments 
from our laboratory measuring resting muscle metabolic rate after inhibition of RyR Ca2+ 
leak using MgCl2 revealed a 40-50% reduction in O2 consumption, which we attributed to a 
decrease in SERCA ATP usage (4).  While this finding prompted further studies to assess 
SERCA as a control point for energy balance regulation and as a potential target for 
metabolic alterations to oppose obesity (2, 3), it also highlights SERCA’s significant 
contribution in maintaining resting [Ca2+]i in skeletal muscle.  
SERCAs are 110 kDa integral membrane proteins belonging to a family of cation 
transporters, namely, P-type ATPases, so called because a phosphorylated intermediate 
involving an Asp residue is formed during the catalytic cycle (11).  Structurally, these pumps 
consist of 10 transmembrane domains (M1-M10) and three cytoplasmic domains (actuator, 
nucleotide binding and phosphorylation; together referred to as the headpiece) (12).  Two 
Ca2+ binding sites (site I and II) are formed between transmembrane helices M4, M5, M6, 
and M8 (13, 14).  In vertebrates, there are three distinct genes (ATP2a1/serca1, 
ATP2a2/serca2, ATP2a3/serca3) that produce more than 10 isoforms through alternative 
splicing (15).  Specifically, in adult skeletal muscle, two SERCA isoforms predominate, 
namely SERCA1a and SERCA2a; the expression of which, has been suggested to be 
dependent on muscle fiber type (15-18).  The SERCA1a isoform consists of 1001 amino 
acids and is expressed predominately in adult fast-twitch skeletal muscle, whereas SERCA2a 
is made up of 997 amino acids and is expressed in heart and slow-twitch skeletal muscle (19).  
However, Western blot analysis from our laboratory on human vastus lateralis single fibres 
suggests that both SERCA1a and SERCA2a may be present in either type I or type IIa fibres 
(20).  
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Phospholamban and Sarcolipin 
Phospholamban (PLN) and sarcolipin (SLN) are structural homologs both capable of 
physically interacting with SERCAs and inhibiting their function.  In the heart, SLN and 
PLN both regulate SERCA2a; however, SLN is expressed greatly in the atria, whereas PLN 
is expressed predominantly in the ventricles (21-23).  In human skeletal muscle, SLN and 
PLN may regulate both SERCA1a and SERCA2a; however, results from single fibre 
Western blots on vastus lateralis muscle suggest that SLN may preferentially regulate 
SERCA1a whereas PLN may preferentially regulate SERCA2a (20).  In general, SLN and 
PLN expression in rodent skeletal muscle is far lower compared to larger mammals (22, 24, 
25).  Specifically, in rodent skeletal muscle SLN and PLN are found predominantly 
expressed in soleus muscles (26).  In mouse soleus, both SERCA1a and SERCA2a are 
expressed (4) which suggests that SLN and PLN may regulate either SERCA isoform.  
Indeed, single fibre Western blotting could determine if SLN and PLN may selectively 
regulate one specific SERCA isoform similar to that in human skeletal muscle, but is 
complicated due to limits in both levels of protein and SLN/PLN expression.  
SLN is a 31 amino acid single-pass integral SR membrane protein with a 
transmembrane domain (19 amino acids), a cytoplasmic domain (7 amino acids), and a 
highly conserved lumenal domain (5 amino acids) (27, 28).  On the other hand, PLN is a 52 
amino acid single-pass integral SR membrane protein with a transmembrane domain (19 
amino acids), a long cytoplasmic domain (30 amino acids), and a short lumenal domain (3 
amino acids) (29).  Structurally, SLN and PLN are similar in their transmembrane domain 
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with 7 amino acids being identical (30) and 8 amino acids that are highly conserved as L, I, V 
or M (31) (Figure 1).  More importantly, the transmembrane domains of both SLN and PLN 
share a common binding site in between SERCA transmembrane helices M2, M4, M6 and 
M9 (30, 32).  Highly conserved amino acids between SLN and PLN are also present in the 
cytoplasmic domain (Figure 1). 
 
 
Figure 1.1. Amino acid sequence alignment of SLN and PLN from mouse.  Adapted from 
(28).  Identical amino acids across species are shaded in grey whereas the highly conserved 
amino acids across species are letters in bold (30).  
  
 
By physically interacting with either SERCA1a or SERCA2a, both SLN and PLN have been 
shown to reduce SERCA’s affinity for Ca2+ in a cell model expression system (33).  
Specifically, this was depicted as an increased Ca2+ requirement to reach half-maximal rates 
of SERCA Ca2+ uptake.  In addition, experiments with co-reconstituted proteoliposomes 
containing SLN or PLN with SERCA1a also depicted a reduction in SERCA affinity for Ca2+ 
through increased Ca2+ requirements to reach half-maximal rates of SERCA activity (ATP 
hydrolysis) (28).  The results from these studies are summarized in Table 1.  In mice, genetic 
deletion of Sln (Sln-/-) and Pln (Pln-/-) improved SERCA affinity for Ca2+ in the atria (21) and 
ventricles (34), respectively, and was associated with increased relaxation rates and increased 
contractility.  In skeletal muscle, similar effects were reproduced in our laboratory using the 
soleus muscles of Sln-/- mice (26) and, although enhanced contractility and increased 
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relaxation rates were also observed in skeletal muscles from Pln-/- mice presumably due to 
improved SERCA Ca2+ uptake (35), there have been no studies to date assessing SERCA 
function in these mice.  
 
Table 1.1.  Calculated and reported reductions in SERCA affinity for Ca2+ in the presence of 
SLN or PLN.  
 Expression system ΔKCa 
Ca2+-ATPase 
  Proteoliposomes (28) 
  
SLN + SERCA1a 
PLN + SERCA1a 
 
-0.20 
-0.25 
 
Ca2+ uptake 
  HEK-293 cells (33) 
  
SLN + SERCA1a 
PLN + SERCA1a 
 
SLN + SERCA2a 
PLN + SERCA2a 
-0.22 
-0.36 
 
-0.37 
-0.40 
The effects of the SLN PLN were compared with SERCA alone in either proteoliposomes or 
HEK-293 cells.  KCa is the Ca2+ concentration required to attain the half-maximal Ca2+-
ATPase or uptake activity rate reported in pCa (negative logarithm) units. ΔKCa were 
reported in the study of HEK-293 cells and were calculated based on reported averages in the 
study of proteoliposomes. 
 
The inhibitory actions of SLN and PLN on SERCA can be relieved by 
phosphorylation (36-40).  With respect to PLN in cardiac muscle, the effects of 
phosphorylation are well established.  Specifically, β-adrenergic stimulation causes 
phosphorylation of PLN residues Ser16 by protein kinase A (PKA) and Thr17 by Ca2+-
calmodulin dependent kinase II (CAMKII) that ultimately leads to enhancements in cardiac 
muscle contraction and relaxation (37).  It is unclear whether phosphorylation of PLN 
regulates its inhibitory action in skeletal muscle as discrepant results from the same 
laboratory have been reported (35, 41).  Specifically, in one study, the use of a β-adrenergic 
agonist, isoproterenol, reduced half-relaxation time presumably due to PLN phosphorylation 
and improved SERCA function (35); however, this effect could not be reproduced in a study 
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7 years later (41).  In regards to SLN, experiments in a model of cardiac overexpression of 
Sln in Pln-/- mice revealed a reduction of SERCA affinity for Ca2+ that was attributed solely 
to SLN protein, which could be relieved upon isoproterenol treatment (40).  In this study, 
Gramolini and colleagues attributed the β-adrenergic effect to the phosphorylation of SLN at 
Thr5 by serine/threonine kinase.  Moreover, experiments in ventricular myocytes using point 
mutation of Thr5 support the significance of this phosphorylation site and highlight a role for 
CAMKII in isoproterenol-mediated phosphorylation (36).  It is important to note that 
whether phosphorylation of SLN can relieve SERCA inhibition in skeletal muscle has not 
been investigated.  
One additional mechanism that may govern SLN- and PLN-mediated inhibition of 
SERCA is the formation of homo-oligomeric structures that likely prevents physical 
interactions with the SERCA pumps.  PLN is capable of oligomerizing to form a pentameric 
structure and is visible as a ~20 kDa band using Western blot protocols where muscle 
homogenates have not been boiled prior to gel loading (26).  In contrast, SLN was initially 
shown to be incapable of oligomerization (33); however, a recent study using fluorescence 
resonance energy transfer spectroscopy and microscopy, showed that, in vitro, SLN is indeed 
capable of forming homo-oligomers of both low (n=2) and high order (n>2) (42).  The 
presence of these SLN oligomers have yet to be detected through Western blotting of cardiac 
and skeletal muscle homogenates in our laboratory and is complicated due to the amount of 
non-specific binding of the SLN antibody occurring above 10 kDa (3). 
 
Divergence between SLN and PLN  
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Despite the structural and functional similarities in SLN and PLN, there are a few 
significant differences between these two SERCA-regulatory proteins.  For example, along 
with the transmembrane domain, PLN has a relatively larger cytoplasmic domain that is also 
capable of interacting with SERCA and is vital for its inhibitory action (43).  In addition, we 
have shown that SLN reduces the apparent coupling ratio of SERCA (3) presumably leading 
to greater energy released as heat.  In support of this, Sln-/- mice developed hypothermia 
when exposed to acute cold temperature (30, 44), and were more susceptible to diet induced 
obesity when compared to their WT littermates (2, 44).  In contrast, results from previous 
reports examining the role of PLN as an uncoupler of SERCA are more complex.  Earlier 
findings from Dr. Jones’ and Dr. Kranias’ group have both shown that PLN is capable of 
uncoupling SERCA2a in cardiac muscles at low [Ca2+]i (> 6.5 pCa) (45, 46); however, the 
fact that Pln-/- mice did not develop hypothermia after cold exposure led Dr. Periasamy’s 
group to suggest that PLN may not uncouple SERCA like SLN (30).  To investigate this 
theory further, Sahoo and colleagues used HEK-293 cells transfected with a number of 
mutant SERCA, PLN, and SLN variants and presented 3 major findings.  First, although SLN 
and PLN bind within the same groove in the SERCA transmembrane domain, they may bind 
to different amino acids.  Second, SLN is capable of binding to SERCA even when exposed 
to high Ca2+ levels while PLN cannot.  Finally, SLN can bind to SERCA throughout its 
catalytic cycle while PLN may only bind to SERCA at one point during its catalytic cycle.  
Thus, the ability of PLN to uncouple SERCA2a in cardiac muscles only at low [Ca2+]i (45, 
46) may be explained by changes in binding affinities as [Ca2+]i increases (30), and could 
account for the lack in developed hyperthermia upon cold exposure.  Of note, changes in 
SLN expression in Pln-/- mice may also account for these differences observed with cold 
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exposure; however this was not examined in the study by Sahoo and colleagues.  
Furthermore, the possibility that PLN can uncouple SERCA2 or SERCA1 in skeletal muscle 
or its role in offsetting the obesigenic effects of a high-fat diet have not yet been fully 
investigated. 
 
Superinhibition 
Due to specific amino acids found in SLN (V19, I22) and PLN (I47, I48) these two 
proteins are able to physically bind with each other to form a binary complex (31).  
Structurally, this binary complex may fit within the SERCA groove formed by 
transmembrane helices M2, M4, M6 and M9 where individual PLN and SLN molecules 
normally bind (31, 32).  Functionally, when SLN and PLN are expressed together with 
SERCA in HEK-293 cells (33) or proteoliposomes (28), superinhibition occurs and leads to 
drastic reductions in SERCA affinity for Ca2+ and maximal rates of ATP hydrolysis and 
Ca2+-uptake (Table 2).  It has been proposed that by binding to PLN, SLN inhibits PLN from 
forming pentamers thereby increasing the amount of PLN monomers capable of inhibiting 
SERCA (33).  While this would explain further reductions in Ca2+ affinity, it may not explain 
reductions in maximal SERCA activity that are tested at high Ca2+ concentrations capable of 
dissociating PLN from SERCA (30).  It is possible that the binary complex of SLN-PLN 
allows for PLN to bind to SERCA throughout the whole catalytic cycle, however this has yet 
to be investigated.  
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Table 1.2.  Calculated and reported reductions in SERCA affinity for Ca2+ and maximal rates 
of Ca2+ ATPase activity and Ca2+ uptake during ternary superinhibition.  
 SERCA % ΔVmax ΔKCa 
Ca2+-ATPase 
  Proteoliposomes 
  (28) 
 
 
SERCA1a 
 
 
-20%  
 
 
-0.40 
    
Ca2+ uptake 
  HEK-293 cells 
  (33).   
 
SERCA1a 
SERCA2a 
 
-32%  
-42%  
 
-0.93 
-1.01 
The effects of the superinhibitory complex were compared with SERCA alone in either 
proteoliposomes or HEK-293 cells.  % ΔVmax were calculated based on average values 
reported in the respective study.  KCa is the Ca2+ concentration required to attain the half-
maximal Ca2+-ATPase or uptake activity rate reported in pCa (negative logarithm) units. 
ΔKCa were reported in the study of HEK-293 cells and were calculated based on reported 
averages in the study of proteoliposomes. 
 
In addition to mediating ternary superinhibition of SERCA, SLN alone may 
drastically impair SERCA function when expressed in high concentration (28).  When 
recombinant SLN protein and SERCA1a were reconsitituted into proteoliposomes in a 4.5:1 
molar ratio, Gorski and colleagues observed reductions in Ca2+ affinity and maximal rate of 
ATP hydrolysis (-30%).  Moreover, progessive increases in SLN/SERCA molar ratio from 
0:1 to 20:1 in lipid vesicles resulted in progressive reductions in SERCA mediated Ca2+ 
uptake (47, 48).  Therefore, at higher SLN concentrations, SLN may act alone or together 
with PLN to drastically impair SERCA function.  In support of this, forced overexpression of 
SLN in rat soleus through electroporation, reduced maximal rates of Ca2+ uptake by 31% (49).  
Together these findings may have implications in skeletal muscle myopathy where SERCA 
function is impaired and SLN protein expression is often upregulated. 
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SERCA and Ca2+ dysregulation in Skeletal Muscle Myopathies  
Skeletal muscle myopathy is a broad term that describes a state in which the muscle is 
suffering.  It may result from a number of abnormalities and can be placed into a variety of 
categories including: channelopathy, mitochondrial and metabolic myopathy, nucleoskeleton 
myopathy, acquired myopathy and congenital myopathy (50-55).  Dysregulated Ca2+-
handling is a common feature in most, if not all, skeletal muscle myopathies, and is 
exemplified clearly in congenital myopathies (56-59).  Congenital or inherited muscle 
myopathies are a genetically heterozygous diverse group of static or progressive muscle 
diseases that often result in muscle weakness, atrophy, hypotonia, cardiac- and respiratory 
dysfunction (60-63).  These myopathies may be either non-dystrophic or dystrophic where 
the former are caused by genetic defects in the contractile apparatus of muscle, and are 
defined by distinctive histochemical or ultrastructural changes on muscle biopsy (60).  
Conversely, the muscular dystrophies are diseases of muscle membrane or supporting 
proteins characterized by extensive muscle degeneration/regeneration cycling, fibrosis, 
inflammation, and often, elevated serum creatine kinase levels (60, 63).  
Core myopathies, centronuclear myopathies (CNM), and nemaline myopathies (NM) 
make up the three most common inherited non-dystrophic myopathies (61, 62).  Their 
differential diagnosis is based on histopathological analyses of skeletal muscle biopsies.  In 
core myopathies, oxidative stains typically using NADH-TR, SDH, and COX stains reveal 
unstained cores in the sarcomeres of type I fibres (62).  Two core myopathies have been 
defined to date: 1) central cores disease (CCD) where the cores run the length of the 
myofibre and 2) multiple minicores disease (mMD) that is characterized by smaller multiple 
cores that do not extend along the myofibre (62).  CNMs are characterized by excessive 
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internalized/centralized nuclei within myofibres without prominent findings of degeneration 
or regeneration, type I fibre predominance and hypotrophy, and central aggregation of 
oxidative activity (61, 64).  Lastly, nemaline myopathies are diagnosed on the basis of rod-
like accumulations of Z-disk-derived material found in either the sarcoplasm or nuclear 
membranes (62, 65, 66). 
It is important to note that these non-dystrophic myopathies do not occur as mutually 
exclusive events as there are variable levels of overlapping histological phenotypes amongst 
patients (61, 67).  Evidence within the literature suggests that dysregulated Ca2+ may be a 
common factor in their etiology and likely contributes to the overlapping phenotypes.  In fact, 
although a number of genetic defects in a variety of proteins can cause CCD, NM, or CNM, 
respectively, a mutation in the RYR1 gene that encodes for the RyR1 protein found in skeletal 
muscle may result in all three myopathies (59, 61).  The RYR1-related myopathies are 
thought to result from abnormal ECC secondary to leaky RyR Ca2+ channels and or 
uncoupled RyR-DHPR interactions, however, how this relates to the histological 
development of sarcomere lesions remains unclear (68).  Nevertheless, with respect to 
increased RyR leak, one may question why SERCA pumps can no longer compensate for 
RyR leak during these myopathies as SERCA pumps are able to catalyze the re-uptake of 
Ca2+ leaked from RyR channels in healthy resting skeletal muscle (4).  Apart from mutations 
in RYR1, mice lacking nebulin, a giant protein (800 kDa) that spans the entire length of the 
thin filament, phenotypically recapitulates human NM (69).  In the quadriceps muscles of 
these transgenically modified mice, severe impairments in maximal SERCA Ca2+ uptake 
(%ΔVmax = -70%) were reported when compared to their WT littermates (69).  Collectively, 
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these studies demonstrate SERCA’s potential involvement in the pathology of the various 
non-dystrophic congenital myopathies. 
With respect to the dystrophic myopathies, Duchenne’s muscular dystrophy (DMD) 
is the most severe form of muscular dystrophy affecting 1 in 3500 males (70) resulting from 
an X-linked mutation that renders patients without the dystrophin protein.  Without 
dystrophin, the dystrophin-glycoprotein complex found within the sarcolemmal membrane 
becomes disarrayed (71) which compromises the structural integrity of the membrane 
thereby making them more fragile and susceptible to exercise-induced damage.  DMD is a 
progressive muscle-wasting disease and early death often results from respiratory failure and 
cardiac dysfunction.  Studies using muscle biopsies from DMD patients as well as muscles 
from the mdx mouse, which less severely recapitulates the DMD phenotype, have linked 
[Ca2+]i overload to the necrosis and muscle degeneration (57, 58, 72, 73).  Specifically, 
[Ca2+]i overload can promote many detrimental processes that are involved with muscular 
dystrophy including: activation of proteolytic calpains, activation of caspases, elevating 
reactive oxygen specie (ROS) production, induction of mitochondrial apoptosis, enhancing 
inflammation and promoting fibrosis (56, 74-79).  While increased membrane fragility would 
presumably increase sarcolemmal Ca2+ permeability and would likely contribute to the 
[Ca2+]i overload, there may also be a role for SERCA.  In a study using the dystrophic mdx 
mouse and the more phenotypically severe mdx/utrophin-null (mdx/Utr-/-) mouse, SERCA-
mediated Ca2+ uptake was far more impaired in the mdx/Utr-/- mice suggesting that impaired 
SERCA function is at least associated with an increase in dystrophic pathology (80).  
Interestingly, many studies have now shown that impaired SERCA contributes to the 
dystrophic pathology since improving its function by genetic overexpression of SERCA or 
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heat shock protein 72, which protects SERCA from oxidative damage (81), mitigates the 
disease and improves muscle contractility and structure (57, 58, 82, 83). 
Even in the acute setting, SERCA may have a potential role.  For example, 
corticosteroid treatment of asthmatic patients often leads to acute myopathy characterized by 
skeletal muscle wasting and weakness (84, 85), and, in a previous study, daily intramuscular 
injections of triamcinolone for 5 days led to atrophied diaphragm muscles and prolonged 
half-relaxation times in Wistar rats (86).  The slowed relaxation time supports a role for 
SERCA function and can be accounted for, at least in part, by a down-regulation of 
SERCA1a and -2a mRNA (87).  Taken together, impaired SERCA function may be involved 
in congenital myopathies, muscular dystrophies, and even in conditions of acute injury. 
 
SLN and PLN in skeletal muscle myopathies 
 It is now well established that SLN expression is upregulated under conditions of 
muscle disease, disuse, and injury (summarized in Table 1.3).  What is fascinating about SLN 
expression in myopathy is that it also seems to increase along with disease severity.  This is 
demonstrated clearly in the muscles from mdx/Utr-/- mice that display greater fold-inductions 
of SLN content compared with mdx mice (Table 1.3).  Thus, it is possible that SLN 
contributes to the progressive decline in SERCA function that worsened according to disease 
pathology in the mdx and mdx/Utr-/- mice (88); however the exact role of SLN in muscular 
dystrophy or any other form of myopathy remains unknown.  In contrast to SLN, the pattern 
of expression of PLN across myopathies has not been studied well (summarized in Table 1.4). 
Furthermore, the results from the few studies assessing PLN mRNA or protein expression 
across muscle diseases/conditions, along with unpublished results from our laboratory, show 
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that unlike SLN, PLN expression does not consistently increase in response to disease, disuse, 
or injury (Table 1.4).  
Table 1.3.  Summary of the current literature demonstrating upregulated SLN expression in 
skeletal muscle disease, disuse, and injury. 
Mouse model Muscle mRNA/protein fold-induction  
NM 
   (nebulin knockout) 
quadriceps 
soleus 
EDL 
protein 
protein 
protein 
+20-fold 
+1.7-fold* 
+10-fold* 
(69) 
(69) 
(69) 
CNM 
   (Srpk3 knockout) 
 
tibialis anterior 
 
mRNA 
 
+3.5-fold* 
 
(89) 
   (miR133a knockout) 
   (miR133a knockout) 
tibialis anterior 
tibialis anterior 
mRNA 
protein 
+35-fold 
+3.5-fold* 
(90) 
(90) 
Disuse 
   (denervation) 
gastrocnemius 
soleus 
EDL 
mRNA 
protein 
protein 
+7-fold 
+20-fold 
ectopic 
(91) 
Unp. 
Unp. 
ALS 
   (SOD1G93A) 
 
gluteus superficialis 
 
mRNA 
 
+2-fold 
 
(91) 
Corticosteroid myopathy diaphragm mRNA +2-fold (87) 
Cardiotoxin injury d.n.s mRNA d.n.s. (91) 
Myotonic dystrophy 
   (HSALR20b) 
   (HSALR41) 
   (Mbln-/-) 
 
quadriceps 
quadriceps 
quadriceps 
 
mRNA 
mRNA 
mRNA 
 
98.3-fold 
72.8-fold 
42.6-fold 
 
(92) 
(92) 
(92) 
Muscular dystrophy 
   (human limb girdle) 
   (human limb girdle) 
 
vastus lateralis 
deltoid 
 
mRNA 
mRNA 
 
d.n.s. 
d.n.s. 
 
(93) 
(93) 
   (mdx) 
   (mdx) 
   (mdx) 
soleus 
diaphragm 
quadriceps 
protein 
protein 
protein 
+10-fold 
+3-fold 
+ectopic 
(88) 
(88) 
(88) 
   (mdx/Utr-/-) 
   (mdx/Utr-/-) 
   (mdx/Utr-/-) 
soleus 
diaphragm 
quadriceps 
protein 
protein 
protein 
+20-fold 
+8-fold 
ectopic (2-fold†) 
(88) 
(88) 
(88) 
NM, nemaline myopathy; CNM, centronuclear myopathy; Srpk3, gene encoding for serine arginine rich protein-
specific kinase-3; miR133a, gene encoding for microRNA 133a; ALS, amyotrophic lateral sclerosis disease; 
SOD1G93A, transgenic mouse model with a G93A mutation in the superoxide dismutase gene; HSALR20b and 41, 
human skeletal actin long repeat transgenic mouse models of myotonic dystrophy; Mbln-/-, muscleblind-like 
protein knockout mice as a mouse model of myotonic dystrophy; mdx, mouse model for DMD; mdx/Utr-/-, 
mouse model for DMD. *Fold-induction relative to the control (wild-type or sham condition) calculated from 
representative images in the respective publications using imageJ software. Unp., unpublished data from R. 
Tupling laboratory; d.n.s., data not shown, although the upregulation of Sln mRNA was suggested but not 
shown. †Represents a 2-fold increase in SLN protein compared to mdx quadriceps. 
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Table 1.4.  Summary of the current literature demonstrating varied PLN expression in 
skeletal muscle disease, disuse, and injury. 
Mouse model Muscle mRNA/protein fold-induction  
NM 
   (nebulin knockout) 
 
quadriceps 
 
protein 
 
unaltered 
 
(69) 
CNM 
   (Srpk3 knockout) 
 
tibialis anterior 
 
mRNA 
 
unaltered 
 
(89) 
   (miR133a knockout) tibialis anterior protein +1.4-fold* (90) 
Disuse 
   (denervation) 
   (denervation) 
 
soleus 
EDL 
 
protein 
protein 
 
+40-fold 
ectopic† 
 
Unp. 
Unp. 
Corticosteroid myopathy diaphragm mRNA unaltered (87) 
Muscular dystrophy 
   (mdx) 
   (mdx) 
 
soleus 
diaphragm 
 
protein 
protein 
 
-5.8-fold 
unaltered 
 
Unp. 
Unp. 
   (mdx/Utr-/-) 
diaphragm protein +3.3-fold Unp. 
NM, nemaline myopathy; CNM, centronuclear myopathy; Srpk3, gene encoding for serine arginine rich protein-
specific kinase-3; miR133a, gene encoding for microRNA 133a,; ALS, amyotrophic lateral sclerosis disease;; 
mdx, mouse model for DMD; mdx/Utr-/-, mouse model for DMD. 
*Fold-induction relative to the control (wild-type or sham condition) calculated from representative images 
using imageJ software. 
Unp., unpublished data from R. Tupling laboratory. 
†ectopic expression, based on the fact that PLN could not be detected in WT muscle with equal loading.  PLN 
can be detected in non-transforming EDL muscle (Figure 1.2); however, in this case could have been interfered 
with by the strong antigen:antibody complex signals that compete for the chemiluminescent substrate. 
 
 
Interestingly, although PLN expression is not consistently upregulated across 
different skeletal muscle myopathies, overexpression of PLN (PlnOE) in rabbit type I fibres 
leads to a dystrophic-like myopathy in their slow-twitch dominant soleus muscles (~ 90% 
type I fibres (94)) with severe muscle wasting, fibrosis, fatty infiltration, and skeletal muscle 
weakness (95).  The mouse soleus is comprised of approximately 35% type I fibres (96), and 
PLN-overexpression in these fibres resulted in reduced muscle mass and muscle cross-
sectional area; however, unlike the PlnOE rabbit, there were no observed pathological 
alterations using light microscopy (41).  Surprisingly, when we purchased these 
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commercially available mice to study the role of PLN as an uncoupler of SERCA and its 
effects on high-fat feeding, we found obvious signs of myopathy in the soleus muscles along 
with the previously observed muscle atrophy (Figure 1.3a,b).  Furthermore, when we 
examined SLN content, we found that its expression was upregulated approximately 9-fold 
(Figure 1.3c).  Thus, the PlnOE mouse is a valuable model to determine the role of PLN and 
SLN in skeletal muscle myopathy.     
 
 
Figure 1.2.  Phospholamban overexpressing (PlnOE) mice display soleus muscle atrophy, 
pathology and greater SLN content.  a Image illustrating soleus muscle atrophy observed in 
heterozygous PlnOE mice compared with wild-type (WT).  b Representative H&E-stained 
sections showing muscle pathology in heterozygous PlnOE mice.  Scale bars are set to 50 µm.  
c Representative Western blot image demonstrating sarcolipin (SLN) up-regulation in soleus 
muscle homogenates from heterozygous PlnOE mice.  25 µg of protein were loaded and α-
actin was used as a loading control.  
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Statement of the problem 
This literature review has highlighted the potential impact of SERCA dysfunction on a 
number of muscle myopathies.  SLN and PLN are two small inhibitory proteins that regulate 
the SERCA pump, and SLN, specifically, is considered a marker of muscle disease given its 
consistent upregulation in protein and/or mRNA.  In contrast, the pattern of PLN expression 
in skeletal muscle myopathies is less defined and more variable.  Nevertheless, PLN 
overexpression in mice exhibits signs of myopathy and a 9-fold increase in SLN content.  
This thesis sought to characterize the PlnOE induced myopathy and determine the role of SLN.  
 
Objectives and hypotheses for Thesis Study I 
The main objectives for Study I were: 
1. Characterize SERCA function in the soleus and gluteus minimus muscles from PlnOE 
mice. 
2. Characterize the myopathic phenotype as non-dystrophic or dystrophic as well as 
progressive or non-progressive. 
3. Characterize the soleus muscle atrophy in the PlnOE muscles and examine the role of 
the major proteolytic pathways (ie. calpain, caspase-3, cathepsin, and ubiquitin-
proteasome).  
4. Characterize in vitro soleus muscle contractility with respect to force produced and 
twitch kinetics. 
5. Characterize whole body muscle performance with treadmill exercise running. 
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The specific hypotheses (outcomes) for Study I were: 
1. Since PLN and SLN are inhibitors of the SERCA pump, it was hypothesized that 
maximal SERCA activity, rates of Ca2+ uptake, and SERCA’s affinity for Ca2+ would 
be reduced in PlnOE soleus and gluteus minimus muscles compared with WT. 
(The data are consistent with the hypothesis as SERCA dysfunction was clearly 
evident in these muscle types). 
2. Consistent with the PlnOE rabbit, it was hypothesized that the myopathy in the PlnOE 
mice would resemble a dystrophic phenotype with greater central nuclei, greater 
fibrosis, plasma creatine kinase concentration, and immune cell infiltration. 
(The data are inconsistent with the hypothesis.  Although the PlnOE soleus and gluteus 
minimus muscles displayed some dystrophic features including greater central nuclei, 
fibrosis, and slightly elevated plasma creatine kinase, the myopathy in these mice was 
diagnosed as CNM based on the additional findings of type I fibre predominance and 
hypotrophy and central aggregation of oxidative activity).   
3. Based on its Ca2+ dependency, it was hypothesized that calpains would display 
greater activity in the PlnOE mice and would account for the soleus muscle atrophy. 
(The data are consistent with the hypothesis in that calpains were more active; 
however caspase-3 and cathepsins were also more active, and there was also greater 
total protein ubiquitinylation).  
4. Based on the muscle damage and atrophy observed in the soleus muscles it was 
hypothesized that they would exhibit lower force production.  In addition, it was 
hypothesized that twitch relaxation rates and rates of force development would be 
depressed.  
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(The data are consistent with the hypotheses.  Force production, rates of relaxation, 
and rates of force development were all significantly depressed in the PlnOE muscles).   
5. It was hypothesized that PlnOE mice would be more susceptible to fatigue during 
treadmill exercise compared with WT. 
(The data are consistent with the hypothesis and PlnOE mice had, on average, a shorter 
time to fatigue during treadmill exercise). 
 
Objectives and hypotheses for Thesis Study II 
Based on the diagnosis of a CNM-like phenotype in the PlnOE soleus and gluteus minimus 
muscles, this study sought to assess the diaphragm muscles, since studies examining 
respiratory or diaphragm function in animal models of CNM are limited.  The main 
objectives for Study II were: 
1. Characterize SERCA function with respect to SERCA activity, Ca2+ uptake, and 
SERCA’s apparent affinity for Ca2+. 
2. Determine whether the diaphragm muscles displayed the three typical hallmarks of 
CNM (ie. central nuclei, type I fibre predominance and hypotrophy, and central 
aggregation of oxidative activity). 
3. Determine whether SLN content was increased in the PlnOE diaphragm muscles like 
the soleus and gluteus minimus muscles. 
4. Determine whether the PlnOE diaphragm muscles exhibited muscle weakness and 
slower twitch kinetics upon in vitro contractility assessment. 
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The specific hypotheses (outcomes) for Study II were: 
1. It was hypothesized that SERCA activity, rates of Ca2+ uptake and SERCA’s apparent 
affinity for Ca2+ would be reduced in the PlnOE diaphragm compared with wild-type 
since these muscles normally comprise of 10% type I fibres that would overexpress 
PLN.   
(The data are inconsistent with the hypothesis.  SERCA’s apparent affinity was 
reduced and but rates of Ca2+ uptake were non-significantly different.  In addition, 
maximal rates of SERCA activity were unaltered.  Taken together, the level of 
SERCA impairment was not as pronounced in the PlnOE diaphragm compared with 
the soleus and gluteus minimus muscles). 
2. It was hypothesized that similar to the soleus and gluteus minimus muscles the 
diaphragm muscles would display a CNM-like phenotype. 
(The data are inconsistent with the hypothesis.  The diaphragm muscles did not 
display all of the features commonly observed in CNM with only type I fibre 
hypotrophy being evident without any elevations in central nuclei, central aggregation 
of oxidative activity, or type I fibre percent). 
3. It was hypothesized that similar to the soleus and gluteus minimus muscles SLN 
content would be upregulated in the diaphragm muscles as a general marker of 
muscle disease.   
(The data are consistent with the  hypothesis; however SLN was only upregulated 
2.5-fold in the PlnOE diaphragm compared with the 7-9-fold increase observed in the 
soleus and gluteus minimus muscles from Study I). 
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4. It was hypothesized that similar to the soleus muscles PlnOE diaphragm strips would 
exhibit muscle weakness and slower twitch kinetics.   
(The data are inconsistent with the hypothesis.  The diaphragm strips from PlnOE mice 
were not weaker than those from wild-type mice, nor did they have slower rates of 
relaxation or rates of force development). 
 
Objectives and hypotheses for Thesis Study III 
This study sought to determine the role of SLN in the PlnOE-induced CNM.  Subsequently, 
based on the results from these experiments, this study then sought to determine the role of 
SLN under conditions of mechanical overload, soleus muscle tenotomy, and in the dystrophic 
mdx mouse model.  The main objectives for Study III were: 
1. To generate a PlnOE/SlnKO mouse by breeding PlnOE mice with SlnKO mice. 
2. To characterize SERCA function in the PlnOE/SlnKO mice. 
3. To characterize the CNM-like phenotype in the soleus muscles from the PlnOE/SlnKO 
mice. 
4. To characterize in vitro soleus muscle force production in PlnOE/SlnKO mice. 
5. To characterize the soleus muscle atrophy and proteolytic pathways in the 
PlnOE/SlnKO mice. 
6. To determine the effects of genetic Sln deletion on the myofibre growth and 
remodeling seen during mechanical overload. 
7. To determine the effects of genetic Sln deletion on the myofibre atrophy and 
remodeling seen during soleus muscle tenotomy. 
8. To generate an mdx/SlnKO mouse by breeding mdx mice with SlnKO mice. 
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9. To determine the effects of genetic Sln deletion on myofibre size, remodeling, and 
muscle pathology in mdx mice. 
 
The specific hypotheses (outcomes) for Study II were: 
1. It was hypothesized that Sln deletion would rescue SERCA function in the PlnOE 
soleus. 
(The data are inconsistent with the hypothesis.  SERCA activity, rates of Ca2+ uptake, 
and SERCA’s apparent affinity for Ca2+ were similarly reduced in the PlnOE/SlnKO 
and PlnOE/SlnWT mice). 
2. It was hypothesized that Sln deletion would mitigate the CNM-like phenotype 
observed in the PlnOE soleus. 
(The data are inconsistent with the hypothesis.  The PlnOE/SlnKO soleus still exhibited 
greater central nuclei, central aggregation of oxidative activity, and type I fibre 
predominance and hypotrophy.  Additional ultrastructural abnormalities of triad 
disruption, commonly seen in CNM, were observed in both PlnOE/SlnKO and 
PlnOE/SlnWT soleus). 
3. It was hypothesized that Sln deletion would improve force production in the PlnOE 
soleus. 
(The data are inconsistent with the hypothesis.  Force production in the PlnOE/SlnKO 
soleus was further impaired being significantly reduced at submaximal and maximal 
frequencies). 
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4. It was hypothesized that Sln deletion would alleviate the soleus muscle atrophy seen 
in response to Pln overexpression partly by attenuating the activities of the major 
proteolytic enzymes in skeletal muscle. 
(The data are inconsistent with the hypothesis.  Sln deletion worsened the soleus 
muscle atrophy in response to Pln overexpression and this could not be accounted for 
by any augmentations in calpain, caspase-3, cathepsin, or 20S proteasome activity.  
Instead Sln deletion caused a failure of type II fibres to hypertrophy, and combined 
with the failure of type IIA fibres to transition into type I fibres, provided the 
rationale to perform mechanical overload experiments). 
5. Similar to the PlnOE soleus, it was hypothesized that Sln deletion during mechanical 
overload would attenuate the type II fibre hypertrophy and fast-to-slow fibre type 
transitions. 
(The data are consistent with the hypothesis.  For the first time ectopic SLN 
expression was observed in the overloaded plantaris muscles; and when Sln was 
removed, it led to a failure of type II fibres to hypertrophy and transition towards a 
slow-oxidative phenotype). 
6. Similar to the PlnOE soleus, it was hypothesized that Sln deletion during muscle 
tenotomy would exacerbate the soleus muscle atrophy.  In addition, it was 
hypothesized that Sln deletion would accelerate the slow-to-fast fibre type transitions 
commonly observed with soleus muscle unloading. 
(The data are consistent with the hypothesis.  Sln deletion exacerbated the soleus 
muscle atrophy and appeared to have larger percent reductions in myofibre CSA.  Sln 
deletion also accelerated the slow-to-fast fibre type transitions). 
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7. It was hypothesized that Sln deletion would reduce myofibre CSA, cause a slow-to-
fast fibre type transition, and lower utrophin expression in the soleus and diaphragm 
muscles from mdx mice.  It was further hypothesized that mdx/SlnKO mice would 
display a worsened dystrophic pathology with greater serum creatine kinase 
concentration and variability in the minimal Feret’s diameter.   
(The data are consistent with the hypothesis.  The mdx/SlnKO mice displayed 
worsened dystrophic pathology with smaller myofibre sizes, a slow-to-fast fibre type 
transition, lower utrophin expression, greater serum creatine kinase, and greater 
variability in the minimal Feret’s diameter). 
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2.1 Preface 
This Chapter presents Thesis Study I as a ‘Full Text’ reproduction of the article 
Phospholamban overexpression in mice causes a centronuclear myopathy-like phenotype 
published in 2015 by Disease Models and Mechanisms as referenced above.  Prior to this 
work, the role of PLN in SERCA regulation and overall muscle health was based on studies 
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on cardiac tissue (97), with mutations in PLN being associated with cardiomyopathy (98).  In 
addition, with the discovery of SLN’s role as an uncoupler of SERCA activity and a regulator 
of muscle-based thermogenesis in skeletal muscle (for review see, (99)), the academic 
community was seemingly beginning to overlook PLN’s role in skeletal muscle health.  This 
work published in Disease Models and Mechanisms showcases the importance of PLN in 
regulating SERCA and overall muscle health suggesting that increased PLN expression can 
cause a CNM-like phenotype in mice, and may have a potential role in human CNM.  
Articles published in Disease Models and Mechanisms are under the Creative 
Commons Attribution (CC-BY) license.  This license was developed to facilitate open 
access-namely, free immediate access to, and unrestricted reuse of, original works of all 
types.  This allows for inclusion of any version including final published PDF so long as the 
source is attributed by citing and linking to the published article on the journal website. 
Included in this Chapter are the Overview (Section 2.2), Introduction (Section 2.3), 
Results (Section 2.4), Discussion (Section 2.5), and Materials and Methods (Section 2.6) of 
the article, reproduced as published, except in the format of this thesis. Figures (2.1 to 2.5) 
and Tables (Table 2.1 to 2.2) corresponding to the Results are located in order at the end of 
Section 2.4. The Supplemental Material for this article, published as an Online Supplement 
as referenced above, is reproduced in Appendix A as published, except in the format of this 
thesis.  The Supplemental Material includes Supplemental Results comprised of 
Supplemental Figures A1 – A6 and Tables A1 – A3. 
 
2.2 Overview 
Centronuclear myopathy (CNM) is a congenital myopathy that is histopathologically 
characterized by centrally located nuclei, central aggregation of oxidative activity, and type I 
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fibre predominance and hypotrophy. Here, we obtained commercially available mice 
overexpressing phospholamban (PlnOE), a well-known inhibitor of sarco(endo)plasmic 
reticulum Ca2+-ATPases (SERCAs), in their slow-twitch type I skeletal muscle fibres to 
determine the effects on SERCA function. As expected with a 6-7-fold overexpression of 
PLN, SERCA dysfunction was evident in PlnOE muscles with marked reductions in rates of 
Ca2+ uptake, maximal ATPase activity and the apparent affinity of SERCA for Ca2+. 
However, our most significant discovery was that the soleus and gluteus minimus muscles 
from the PlnOE mice displayed overt signs of myopathy histopathologically resembling 
human CNM with centrally located nuclei, central aggregation of oxidative activity, type I 
fibre predominance and hypotrophy, progressive fibrosis, and muscle weakness, a phenotype 
that is associated with significant up-regulation of muscle sarcolipin and dynamin 2 content, 
increased Ca2+-activated proteolysis, oxidative stress, and protein nitrosylation. Moreover, in 
our assessment of muscle biopsies from three human CNM patients, we found a significant 
53% reduction in SERCA activity and trending increases in both total and monomeric PLN 
content compared to five healthy subjects, thereby justifying future studies with more CNM 
patients. Altogether our results suggest that the commercially available PlnOE mouse 
represents a novel mouse model phenotypically resembling human CNM and may be used to 
test potential mechanisms and therapeutic strategies. To date there is no cure for CNM and 
our results suggest that targeting SERCA function, which has already been shown to be an 
effective therapeutic target for murine muscular dystrophy and human cardiomyopathy, may 
represent a novel therapeutic strategy to combat CNM.      
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2.3 Introduction 
The sarco(endo)plasmic reticulum Ca2+-ATPase (SERCA) pumps catalyze the active 
transport of Ca2+ into the sarcoplasmic reticulum (SR) and play a crucial role in muscle 
relaxation and the maintenance of resting intracellular Ca2+ [Ca2+]i, which ranges from 30 to 
100 nM in skeletal muscle (1, 8).  Phospholamban (PLN) is a small, 52-residue, SR protein 
capable of physically interacting with and inhibiting SERCA activity by reducing its apparent 
affinity for Ca2+ (31).  Mouse (41) and rabbit (95) models overexpressing PLN in slow-twitch 
(type I) muscle fibres (PlnOE) have been generated by attaching a Pln transgene to the β 
myosin heavy chain (β-MHC) promoter, which preferentially directs high levels of type I 
skeletal-muscle-specific transgene expression (100-102).  In the PlnOE rabbit, obvious signs 
of muscular dystrophy, including central nucleation, severe muscle wasting, fibrosis, fatty 
infiltration and muscle weakness, were observed in soleus muscles, which are rich in type I 
fibres (95).  In contrast, PlnOE mice exhibited soleus muscle atrophy but no other signs of 
myopathy were visualized under the light microscope (41).     
We purchased these commercially available PlnOE mice and their wild-type (WT) 
littermates (000067-MU, FVB/N background, Mutant Mouse Regional Resource Centre, 
Columbia, MO) to assess SERCA function because the effect of PLN overexpression on 
SERCA activity and Ca2+ transport in skeletal muscle remains uncharacterized.  Unlike the 
study by Song et al., (4), we discovered that the postural soleus and gluteus minimus muscles 
from PlnOE mice exhibited overt signs of myopathy.  Collectively, our data suggest that the 
PlnOE mouse is a novel myopathy model resembling human centronuclear myopathy (CNM) 
with additional dystrophic features and potential core-like lesions. 
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2.4 Results 
SERCA function is impaired in PlnOE muscle 
PlnOE mice were generated in order to examine the functional importance of PLN in skeletal 
muscle; however, in the only study published using these mice (41), no measurements of 
SERCA function were reported because of technical limitations.  In order to better define the 
functional role of PLN in skeletal muscle we assessed SERCA function in these mice 
focusing our analyses on the postural muscles, soleus and gluteus minimus, since these 
muscles normally contain approximately 55-65% and 27% type I fibre proportions, 
respectively. However, these type I fibre levels increase in response to PLN overexpression 
(discussed below). Western blotting of whole homogenates demonstrated clear 
overexpression of PLN in these muscles since only 2.5 µg of total protein were loaded for 
PlnOE mice compared to the 25 µg required for WT mice (Figure 2.1A and supplementary 
material Figure A3A).  Specifically, in the PlnOE soleus relative to WT (n = 7-9 per 
genotype), monomeric and pentameric PLN levels, normalized to actin, were 6.3-fold (P = 
0.00001) and 80-fold (P = 0.0007) higher, respectively.  In the PlnOE gluteus minimus 
muscles relative to WT (n = 5-6 per genotype), monomeric and pentameric PLN levels were 
6.7-fold (P = 0.0001) and 23-fold (P = 0.0001) higher, respectively.  In addition to the 
analysis in homogenates, we also performed single-fibre western blot analyses confirming 
overexpression of PLN specific to type I fibres in this model (supplementary material Figure 
A1).  In contrast, PLN was barely detectable in some WT type I and type IIA fibres 
(supplementary material Figure A1). This corresponds well with the fact that PLN expression 
in rodent skeletal muscle is far lower than that in human skeletal muscle where PLN can be 
found in all type I and type IIA fibres in the vastus lateralis (20).   
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In agreement with the known effects of PLN overexpression on SERCA function in 
HEK-293 cells and in transgenic hearts (23, 97), we observed a reduction in SERCA’s 
apparent affinity for Ca2+ as indicated by a higher KCa value and a corresponding rightward 
shift in the activity-pCa curve in soleus homogenates prepared from PlnOE mice compared 
with WT (Table 2.1 and Figure 2.1B).  Furthermore, maximal rates of SERCA activity (-
27%) and rates of Ca2+ uptake (-74%) were reduced in the PlnOE soleus compared with WT 
(Figure 2.1B and C and Table 2.1).  The SERCA dysfunction in PlnOE soleus cannot be 
explained by altered SERCA expression since western blot analysis showed that SERCA1a 
content is similar in WT and PlnOE muscles (Figure 2.1D), whereas a significant 3-fold 
increase in SERCA2a expression was observed in the soleus of PlnOE mice (Figure 2.1E).  
Sarcolipin (SLN), a small SR protein that is structurally and functionally homologous with 
PLN (32, 33), was also found to be up-regulated by 9-fold in the soleus of PlnOE mice 
compared with WT (Figure 2.1F).  As SLN can inhibit SERCA pumps alone or in 
combination with PLN (32), these results suggest that SLN may also contribute to the 
impaired SERCA function we observed in PlnOE muscles. Indeed, forced over-expression of 
SLN acutely in rat soleus reduces SR Ca2+ transport (-31%) and causes severe contractile 
dysfunction (49). 	  
Soleus muscle atrophy and Ca2+-activated proteolysis in PlnOE mice  
Similar to previously described results (41), we also observed atrophy of soleus muscles in 
PlnOE mice (Figure 2.2A and supplementary material Table A1).  Interestingly, when 
breeding male and female PlnOE mice, soleus muscles weighing <1 mg were observed, 
presumably from homozygous PlnOE mice (+/+) because these muscles were no longer seen 
after breeding male PlnOE mice with female WT mice (Figure 2.2A).  Owing to this 
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limitation of the tissue, we restricted all of our analyses in the present study to heterozygous 
PlnOE mice (+/-).  In the study published by Song et al., (2004), a 35-40% reduction in 
soleus:body weight ratio was observed in PlnOE mice at 10-12 weeks of age.  In our hands, 
assessment of soleus:body weight ratio in PlnOE mice at 1 month, 4-6 months, and 10-12 
months of age indicates a 21%, 43%, and 41% reduction, respectively, when compared to 
WT mice (supplementary material Table A1).  When we include age as a factor, absolute 
soleus weight and the soleus:body weight ratios were significantly different at 4-6 months 
and 10-12 months but not at 1 month.  To elucidate the mechanisms behind the diminished 
soleus muscle mass, Song and colleagues reported an approximate 2-fold increase in calpain 
expression (41).  Calpains are a class of proteolytic enzymes that are activated by high levels 
of [Ca2+]i (103), and our results show that calpain activity was 1.5-fold higher in soleus from 
PlnOE mice compared with WT (Figure 2.2B), which probably results from reduced SERCA 
function and greater [Ca2+]i in PlnOE mice.  We also observed a significant 1.5- to 2-fold 
increase in other proteolytic pathways such as caspase-3, cathepsin-B/L activity, and protein 
ubiquitylation (Figure 2.2C-E), which suggests that the soleus muscle atrophy in PlnOE mice 
is due to a general overall enhancement of proteolytic activity in those muscles. 
 
Central nuclei, progressive fibrosis and oxidative stress in PlnOE mice 
As mentioned earlier, previous analyses of PlnOE mice revealed no signs of myopathy under 
the light microscope (41).  Consequently, we were surprised that our histological analyses of 
the soleus muscles from PlnOE mice showed obvious signs of pathology that were repeatedly 
observed (Figure 2.3).  In fact, the myopathy was at least partially consistent with the 
dystrophic-like phenotype observed in PlnOE rabbits (95), including greater central nucleation 
	  32 
of fibres, fibre-splitting, atrophy, and progressive fibrosis which became evident at 4-6 
months of age (Figure 2.3A to D). Corresponding well with the dystrophic phenotype, we 
also observed greater whole muscle oxidative stress as indicated by DCF (2’, 7;-
dichlorofluorescein) fluorescence and protein nitrosylation, effects that may be explained by 
Ca2+ dysregulation (56).  Furthermore, we found elevated plasma CK in 4- to 6-month-old 
PlnOE mice (Figure 2.3E to G); however, the relatively small increase in plasma CK suggests 
that the dystrophic-like phenotype in PlnOE mice is likely a direct result of impaired SERCA 
activity and elevated [Ca2+]i and less likely to be caused by sarcolemmal damage per se.  A 
similar finding has been reported in mice overexpressing transient receptor potential 
canonical 3 which led to greater Ca2+ influx, muscular dystrophy, and only slightly elevated 
plasma CK as a result of a generally intact sarcolemmal membrane (72). 
 
CNM in the PlnOE mouse 
Although central nucleation might be an active marker in muscle regeneration and a common 
feature in muscular dystrophy (104-106), we observed only a small proportion of fibres that 
were positive for embryonic MHC (supplementary material Figure A2), which is normally 
expressed transiently during muscle regeneration (107-109). These results, combined with 
the small elevation in plasma CK, suggest that very little degeneration-regeneration cycling 
is occurring in PlnOE muscle.  Therefore, the PlnOE mouse does not resemble closely 
dystrophic myopathy; however, central nucleation in the face of low regeneration, 
progressive fibrosis, and moderate elevations in CK levels is also found in CNM (110).  
CNM is a congenital myopathy that is diagnosed by the existence of three histopathological 
features found in muscle biopsies, which include: 1) central nucleation, 2) central 
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aggregation of oxidative activity, and 3) predominance of type I fibres and hypotrophy (64, 
110).  Both central aggregation of oxidative activity and type I fibre hypotrophy were evident 
in soleus sections as early as 1 month of age in PlnOE mice (Figure 2.4A and B and Table 
2.2).  Type I fibre predominance was established at 4-6 months of age whereas at 1 month, 
fibres were still transitioning towards the type I fibre distribution since the PlnOE soleus had 
lower type IIA and greater type I/IIA content compared with WT (Figure 2.4A and Table 
2.2).  The type I fibre predominance found from 4-6 months is in agreement with previous 
findings (41), and the increase in the slow-twitch SERCA2a isoform in PlnOE soleus (Figure 
2.1E) is also consistent with type I fibre predominance.  Taken together, these results indicate 
that the PlnOE mouse model is a phenocopy of the histological features found in human CNM.  
Importantly, the soleus muscle was not the only muscle affected by PLN overexpression 
because the postural gluteus minimus muscle, which normally comprises roughly 27% type I 
fibres in WT mice, also displayed signs of impaired SERCA function, CNM, and endomysial 
fibrosis (supplementary material Figure A3, Table A2, and Table A3).  Despite a similar 
level of monomeric PLN overexpression, the relative impairment in SERCA function in the 
gluteus minimus muscles compared with the PlnOE soleus was lower, with only a 20% 
reduction in the rates of Ca2+ uptake (supplementary material Figure A3C). This may be 
explained by the fact that the gluteus minimus muscles have a greater number of type II 
fibres that do not overexpress PLN, which could mask the inhibition of SERCA pumps 
occurring in the type I fibres.  In any event, both the PlnOE soleus and gluteus minimus 
muscles resembled the histopathological features associated with CNM.    
 To date, CNMs are known to be genetically heterogeneous (67, 111) and have been 
attributed to X-linked recessive mutations in the MTM1 gene encoding myotubularin (112), 
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autosomal-dominant mutations in the DNM2 gene encoding dynamin-2 (113) and the BIN1 
gene encoding amphiphysin-2 (114), and autosomal-recessive mutations in BIN1 (115), 
RYR1 encoding the SR ryanodine receptor (116, 117), and TTN encoding titin (118).  Many 
different structural abnormalities have been identified that aid in distinguishing between the 
various human CNMs (64, 67).  For example, the autosomal dominant DNM2-related CNMs 
present with radiating SR strands and marked contrast of the diameters between type I and 
type II fibres (64).  In addition to these features, increases in connective tissue and the 
presence of core formations can also be observed in DNM2-related CNMs (67).  Since we 
observed radiating SR strands (Figure 2.4C), type II fibre hypertrophy (Table 2.2 and 
supplementary material Table A3), progressive fibrosis (Figure 2.3C and D), and potential 
core-like formations (Figure 2.5) in the PlnOE mice, our results suggest that the CNM 
phenotype found in these mice resembles autosomal dominant DNM2-related CNM.  
However, because increases in endomysial connective tissue and the presence of core 
formations may also be observed in RYR1-related and TTN-related CNM (67, 117), the PlnOE 
mouse also shares a resemblance to these forms of CNM.  We use the term ‘potential core-
like lesions’ since future studies with electron microscopy are required to verify the presence 
and characterize the structure of cores in the PlnOE mouse. 
 
Muscle function in the PlnOE mouse 
General muscle weakness is common in cases of CNM and our analyses of contractile 
function in isolated intact soleus muscle as well as whole body endurance during treadmill 
exercise demonstrate that muscle function is impaired in PlnOE mice (supplementary material 
Figure A4A to E).  Specifically, we found that PlnOE mice generate lower normalized force at 
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both submaximal and maximal stimulation frequencies (30-100 Hz) (supplementary material 
Figure A4D) and reached exhaustion much sooner than WT mice during a treadmill exercise 
test (supplementary material Figure A4E).  In agreement with previous findings (41), we 
found that normalized twitch force generation of soleus muscle was not different between 
PlnOE and WT mice, whereas the twitch kinetics were significantly slower in PlnOE compared 
with WT (supplementary material Figure A4A to C). 
 
PLN and SERCA dysfunction in human CNM 
Thus far, it is evident that PLN overexpression in mouse skeletal muscle leads to CNM; 
however, whether PLN plays a primary pathogenic role in CNM remains unknown. In 
support of this notion, PLN protein was found to be up-regulated in the tibialis anterior 
muscles from mice lacking microRNA 133a-1 and 133a-2 where CNM was observed (90).  
In addition, we obtained muscle biopsies from three patients with CNM and when compared 
to biopsies from five healthy controls, we found that the maximal rate of SERCA activity 
was significantly reduced by 53% (supplementary material Figure A5A,) and that monomeric 
PLN (P = 0.12) and total PLN (P = 0.08) content were greater (supplementary material 
Figure A5B).  Therefore, we provide the first indication of a potential role for SERCA 
dysfunction and elevated PLN in human CNM; however, caution should be taken when 
interpreting these results.  Recently, we established through single fibre western blotting and 
immunohistochemical analyses that PLN expression follows SERCA2a and MHC I 
expression, whereas SLN follows SERCA1a and MHC II expression in healthy human vastus 
lateralis (20). Since we observed a trend for higher MHC I (supplementary material Figure 
A5C, P = 0.10) and SERCA2a (Figure A5D, P = 0.10) expression, and significant reductions 
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in both SERCA1a (supplementary material Figure A5E) and SLN (supplementary material 
Figure A5F) in CNM muscles compared with healthy controls, it is possible that these 
differences, including upregulated PLN, are due mostly to the expected type I fibre 
predominance in CNM patients.  Furthermore, in addition to the low sample size used in the 
present study, the CNM cases obtained were of notable age variability and were genetically 
unrelated, with one patient harboring a DNM2 mutation (R369W) and the other two patients 
remaining genetically unresolved.  Importantly, despite these limitations, we were still able 
to show a 53% reduction in SERCA activity and the expression patterns of the SERCA 
isoforms, SLN, and PLN are consistent with the expected type I fibre predominance often 
found in CNM.  
 
Dynamin 2 levels in CNM 
As a result of the dominant inheritance of the DNM2 mutation, one theory is that DNM2-
related CNM may be caused by a toxic gain-of-function in dynamin 2 (111, 119).  In support 
of this, overexpression of WT dynamin 2 in skeletal muscle results in features associated 
with CNM (90, 120).  In addition, up-regulation of dynamin 2 was observed in skeletal 
muscles from mtm1-/y mice, which accurately models human X-linked myotubular myopathy 
(XLCNM), and heterozygous knockdown of dynamin 2 in the mtm1-/y mouse improves 
muscle pathology and function (119).  We analyzed dynamin 2 protein content in PlnOE 
muscles and found a 5-fold (supplementary material Figure A6A) and 3-fold (supplementary 
material Figure A6B) higher level in the soleus and gluteus minimus muscles, respectively, 
compared with WT.  Whether dynamin 2 plays a pathological role in the CNM found in the 
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PlnOE mouse and the exact mechanism leading to its augmented expression requires further 
investigation.    
 Elevated levels of dynamin 2 are thought to also play a pathological role in human 
CNM because results from Laporte’s laboratory have shown an approximate 1.5-fold 
increase in dynamin 2 expression in muscle lysates from three XLCNM patients compared 
with two healthy controls (90, 119).  To confirm whether elevated dynamin 2 contributes to 
human CNM pathology, we assessed the dynamin 2 protein content in the three CNM muscle 
biopsies obtained here; however, in contrast to what was previously found in human CNM 
(90, 119), we found a 35% reduction in dynamin 2 compared to healthy subjects 
(supplementary material Figure A6C).  Notwithstanding the aforementioned sample size and 
other limitations with our human CNM cases, these findings may suggest that reducing 
dynamin 2 as a therapeutic strategy may not be appropriate for all forms of human CNM as 
previously suggested (121) and may be limited to XLCNM.   
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Figure 2.1. SERCA function in soleus muscles in PlnOE mice at 4-6 months of age.  (A) Western blotting for 
PLN in WT and PlnOE mice from soleus muscle homogenates.  For WT mice, 25 µg of total protein was loaded 
whereas only 2.5 µg was required for PlnOE mice to detect PLN protein.  (B) Ca2+-ATPase activity-pCa curves 
in WT (n = 5) and PlnOE mice (n = 6) in the presence of the Ca2+ ionophore.  (C) Ca2+ uptake assessed in soleus 
muscles from WT (n = 4) and PlnOE mice (n = 5). Western blotting for SERCA1a (D), SERCA2a (E), and SLN 
(F) in soleus from WT and PlnOE mice (n = 6 per genotype).  Actin was used as a loading control and all values 
are expressed relative to WT.  *P < 0.05 versus WT.  All values are presented as mean ± standard error.  PLN 
(p), PLN pentamer; PLN (m), PLN monomer.     
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Figure 2.2. Soleus muscles of PlnOE mice are atrophied at 4-6 months of age. (A) Representative images of 
soleus muscles extracted from WT and PlnOE mice. +/-, heterozygous; +/+, homozygous. (B) Calpain activity in 
soleus homogenates from WT (n = 4) and PlnOE mice (n = 5). (C) Caspase-3 activity in soleus homogenates 
from WT (n = 4) and PlnOE mice (n = 7). (D) Cathepsin-B/L activity in soleus homogenates from WT and PlnOE 
mice (WT n = 4, PlnOE n = 6). Calpain activity, caspase-3 activity, and cathepsin-L activity are in arbitrary units 
normalized to mg protein and are presented relative to WT. (E) Total protein extracts from soleus muscles (15 
µg) were immunoblotted with anti-ubiquitin (Ub) antibody. Ponceau stain was used as a loading control. The 
sum of optical densities from detectable ubiquitinated proteins (p-Ub) as well as the optical density of 
monomeric ubiquitin (m-Ub, 10 kDa) was measured and compared between genotypes (n = 4 per group). 
Values were normalized to the sum of optical densities of bands visualized through Ponceau stain. *P < 0.05 
versus WT. All values are presented as mean ± standard error. 
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Figure 2.3. Dystrophic features in the soleus muscles from PlnOE mice.  (A) H&E-stained sections of the soleus 
muscles from WT and PlnOE mice at 1 month, 4-6 months, and 10-12 months of age.  (B) Percent of fibres 
containing central nuclei in the soleus at 1 month, 4-6 months, and 10-12 months of age (n = 3 per genotype at 
each age with 300-600 fibres counted per mouse).  (C) Van Geison stained sections of the soleus muscles from 
WT and PlnOE mice at 1 month, 4-6 months, and 10-12 months of age.  (D) Quantitation of fibrotic area in the 
soleus at 1 month, 4-6 months, and 10-12 months of age (n = 3-4 per group at each age).  ImageJ software was 
used to quantify fibrotic area.  (E) Whole soleus reactive oxygen species generation determined using DCF 
assay at 4-6 months of age (WT n = 4, PlnOE n = 5).  (F) Total protein extracts from soleus muscles (15 µg) 
were immunoblotted with anti-nitrotyrosine antibody.  The sum of optical densities from detectable nitrosylated 
proteins (50 – 100 kDa) was measured and compared between genotypes at 4-6 months of age (n = 6 per group).  
Values were normalized to the sum of optical densities of bands visualized through Ponceau stain.  (G) Plasma 
CK levels in WT (n = 5) and PlnOE mice (n = 9) at 4-6 months of age. Scale bars in (A) and (C) are set to 50 µm. 
*P < 0.05 versus WT using two-way ANOVA and Tukey’s post-hoc analysis for %central nuclei and %fibrosis; 
Student’s t-test for DCF, protein nitrosylation, and plasma CK.  All values are presented as mean ± standard 
error.      
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Figure 2.4. Centronuclear myopathy in the soleus muscles from PlnOE mice. (A) Representative images of 
soleus muscles showing type I fibre predominance and hypotrophy. MHC immunofluorescence stained sections 
of the soleus muscles at 1 month, 4-6 months, and 10-12 months of age.  Cross sections were stained with MHC 
antibodies to identify type I (blue), type IIA (green), type IIB (red), and type IIX (unstained) fibres.  (B) 
Representative images of soleus muscles showing central accumulation of oxidative activity. SDH stained 
sections of the soleus muscles display central aggregation of oxidative activity in the PlnOE mice at 1 month, 4-6 
months, and 10-12 months of age.  (C) NADH-TR–stained cross sections demonstrating radiating sarcoplasmic 
reticulum strands in soleus muscles from PlnOE mice (arrows).  Asterisks represent the same fibre across 
cryosections.  All scale bars are set to 50 µm. 
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Figure 2.5. Potential core-like lesions in PlnOE mouse at 4-6 months of age.  SDH stained sections from the 
soleus muscle show areas devoid of oxidative staining representing potential core-like lesions (yellow arrows).  
Corresponding H&E stained serial section shows that the lack of oxidative staining with SDH is not due to the 
presence of a vacuole or an artifact in the muscle fibre.   
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Table 2.1. SERCA activity in mouse soleus muscles from WT and PlnOE mice at 4-6 months 
of age. 
 Vmax KCa ΔKCa 
   WT 248.4 ± 11.5 6.63 ± 0.05 - 
   PlnOE 181.6 ± 23.8* 6.47 ± 0.04* 0.16 
Values are means ± standard error.  Homogenates were isolated from WT (n = 6) and PlnOE 
(n = 5) mouse soleus muscles and were analyzed for Ca2+-ATPase activity over Ca2+ 
concentrations ranging from pCa 7 to pCa 4.5 to obtain KCa.  KCa is the Ca2+ concentration 
required to attain the half-maximal Ca2+-ATPase activity rate and is expressed in pCa units. 
*Significantly different from WT using Student’s t-test, P < 0.05.  
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Table 2.2. Quantitative analysis of fibre type distribution and cross-sectional area (CSA) in 
soleus muscles from WT and PlnOE mice at 1 month, 4-6 months, and 10-12 months of age. 
Values are means ± standard error (n = 3 per genotype).  *Significantly different from WT 
within the same age; aSignificantly different from 1 month within the same genotype; 
bSignificantly different from 4-6 months within the same genotype; P < 0.05 using two-way 
ANOVA including genotype and age as factors and a Tukey’s post-hoc test when necessary.   
  
 1 month 4-6 months 10-12 months 
Fibre distribution (%)    
 Type I     
   WT 56.2 ± 0.8 58.9 ± 6.9 64.1 ± 2.6 
   PlnOE 60.7 ± 2.5b 91.7 ± 2.9*a 94.4 ± 1.8*a 
 Type I/IIA    
   WT 6.4 ± 1.1b 0.5 ± 0.5a 0.6 ± 0.3a 
   PlnOE 13.0 ± 1.5*b 0.6 ± 0.2a 0.7 ± 0.2a 
 Type IIA    
   WT 34.0 ± 1.4 35.5 ± 3.1 31.3 ± 1.8 
   PlnOE 21.9 ± 1.7*b 7.7 ± 2.6*a 4.9 ± 1.7*a 
Fibre CSA (µm2)    
 Type I    
   WT 1895 ± 158 2051 ± 273 2584 ± 343 
   PlnOE 1291 ± 93* 871 ± 28* 1190 ± 90* 
 Type IIA    
   WT 1260 ± 89 1915 ± 126 2225 ± 159a 
   PlnOE 1617 ± 103b 2922 ± 180*a 5342 ± 703*ab 
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2.5 Discussion 
To date, most studies concerning the physiological significance of PLN inhibition of 
SERCA have focused solely on its role in cardiac muscle health and disease (for review see 
(97)).  To our knowledge, our current study is the first to demonstrate an important role for 
PLN and SERCA dysfunction in skeletal muscle health and CNM pathology.  Specifically, 
we obtained commercially available PlnOE mice to determine PLN’s effect on SERCA 
function in skeletal muscle and uncovered a mouse model that phenotypically resembles the 
histopathological features associated with human CNM.  In addition, our results with three 
human CNM patients suggest that SERCA dysfunction, possibly through increased PLN 
expression, contributes to CNM pathology.  Although it is possible that the predominance of 
type I fibres in human CNM may explain the elevations in PLN expression, it is important to 
consider our results from the PlnOE mouse, which indicate that overexpression of PLN 
specifically in type I fibres can cause type I fibre predominance and CNM.  Thus, future 
studies with more CNM patients that are similar in age and genetically related are required to 
better investigate whether PLN plays a primary pathological role in human CNM.  
We cannot fully explain why we repeatedly observed myopathy in the PlnOE mouse 
while Song et al., did not report such a finding (41).  Comparisons are difficult to make since 
SERCA function was not assessed and histology results were not shown in their study.  
Strain differences seem unlikely to account for the discrepant results since both transgenic 
lines were generated on an FVB/N background; however, it is possible that genetic drift and 
the level of PLN overexpression may be significant factors.  Nevertheless, several results are 
in agreement between the two studies, including type I fibre predominance, atrophy, 
increased proteolytic markers and slower force kinetics in soleus muscle.     
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It has been estimated that 25-30% of human CNM cases remain genetically 
unresolved (64, 111) and our results raise the possibility that mutations in Pln leading to 
increased SERCA inhibition could be involved in those cases.  Although Pln mutations either 
resulting in elevated PLN expression (122) or reduced PLN phosphorylation (123, 124) have 
been causally linked to human cardiomyopathy, it is unknown whether these mutations can 
affect skeletal muscle health.  For example, deletion of arginine 14 (R14del) in the coding 
region of the Pln gene results in increased SERCA inhibition through increased monomeric 
PLN and reduced PLN phosphorylation at Ser16 by PKA (123).  Interestingly, one patient 
with an R14del mutation in PLN developed late-onset mild dilated cardiomyopathy but was 
initially evaluated in a muscle dystrophy clinic for a 25-year history of slowly progressive 
muscle weakness (125).  Since there were no significant abnormalities in the staining patterns 
of sarcolemmal proteins, muscular dystrophy was discounted; however, to our knowledge, 
the existence of CNM was not tested.  Recent reports of human cases of CNM coexisting 
with cardiomyopathy (118, 126, 127) further highlight the importance of assessing the 
existence of CNM in skeletal muscles from patients with cardiomyopathy arising from PLN 
mutations.  
 Currently the mechanisms leading to CNM are not completely understood; however 
several mechanisms have been suggested, including abnormalities of triad structure and 
function (111, 114, 128-130).  As a result of these triad defects, aberrant Ca2+ handling and 
excitation-contraction (EC) coupling are also thought to be important for CNM pathogenesis.  
Indeed, the identification of mutations in RYR1 leading to CNM (116, 117) further supports 
the notion that triad dysfunction, Ca2+ dysregulation, and EC coupling are key pathogenic 
drivers of CNM (111).  Since the SERCA pumps regulate SR Ca2+ load and, thus, 
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contractility, the SERCA pumps are also crucial for Ca2+ regulation and EC coupling.  Thus, 
our results with the PlnOE mice add further support to the hypothesis that defects in triad 
function, Ca2+ handling and EC coupling are important for CNM pathogenesis and extend the 
hypothesis by adding SERCA dysfunction as a potential pathogenic mechanism.  Since 
abnormalities in triad structure are often found in human and animal CNM, future studies 
using electron microscopy should examine the triad structure in the PlnOE mouse to 
determine whether structural abnormalities also contribute to the Ca2+ dysregulation seen in 
these mice.  Furthermore, although the areas devoid of oxidative staining that cannot be 
explained by artifacts or the presence of vacuoles may represent core formations in the PlnOE 
mouse, future studies with electron microscopy will confirm and characterize these potential 
core-like lesions.   
 One other interesting question raised by our study pertains to the role of SLN in CNM.  
Similar to PLN, SLN is a SERCA pump inhibitor (28, 32, 33), which suggests that the 7- to 
9-fold upregulation in SLN protein found in the PlnOE soleus and gluteus minimus muscles 
may contribute to the SERCA dysfunction, Ca2+ dysregulation, and CNM pathology. (33) 
Interestingly, this response in SLN expression is consistent with other mouse models of 
myopathy (69, 80, 89-91, 129), but the role of SLN remains unknown.  Our finding that SLN 
content was reduced in human CNM reveals a potential species difference and suggests that 
this SERCA regulator may have minimal contribution to the SERCA dysfunction and overall 
CNM pathology.  To test whether or not SLN actively contributes to the CNM phenotype 
found in the PlnOE mice, future studies targeting the Sln gene are required.  Furthermore, a 
novel micropeptide, myoregulin (MLN), was found to be structurally and functionally 
homologous with both PLN and SLN (131).  When new antibodies targeting MLN protein 
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expression become available, it will be interesting to determine its response and potential 
involvement in murine and human CNM and myopathy in general. 
 In summary, the commercially available PlnOE mouse histopathologically resembles 
human CNM.  To date, there is no cure for CNM and many unresolved questions remain, 
including the mechanisms leading to skeletal muscle defects in patients.  Mechanistically, our 
results from the PlnOE mouse are consistent with the hypothesis that triad dysfunction, 
aberrant Ca2+ handling and EC coupling are important for CNM pathogenesis; but whether it 
is higher cytosolic Ca2+ and/or altered Ca2+ dynamics that lead to CNM histopathology, and 
how the muscle translates this dysregulated Ca2+ into the CNM phenotype remains unknown 
and future studies using the PlnOE mouse will prove valuable.  Furthermore, treatment 
strategies aimed at improving SERCA function have already shown promise in murine 
muscular dystrophy (57, 58, 132) and human cardiomyopathy (133-135).  Thus, future 
studies that improve SERCA function through various modes, including adjustment of PLN 
levels, in the PlnOE mouse and other animal models of CNM, could lead to the development 
of viable therapeutic strategies for CNM patients.   
 
2.6 Materials Methods	  
PlnOE mice.  The PlnOE mice were resuscitated from cryopreserved embryos by the mmRRC 
(000067-MU, FVB/N background) to generate a breeding colony with WT FVB/N mice in 
our facility.  The Pln transgene was attached to the β-MHC promoter so that these mice 
overexpress PLN in their slow-twitch type I skeletal muscle fibres. Animals were housed in 
an environmentally controlled room with a standard 12:12-hour light-dark cycle and allowed 
access to food and water ad libitum.  Experiments were performed on littermate heterozygous 
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PlnOE and WT males that were between the ages of 1 and 12 months.  Reintroduction of 
homozygous PlnOE mice was avoided by breeding heterozygous male PlnOE mice with 
female WT mice.  Analysis of 287 newborn mice showed that WT and heterozygous PlnOE 
mice were born at the expected mendelian frequency with a ratio of 137:150.  All animal 
procedures were reviewed and approved by the Animal Care Committee of the University of 
Waterloo and are consistent with the guidelines established by the Canadian Council on 
Animal Care. 
 
Human subjects.  Five healthy untrained university students were used as healthy controls.  
All subjects were fully informed of all experimental procedures and all associated risks 
before written consent was obtained.  Written approval for the research was granted by the 
Human Research Ethics Committee at the University of Waterloo. Three patients with CNM 
from McMaster University Medical Centre were used in this study.  One female (55 years 
old) patient had CNM due to a missense mutation in dynamin 2 (DNM2, 1105CàT, R369W) 
whereas the other two male CNM patients (17 and 44 year old) remain genetically 
unresolved.  Of the two unresolved cases, one underwent 163-gene next generation 
sequencing, which included MTM1, DNM2, RYR1, CACNA1S, and TTN.  The other 
unresolved patient was screened for MTM1 and DNM2; however, he did not return to 
complete a screen for additional genes.  Written approval for the use of material from 
previously consented and diagnosed patients was granted by the Chair of the Human 
Research Ethics Committee at McMaster University.  All muscle tissue samples (~100 mg) 
were obtained from the vastus lateralis using the needle biopsy technique under suction (136).  
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These samples were homogenized and then frozen at -80°C prior to being used for western 
blotting and SERCA activity assays.  
 
SERCA activity and Ca2+ uptake.  Ca2+-dependent SERCA activity was assessed in 
homogenates prepared from mouse (WT and PlnOE) soleus and gluteus minimus muscles and 
human vastus lateralis muscles over Ca2+ concentrations ranging from pCa 7.5 to 4.5 in the 
presence of the Ca2+ ionophore A23187 (Sigma C7522) using a spectrophotometric plate 
reader assay that has been described previously (137).  SERCA activity-pCa curves were 
generated with GraphPad PrismTM by non-linear regression curve fitting using an equation 
for a general cooperative model for substrate activation.  Ca2+ uptake was measured in 
homogenates in the presence of the precipitating anion, oxalate, using the fluorescent dye 
Indo-1 and a spectrofluorometer equipped with dual-emission monochromators (138).  Rates 
of Ca2+ uptake assessed at a free cytosolic Ca2+ concentration of 1500 nM are reported. 
 
Antibodies.  Primary antibodies against SERCA2a (2A7-A1), PLN (2D12), and dynamin 2 
(PA5-19800) were obtained from Pierce Antibodies.  The primary antibody for SERCA1a 
(A52) was a kind gift from Dr. David MacLennan (University of Toronto) (139).  The 
primary antibody directed against SLN was generated by Lampire Biological Laboratories 
(20).  Anti-ubiquitin (P4D1) and anti-nitrotyrosine (189542) antibodies were obtained from 
Cell Signaling Technology and Cayman Chemicals, respectively.  The primary antibody 
against α-actin (A4700) was obtained from Sigma Aldrich.  The primary antibodies against 
MHCI (BA-F8), MHCIIa (SC-71), MHCIIb (BF-F3), embryonic MHC (BF-F6) (140, 141) 
and dystrophin (3B7) (142) were obtained from Developmental Studies Hybridoma Bank.  
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Secondary antibodies for western blotting, goat anti-mouse IgG (peroxidase conjugated) and 
goat anti-rabbit IgG (peroxidase conjugated) were obtained from Santa Cruz Biotechnology.  
Secondary antibodies for immunofluorescence staining, Alexa Fluor 350 anti-mouse IgG2b, 
Alexa Fluor 488 anti-mouse IgG1, and Alexa Fluor 555 anti-mouse IgM, were obtained from 
Molecular Probes. 
 
Western blot analysis.  Single fibre Western blots were performed as previously described 
(20) to determine fibre-type specificity of PLN overexpression.  Briefly, single fibres 
extracted from soleus muscles of WT and PlnOE mice were placed into 1x solubilizing buffer.  
Solubilized proteins were then separated using tricine-based SDS-PAGE (6%-13% layered 
gel).  Separated proteins were then transferred onto 0.2 µm polyvinylidene difluoride (PVDF) 
membranes.  Membranes were then cut at the 75 kDa band (Western C Precision PlusTM, 
BioRad, CA, USA) and were immunoprobed with PLN (<75 kDa strip) and with MHCI (>75 
kDa strip).  Following this, membranes were immunoprobed with horseradish peroxidase-
conjugated secondary antibodies and antigen-antibody complexes were detected by Luminata 
ForteTM (Millipore, MA, USA) for PLN, and ECL Western Blot Substrate (BioVision, MA, 
USA) for MHCI.  After detection of MHCI, the membrane was stripped and re-probed with 
MHCIIa and antigen-antibody complexes were detected using ECL Western Blot Substrate. 
Similarly, western blot analysis was performed to determine expression levels of SLN, 
PLN, SERCA isoforms, and dynamin 2 as well as levels of protein ubiquitylation (Ub) and –
nitrosylation (Ny) in mouse (WT and PlnOE) and human CNM muscles after homogenates 
were placed into 1x solubilizing buffer.  Solubilized proteins from tissue homogenates, were 
separated using tricine based SDS-PAGE (13% total acrylamide for PLN and SLN) or a 
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standard SDS-PAGE (7.5% total acrylamide for SERCA isoforms and dynamin 2 and a 
7.5%-15% layered gel for Ub and Ny).  Separated proteins were then transferred onto 0.2 µm 
PVDF membranes (PLN, SERCAs, Ub, Ny) or nitrocellulose membranes (SLN).  
Membranes were then immunoprobed with their corresponding primary antibodies.  
Following this, membranes were immunoprobed with horseradish peroxidase-conjugated 
secondary antibodies and signals were detected by SuperSignal West FemtoTM substrate 
(Pierce, Thermo Fisher Scientific Inc.) for SLN; Luminata ForteTM for SERCA2a, PLN, Ub, 
Ny, and RyR; and ECL Western Blot Substrate for SERCA1a and dynamin 2. Quantification 
of optical densities was performed using GeneTools (Syngene, MD, USA) and values were 
normalized to total protein or α-actin. 
 
Histological, histochemical, and immunofluorescent staining. Soleus and gluteus minimus 
muscles from WT and PlnOE mice were removed and embedded in O.C.T. compound 
(Tissue-Tek), frozen in liquid nitrogen-cooled isopentane, stored at -80°C, and cut into 10 
µm thick cryosections with a cryostat (Thermo Electronic) maintained at -20°C.  Histological 
staining included H&E and Van Gieson and histochemical staining included succinate 
dehydrogenase (SDH) and NADH-TR activity. Images were acquired with a brightfield 
Nikon microscope linked to a PixeLink digital camera and quantified with Image-Pro PLUS 
analysis software and ImageJ software.  Immunofluorescence analysis of MHC expression 
was previously described (20, 96, 143) and performed with primary antibodies against MHCI, 
MHCIIa, and MHCIIb.  Additional immunofluorescence analysis of embryonic MHC 
expression was conducted with primary antibodies against embryonic MHC along with 
primary antibodies against dystrophin. Slides were visualized with an Axio Observer Z1 
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fluorescent microscope equipped with standard red, green, blue filters, an AxioCam HRm 
camera, and AxioVision software (Carl Ziess). Quantification of fibres and cross-sectional 
area (CSA) was performed using ImageJ software. 
 
Proteolytic activity and DCF assays. Calpain, caspase-3, and cathepsin-B/L activity were 
determined in soleus muscle homogenates using the substrates, Suc-LLVY-AMC (Enzo-Life 
Sciences), Ac-DEVD-AMC (Alexis Biochemicals), and z-FR-AFC (Enzo Life Sciences), 
respectively (143, 144). These fluorogenic substrates are weakly fluorescent but yield highly 
fluorescent products following proteolytic cleavage by their respective proteases. 
Fluorescence was measured using a SPECTRAmax Gemini XS microplate 
spectrofluorometer (Molecular Devices, Sunnyvale, CA) with excitation and emission 
wavelengths: 360 nm and 440 nm, respectively for caspase-3; 380 nm and 460 nm, 
respectively for calpain; 400 nm and 505 nm, respectively for cathepsin. Calpain activity was 
taken as the difference in fluorescence from homogenate incubated with and without calpain 
inhibitor. Calpain, caspase-3, and cathepsin activities were normalized to total protein 
content and expressed as fluorescence intensity in arbitrary units per mg of protein. 
 Generation of reactive oxygen species in soleus muscle homogenates from WT and 
PlnOE mice was determined as previously described (143) using 2’7’-
dichlorodihydroflurescein-diacetate (DCFH-DA, Invitrogen, Carlsbad, CA) at 37°C. Cellular 
esterases hydrolyze DCFH-DA to the non-fluorescent DCFH, which can then be oxidized by 
a variety of ROS to form highly fluorescent DCF. Fluorescence was measured using a 
SPECTRAmax Gemini XS microplate spectrofluorometer with excitation and emission 
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wavelengths of 490 nm and 525 nm, respectively. Fluorescence intensity was normalized to 
total protein content and expressed as arbitrary units per mg of protein. 
 
Plasma CK analysis. WT and PlnOE mice were anesthetized using somnotol (0.65 mg/kg 
body weight) and blood from the left ventricle was drawn into a heparinized syringe. Blood 
was centrifuged at 5000 g for 8 min and the plasma was decanted and stored at -80°C until 
analysis. CK activity was measured using a kinetic fluorometric assay as previously 
described (145).  
 
Electrical stimulation and muscle contractility measurements. Experiments were 
performed on adult (4-6 month) WT and PlnOE mice. Mice were killed by cervical 
dislocation, and the intact soleus muscles were removed and placed into a bath with 
oxygenated Tyrode solution (95% O2, 5% CO2) containing 121 mM NaCl2, 5 mM KCl, 24 
mM NaHCO3, 1.8 mM CaCl2, 0.4 mM NaH2PO4, 5.5 mM glucose, 0.1 mM EDTA, and 0.5 
mM MgCl2, pH 7.3 (146), and was maintained at 25°C. Muscles were situated between 
flanking platinum electrodes driven by a biphasic stimulator (Model 710B, Aurora Scientific, 
Inc.) and electrically evoked muscle force was assessed across a range of stimulation 
frequencies from 1 to 100 Hz. Data were analyzed using Dynamic Muscle Control Data 
Acquisition software (Aurora Scientific, Inc). Specifically, peak isometric force amplitude 
(mN) and the maximal rates of force development (+dF/dt) and relaxation (-dF/dt) were 
determined during a twitch and across the range of stimulation frequencies. Peak isometric 
force was then normalized to muscle weight (mN/g). 
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Treadmill exercise.  WT and PlnOE mice were assessed for muscle performance by running 
them to exhaustion on an enclosed motorized treadmill. All animals exercised at a running 
speed of 8m/min for 10 min followed by 10 min at 16 m/min and then allowed to reach 
exhaustion at 24 m/min at a 5° incline. 
 
Statistics. All values are presented as means ± standard error.  Statistical significance was set 
to P < 0.05.  Comparisons between WT and PlnOE mice were performed using Students t-
test; however a two-way repeated measures ANOVA was used for force-frequency analysis, 
and when age was included as a factor.  Post-hoc testing was done using Tukey’s HSD.  
Comparisons between healthy controls and human CNM patients were performed using 
Students t-test.   
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3.1 Preface 
This Chapter presents Thesis Study II as the manuscript Diaphragm assessment in mice 
overexpressing phospholamban in slow-twitch type I muscle fibres written in journal article 
style and currently in submission in the open-access journal Brain and Behavior.  Since 
studies on diaphragm and respiratory function in animal models of CNM are limited (147), 
this Chapter assesses diaphragm structure and function in the PlnOE mice.  It was 
hypothesized that the diaphragm muscles, which normally express 10% type I fibres, would 
exhibit similar CNM-like features.   
In addition, in this Chapter, calcineurin, a serine/threonine Ca2+-dependent 
phosphatase, was introduced.  Calcineurin contains a 60 kDa catalytic subunit and 19 kDa 
regulatory subunit (148), and upon Ca2+-calmodulin binding to a region in the catalytic 
subunit, the autoinhibtory domain is ousted from the active cleft thereby increasing 
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calcineurin’s phosphatase activity (149).  The focus on calcineurin in this Chapter was based 
on its effects on stimulating muscle growth and the slow-oxidative fibre type gene program 
[for review see (150)].  To exert its effects, calcineurin dephosphorylates the family of 
transcription factors, nuclear factor of activated T-cells (NFATs), thereby allowing for their 
nuclear translocation and subsequent promotion of genes involved in muscle growth and the 
oxidative phenotype (150, 151).  Of note, calcineurin activation and NFAT nuclear 
localization have been shown to be responsive only to sustained, low-amplitude Ca2+ signals 
rather than high-amplitude Ca2+ transients (152-154).  There are five NFAT members in 
vertebrates, with only NFATc1, NFATc2, NFATc3, and NFATc4 being responsive to 
calcineurin (150, 155-158).  Throughout the literature, NFATc1 has been the predominant 
indicator of calcineurin activation under states of skeletal muscle remodeling, and this 
isoform, specifically, has been shown to promote the genes controlling the expression of 
slows isoform proteins such as myoglobin, troponin I, and MHCI (8, 148, 150, 159-161).   
 Included in this Chapter are the Overview (Section 3.2), Introduction (Section 3.3), 
Material and Methods (Section 3.4), Results (Section 3.5), and Discussion (3.6) of the 
manuscript in the format of this thesis.  Figures (Figures 3.1 to 3.3) and Table 3.1 
corresponding to the Results are located in order at the end of Section 3.5.  The Supplemental 
Material for this article, submitted as Supporting Information is displayed in Appendix B in 
the format of this thesis.  The Supplemental Material includes Supplemental Results 
comprised of Supplemental Figures B1 – B3. 
 
3.2 Overview  
Aims: Phospholamban (PLN) and sarcolipin (SLN) are small inhibitory proteins that regulate 
the sarco(endo)plasmic reticulum Ca2+-ATPase (SERCA) pump.  Previous work from our 
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laboratory revealed that in the soleus and gluteus minimus muscles of mice overexpressing 
PLN (PlnOE), SERCA function was impaired, dynamin 2 (3-5 fold) and SLN (7-9-fold) were 
upregulated, and features of human centronuclear myopathy (CNM) were observed. Here, we 
examined the diaphragm muscles of PlnOE mice, as diaphragm function in mouse models of 
CNM has not been well studied to date.  Methods: Diaphragm muscles from PlnOE and WT 
mice were subjected to histological/histochemical/immunofluorescent staining, Ca2+-ATPase 
and Ca2+ uptake assays, Western blotting, and in vitro electrical stimulation.  Results: Our 
results demonstrate that PLN overexpression reduced SERCA’s apparent affinity for Ca2+ but 
did not reduce maximal SERCA activity or rates of Ca2+ uptake. SLN was upregulated 2.5-
fold whereas no changes in dynamin 2 expression were found. With respect to CNM, we did 
not observe type I fibre predominance, central nuclei, or central aggregation of oxidative 
activity in diaphragm, although type I fibre hypotrophy was present.  Furthermore, in vitro 
contractility assessment of PlnOE diaphragm strips revealed no reductions in force-generating 
capacity, maximal rates of relaxation, or maximal rates of force development.  Conclusions: 
Therefore, the effects of PLN overexpression on skeletal muscle phenotype differ between 
diaphragm and the postural limb muscles, soleus and gluteus minimus. Uncovering the 
mechanisms behind the apparent resistance to CNM in PlnOE diaphragm may aid in the 
development of novel therapeutic strategies.  
 
3.3 Introduction 
Centronuclear myopathies (CNM) are a group of congenital myopathies that, along 
with general muscle weakness, display increased proportion of fibres containing central 
nuclei, type I fibre predominance and hypotrophy, and central aggregation of oxidative 
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activity upon muscle biopsy (62, 64).  Phospholamban (PLN) is a small (52 amino acid) 
protein that physically interacts with and inhibits the sarco(endo)plasmic reticulum Ca2+-
ATPase (SERCA) pump (31).  Recently, we found that the soleus and gluteus minimus 
muscles from mice overexpressing PLN (PlnOE) in their slow-twitch type I skeletal muscle 
fibres had impaired SERCA function and displayed the histopathological features associated 
with human CNM (162).  Based on the appearance of radiating sarcoplasmic strands, type II 
fibre hypertrophy, and endomysial fibrosis, the CNM observed in the PlnOE mice resembles 
human autosomal dominant CNM and, to an extent, RYR1-related and TTN-related CNM 
(67).  
 A recently published review highlighted that although diaphragm and ventilatory 
function have been examined in several murine models of myopathy including Pompe 
disease and Duchenne muscular dystrophy, among other neuromuscular diseases, similar 
reports are not available for animal models of CNM (147).  Murine diaphragm normally 
consists of around 10% type I fibres (163, 164); therefore, in the present study we 
investigated the hypothesis that the diaphragm from PlnOE mice would display impaired 
SERCA function, muscle weakness, and the appearance of the histopathological features 
associated with human CNM. 
 
3.4 Materials and Methods 
Animals and tissue collection  
A total of 15 wild-type (WT; 30.9 ± 1.2 g) and 16 PlnOE (30.7 ± 0.9 g) 4-6 month old 
mice were used in the study.  Animals were housed in an environmentally controlled room 
with a standard 12:12-hour light-dark cycle and allowed access to food and water ad libitum.  
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Mice were sacrificed by cervical dislocation and diaphragm, soleus, and gluteus minimius 
muscles were extracted.  We restricted analyses to the costal regions of the diaphragm 
muscles.  Diaphragm strips were either used for the assessment of SERCA function, 
contractility, or histological/histochemical/immunofluorescence staining.  Nuclear and 
cytosolic fractions from the diaphragm, soleus, and gluteus minmus muscles were extracted 
as previously described (143).  All animal procedures were reviewed and approved by the 
Animal Care Committee of the University of Waterloo and are consistent with the guidelines 
established by the Canadian Council on Animal Care. 
SERCA activity and Ca2+ uptake.   
Ca2+-dependent SERCA activity was assessed in homogenates prepared from mouse 
(WT and PlnOE) diaphragm muscles over Ca2+ concentrations ranging from pCa 7.0 to 4.8 in 
the presence of the Ca2+ ionophore A23187 (Sigma C7522) using a spectrophotometric plate 
reader assay that has been described previously (137).  SERCA activity-pCa curves were 
generated with GraphPad PrismTM by non-linear regression curve fitting using an equation 
for a general cooperative model for substrate activation. Ca2+ uptake was measured in muscle 
homogenates in the presence of the precipitating anion, oxalate, using the fluorescent dye 
Indo-1 and a spectrofluorometer equipped with a monochromator to control the excitation 
wavelength (355 nm) and two photomultiplier tubes to detect emitted light (405 and 485 nm) 
(138).  Rates of Ca2+ uptake were assessed at a free Ca2+ concentration of 1.0µM. 
Antibodies 
 Primary antibodies against SERCA2a (2A7-A1), PLN (2D12), NFATc1 (7A6) and 
dynamin 2 (PA5-19800) were obtained from Pierce Antibodies.  The primary antibody for 
calcineurin was obtained from Milliopore (07-1491).  The primary antibody for SERCA1a 
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(A52) was a kind gift from Dr. David MacLennan (University of Toronto) (139).  The 
primary antibody directed against sarcolipin (SLN) was generated by Lampire Biological 
Laboratories (20).  The primary antibody against α-actin (A4700) was obtained from Sigma 
Aldrich.  The primary antibodies against MHCI (BA-F8), MHCIIa (SC-71), and MHCIIb 
(BF-F3) were obtained from Developmental Studies Hybridoma Bank.  Primary antibodies 
for histone H2B and CuZnSOD were obtained from Upstate Cell Signaling Solutions and 
Stressgen Bioreagents, respectively.  Secondary antibodies for Western blotting, goat anti-
mouse IgG (peroxidase conjugated) and goat anti-rabbit IgG (peroxidase conjugated) were 
obtained from Santa Cruz Biotechnology.  Secondary antibodies for immunofluorescence 
staining, Alexa Fluor 350 anti-mouse IgG2b, Alexa Fluor 488 anti-mouse IgG1, and Alexa 
Fluor 555 anti-mouse IgM, were obtained from Molecular Probes. 
Western blot analysis 
 Western blot analysis was performed to determine expression levels of SERCAs, 
SLN, PLN, and dynamin 2 in the diaphragm muscles from WT and PlnOE mice as previously 
described (162).  In addition, calcineurin expression and NFAT nuclear localization in soleus, 
gluteus minimus, and diaphragm muscles were assessed.  Electrophoretically separated 
proteins were transferred onto 0.2 µm polyvinylidene difluoride (PVDF) membranes (PLN, 
SERCAs, dynamin 2, NFATc, calcineurin) or nitrocellulose membranes (SLN).  Membranes 
were then immunoprobed with their corresponding primary antibodies and thereafter, were 
immunoprobed with horseradish peroxidase-conjugated secondary antibodies.  Antigen-
antibody complexes were detected by SuperSignal West FemtoTM substrate (Pierce, Thermo 
Fisher Scientific Inc.) for SLN; Luminata ForteTM (Millipore, MA, USA) for PLN and 
SERCA2a; and ECL Western Blot Substrate (BioVision, MA, USA) for SERCA1a, NFAT, 
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calcineurin, and dynamin 2. Quantitation of optical densities was performed using GeneTools 
(Syngene, MD, USA) and were normalized to total protein or α-actin. 
Histological, histochemical, and Immunofluorescence staining 
Diaphragm muscles from WT and PlnOE mice were removed and embedded in O.C.T. 
compound (Tissue-Tek), frozen in liquid nitrogen-cooled isopentane, stored at -80°C, and cut 
into 10 µm thick cryosections with a cryostat (Thermo Electronic) maintained at -20°C.  
Haematoxylin and eosin (H&E) staining along with stains for succinate dehydrogenase 
(SDH) activity were performed.  Images were acquired with a brightfield Nikon microscope 
linked to a PixeLink digital camera and quantified with Image-Pro PLUS analysis software 
and ImageJ software.  Immunofluorescence analysis of MHC expression was previously 
described (20, 96, 143) and performed with primary antibodies against MHCI, MHCIIa, and 
MHCIIb. Slides were visualized with an Axio Observer Z1 fluorescent microscope equipped 
with standard red/green/blue filters, an AxioCam HRm camera, and AxioVision software 
(Carl Ziess).  Quantification of fibres and cross-sectional area (CSA) was performed using 
ImageJ software. 
In vitro diaphragm contractile assessment 
Diaphragm strips were isolated and immediately placed into a bath of oxygenated Tyrode’s 
solution (95% O2, 5% CO2) containing 121 mM NaCl2, 5 mM KCl, 24 mM NaHCO3, 1.8 
mM CaCl2, 0.4 mM NaH2PO4, 5.5 mM glucose, 0.1 mM EDTA, and 0.5 mM MgCl2, pH 7.3 
(3) and were maintained at 25°C.  Muscle strips were situated between flanking platinum 
electrodes driven by a biphasic simulator (Model 710B, Aurora Scientific, Inc.) and 
electrically evoked muscle force was assessed across a range of stimulation frequencies from 
1 to 100 Hz at optimum length for force production. Data were analyzed using Dynamic 
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Muscle Control Data Acquisition software (Aurora Scientific, Inc).  Specifically, peak 
isometric force amplitude (mN) and the maximal rates of force development (+dF/dt) and 
relaxation (-dF/dt) were determined across the range of stimulation frequencies.  Peak 
isometric force was then normalized to the calculated CSA of the muscle strip (m / l*d) 
where m is the muscle mass, l is the length, and d is mammalian skeletal muscle density (1.06 
mg/mm3) (165).  A fatigue protocol (70 Hz for 350 ms every 2 seconds for 5 min) was 
performed to determine the number of contractions required to reduce force to 60% of the 
force of the initial 70 Hz contraction.   
Statistics 
All values are presented as means ± standard error.  Statistical significance was set to P < 
0.05.  Most comparisons between WT and PlnOE mice were performed using unpaired 
Students t-tests; however a two-way repeated measures ANOVA was used for force-
frequency analysis of peak isometric force. 
 
3.5 Results 
SERCA function and expression of Ca2+handling proteins 
 Phospholamban overexpression was evident in the diaphragm homogenates from 
PlnOE mice as only 2.5 µg of total protein was required to detect PLN compared to the 25 µg 
required in the WT diaphragm (Figure 3.1A).  PLN overexpression in diaphragm muscles led 
to a rightward shift in the activity-pCa curves (Figure 3.1B) and a significant increase in KCa 
compared to WT (Table 3.1, P = 0.02).  However, maximal SERCA activity was not 
significantly different between genotypes (Table 3.1, P = 0.45). We did observe lower rates 
of Ca2+ uptake in the PlnOE diaphragm homogenates compared to WT (Figure 3.1C), 
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however this only approached statistical significance (P = 0.08). Western blot analysis 
revealed no differences in the expression of SERCA1a (Figure 3.1D) or SERCA2a (Figure 
3.1E) between WT and PlnOE mice.  SLN expression was found to be upregulated nearly 2.5-
fold in the diaphragm homogenates from PlnOE mice compared to WT (Figure 3.1F, P < 
0.001). 
Assessment of CNM features in diaphragm muscles from PlnOE mice 
 H&E and SDH staining of diaphragm cryosections revealed no elevations in the 
percentage of fibres showing central nuclei (WT, 1.2 ± 0.2% vs. PlnOE, 1.2 ± 0.3%, P  = 
0.86) or evidence of central aggregation of oxidative activity in the PlnOE diaphragm (Figure 
3.2A and B).  A significant reduction in the percentage of type I fibres was found (Figure 
3.2C and D, P < 0.001) and although individually the type II fibres (IIA, IIX, IIB) were not 
different between genotypes, there was a significant increase in the collective percentage of 
all type II fibres in the PlnOE diaphragm (WT, 86.5 ± 0.7 % vs. PlnOE, 95.0 ± 1.8%, P < 
0.001).  Furthermore, we observed a significant reduction (P < 0.001) in type I fibre CSA and 
a significant increase in type IIA (P = 0.01), type IIX (P < 0.001), and type IIB (P < 0.001) 
CSA in the PlnOE diaphragm (Figure 3.2E).  Western blotting for dynamin 2 expression in 
diaphragm revealed no significant differences between WT and PlnOE mice (Figure 3.2F, P = 
0.87).  
Diaphragm contractility 
 Representative twitch and tetanic (100 Hz) force tracings illustrate no significant 
differences in absolute force production between WT and PlnOE diaphragm strips (Figure 
3.3A and B).  In addition, twitch kinetics were unaltered with no differences in maximal rates 
of relaxation (-dF/dt: WT, 0.35 ± 0.017 vs. PlnOE, 0.35 ± 0.04, mN/ms, P = 0.89) or maximal 
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rates of force development (+dF/dt: WT, 5.04 ± 0.51 vs. PlnOE, 5.87 ± 0.68 mN/mm2/ms, P = 
0.34).  Interestingly, across submaximal and maximal frequencies, PlnOE diaphragm strips 
generated more specific force compared to WT but the difference was not significant (Figure 
3.3C, P = 0.15).  Finally, in response to a fatiguing stimulation protocol, PlnOE diaphragms 
required on average 100 ± 8 contractions to reach 60% maximum isometric force at 70 Hz 
compared to 132 ± 19 in the WT diaphragm; however, this difference was not statistically 
significant (Figure 3.3D, P = 0.16). 
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Figure 3.1.  SERCA function in diaphragm muscles in PlnOE mice at 4-6 months of age.  A: Western blotting 
for PLN in WT and PlnOE mice from diaphragm muscle homogenates.  For WT mice, 25 µg of total protein was 
loaded whereas only 2.5 µg was required for PlnOE mice to detect PLN protein.  B: Ca2+-ATPase activity-pCa 
curves in WT (n = 6) and PlnOE mice (n = 6) in the presence of the Ca2+ ionophore.  C: Ca2+ uptake assessed in 
diaphragm muscles from WT (n = 4) and PlnOE mice (n = 5). Western blotting for SERCA1a (D), SERCA2a (E), 
and SLN (F) in soleus from WT and PlnOE mice (n = 4-5 per genotype).  Total protein loaded was 1 µg, 4 µg, 
and 25 µg for SERCA1a, SERCA2a, and SLN, respectively.  Actin was used as a loading control and all values 
are expressed relative to WT.  *P < 0.05 versus WT using Student’s t-test.  All values are presented as mean ± 
standard error.      
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Figure 3.2.  Diaphragm muscles from PlnOE mice do not display CNM.  Representative diaphragm cryosections 
from PlnOE and WT mice after H&E staining (A), SDH staining (B), immunofluorescence staining for fibre type 
analysis (C). Cross sections were stained with MHC antibodies to identify type I (blue), type IIA (green), type 
IIB (red), and type IIX (unstained).  D: Quantitative analysis of fibre type distribution in diaphragm muscles 
from WT and PlnOE mice at 4-6 months of age.  E: Quantitative analysis of fibre type cross-sectional area 
(CSA) in diaphragm muscles from WT and PlnOE mice at 4-6 months of age.  F: Dynamin 2 expression in 
diaphragm homogenates from WT and PlnOE mice (n = 6 per genotype). Total protein loaded for dynamin 2 was 
7.5 µg.  *P < 0.05 versus WT using Student’s t-test.  All values are presented as mean ± standard error.  Scale 
bars in A-C are set to 50 µm.         
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Figure 3.3.  Diaphragm contractility in PlnOE and WT mice at 4-6 months of age (n = 6 per genotype).  A: 
Representative twitch (A) and tetanic (B) force tracings from WT and PlnOE diaphragm strips.  C: Force-
frequency curve analysis in diaphragm strips from WT and PlnOE mice.  D: Number of contractions to reduce 
force to 60% of initial isometric force when isolated diaphragm strips underwent a fatiguing stimulation 
protocol (70 Hz for 350 ms every 2 seconds for 5 min). 
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Table 3.1.  SERCA activity in mouse diaphragm muscles from WT and PlnOE mice at 4-6 
months of age. 
Genotype Vmax KCa ΔKCa 
   WT 409.1 ± 29.8 5.98 ± 0.02 - 
   PlnOE 382.1 ± 17.3 5.90 ± 0.02* 0.08 
Values are means ± standard error.  Homogenates were isolated from WT (n = 6) and PlnOE 
(n = 5) mouse diaphragm muscles and were analyzed for Ca2+-ATPase activity over Ca2+ 
concentrations ranging from pCa 7 to pCa 4.8 to obtain KCa.  KCa is the Ca2+ concentration 
required to attain the half-maximal Ca2+-ATPase activity rate and is expressed in pCa units 
(negative logarithm of [Ca2+]). *Significantly different from WT using Student’s t-test, P < 
0.05. 
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3.6 Discussion 
Studies examining diaphragm function in animal models of CNM are limited as 
recently highlighted in a review by Smith, Goddard, and Childers (147).  However, in a study 
published in the same year, Cowling and colleagues showed histopathological abnormalities 
with more atrophic fibres containing mislocalized nuclei in the diaphragm muscles from 
mtm1-/y mice (119), a mouse model which accurately recapitulates human X-linked 
myotubular myopathy (166).  Correspondingly, mtm1-/y mice have a very short lifespan (6-14 
weeks) (166) which is consistent with the severe respiratory complications often leading to 
early death reported in human cases of myotubular myopathy (110).  We have recently 
reported that the PlnOE mouse histopathologically resembles human autosomal dominant 
CNM (162), which, in contrast to myotubular myopathy, is generally less severe, and patients 
often have a normal lifespan with very few respiratory complications (64, 110, 113).  Here, 
we have shown that the PlnOE diaphragm exhibits type I fibre hypotrophy but does not 
display type I fibre predominance, increased central nuclei, central aggregation of oxidative 
activity or muscle weakness.  In agreement with the differences in disease severity found in 
the diaphragm between mouse models, the PlnOE mice live much longer than mtm1-/y mice, 
albeit, shorter than their WT littermates (Supplementary Figure B1).  
Previous studies have shown that elevated dynamin 2 in skeletal muscle can lead to 
features of CNM (90, 120) while reducing its expression can improve muscle function and 
alleviate murine CNM pathology (119).  Since, dynamin 2 is upregulated 3-5 fold in the 
PlnOE soleus and gluteus minimus (162) but not diaphragm (Figure 3.2F), it is possible that 
differences in dynamin 2 expression could explain the lack of CNM phenotype in the PlnOE 
diaphragm.  How PLN overexpression and impaired SERCA function leads to increased 
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dynamin 2 in the affected muscles is unclear.  Furthermore, although dynamin 2 has been 
implicated in the pathology of murine CNM, its role in human CNM is less established since 
we have recently observed a 35% reduction in its expression in muscle biopsies from CNM 
patients (162) while others have seen a 2-fold increase in patients with myotubular myopathy 
(119).     
Our findings of minimal histopathological defects within the PlnOE diaphragm despite 
PLN overexpression may argue against a potential role of elevated PLN in CNM pathology.  
An important difference between diaphragm and the postural limb muscles in the PlnOE 
model is that SERCA function was not impaired in the diaphragm to the extent we observed 
in the soleus and gluteus minimus muscles (162).  Although we did observe a reduction in 
SERCA’s apparent affinity for Ca2+ as indicated by a rightward shift in the activity-pCa 
curves and a significantly higher KCa, maximal SERCA activity was not reduced in the PlnOE 
diaphragm compared to WT.  Furthermore, rates of Ca2+ uptake were only trending to be 
lower in the PlnOE diaphragm compared to WT (-15%), whereas Ca2+ uptake measured at the 
same pCa was significantly reduced in the PlnOE soleus (-75%) and gluteus minimus muscles 
(-25%) (Supplementary Figure B2).  Combined with the unaltered maximal rates of 
relaxation in the PlnOE diaphragm strips, collectively, these results suggest that the relatively 
modest impairment in SERCA function in the PlnOE diaphragm may explain the lack of 
CNM histopathology in that muscle.   
Differences in the severity of SERCA dysfunction across skeletal muscles in the 
PlnOE mouse may also be due to differences in SLN expression.  SLN is a well-known 
structural and functional homolog of PLN (20, 26, 28, 167) and, together, they have been 
shown to form a superinhibitory ternary complex with SERCA that not only reduces 
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SERCA’s affinity for Ca2+, but also the maximal rates of SERCA activity (28) and Ca2+ 
uptake (33).  Interestingly, compared to the soleus and gluteus minimus, where SLN protein 
was upregulated 9-fold and 7-fold, respectively (162), SLN in the diaphragm was only 
elevated 2.5-fold. Upregulated SLN protein and/or mRNA is becoming widely known as a 
common feature in many myopathies (69, 89-91) and findings in the mdx mouse and mdx-
utrophin double knockout model suggest that its expression may be directly proportional to 
disease severity (80).  Similarly, SLN may follow disease severity in the PlnOE mouse since 
the myopathy in the diaphragm, where only abnormalities in fibre CSA were evident, is far 
less severe than that found in the PlnOE soleus and gluteus minimus, where all 
histopathological signs of CNM with additional endomysial fibrosis and core-like aspects 
were evident (162).  However, the role that SLN plays in the PlnOE mouse model of CNM or 
any other animal model of myopathy remains unknown.   
 Another potential explanation for the differences in SERCA function across the 
skeletal muscles may be that the healthy murine diaphragm comprises only 10% type I fibres 
and the PlnOE diaphragm only consists of 4% type I fibres, which overexpress PLN, 
compared to the 99% and 50% previously found in the PlnOE soleus and gluteus minimus 
muscles, respectively (162).  In this model, it is possible that there may be a threshold 
percentage of type 1 fibres required to see impairments in SERCA and the concomitant 
muscle pathology. We suspect that in compensation for the type I fibre hypotrophy, the type 
II fibres of the postural soleus and gluteus minimus muscles exhibit greater load-bearing 
activity thereby leading to the sustained elevations of [Ca2+]i required for calcineurin 
activation.  Calcineurin signaling is known to promote both the slow-oxidative fibre 
phenotype (152, 154, 168) and myofibre hypertrophy (155, 169). Similar to a previous study 
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where calcineurin expression was found to be higher in the PlnOE soleus compared with WT 
(41), our findings indicate greater calcineurin expression and NFAT nuclear content in the 
soleus and gluteus minimus muscles, but not in the PlnOE diaphragm (Supplementary Figure 
B3).  Moreover, calsarcin-2, an endogenous calcineurin inhibitor, is known to be highly 
expressed in diaphragm muscles (170).  Thus, the inability to promote calcineurin-signaling 
may help to explain both the lower percent of type I fibres and the apparent increased 
susceptibility to muscle fatigue in the PlnOE diaphragm compared with WT.  Of note, 
respiratory muscles do not undergo transformation, particularly with respect to MHC isoform, 
due to training and inactivity in the same way as limb muscle fibres (171), which suggests 
that the reduced type I and increased type II fibre population represents a selective loss or 
underdevelopment of type I fibres due to PLN overexpression rather than a shift from slow-
to-fast.  Finally, type II fibre hypertrophy without calcineurin activation in the PlnOE 
diaphragm may be explained by other Ca2+-dependent systems, like calmodulin-dependent 
kinase II which is also important for adaptive muscle growth (172).  Overall, the decreased 
percentage of type I fibres along with an increase in type II fibre CSA could be viewed as an 
adaptive response that helps maintain or even enhance force production and limit the CNM 
phenotype in the PlnOE diaphragm (Figure 3.3C).  This innate response may represent a novel 
therapeutic strategy combatting CNM and other congenital myopathies such as central cores 
since these are all type I fibre-related myopathies (62).   
 In summary, our results indicate that the PlnOE diaphragm, compared with soleus and 
gluteus minimus, is generally more resistant to the CNM phenotype.  Although the bases for 
these muscle differences are unclear, understanding the underlying mechanisms may lead to 
the generation of novel therapeutic strategies.  Our findings here point to differences in SLN 
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expression and type I fibre distribution as potential contributing factors, and future studies 
will determine their impact. 
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4.1 Preface 
Prior to this study, the question asking why SLN is upregulated across many conditions of 
muscle disease and damage had long remained unanswered.  Several results within the 
literature and from this thesis led to the initial hypothesis that removing this upregulation of 
SLN may actually be beneficial for muscle function and integrity.  First, SLN is a well-
known inhibitor of the SERCA pump (28, 32, 33) and improving SERCA function in 
muscular dystrophy either through overexpression (58, 82, 83) or increased protection from 
cytotoxic damage via greater heat shock protein 72 interactions (57) has shown to increase 
muscle force producing capabilities and mitigate the dystrophic pathology by normalizing 
Ca2+ regulation in the muscle.  Second, the increase in SLN content seems to progress with 
disease severity as shown in mdx and mdx/Utr-/- mice (88), and in the PlnOE mice as 
highlighted in Thesis Study II.  Third, acute overexpression of SLN in rat soleus muscle was 
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shown to cause drastic impairments in force production (49).  Thus, with Ca2+ dysregulation 
being a main pathological defect in many myopathies, it is easy to speculate that removing 
SLN and improving SERCA’s ability to regulate [Ca2+]i could benefit muscle function and 
structure. 
Importantly, while [Ca2+]i overload may be a pathogenic factor, other Ca2+-dependent 
processes are required in diseased states to elicit necessary adaptive responses.  One, in 
particular, is calcineurin signaling, which was introduced in Thesis Study II.  In muscular 
dystrophy, calcineurin activation is required to promote the slow-oxidative fibre phenotype 
(154, 155, 173), which is considered a viable therapeutic strategy (174-177).  In fact, 
calcineurin activation has been shown to alleviate mdx pathology by promoting the 
expression of the dystrophin homolog utrophin and by enhancing the muscle’s regenerative 
capacity (175, 178-180).  Conversely, in a previous study, it was shown that inhibiting 
calcineurin activation worsens the dystrophic pathology in mdx mice (177).  In addition, 
calcineurin activation can increase the expression of PGC-1α (181), which has also been 
shown to effectively combat muscular dystrophy and muscle atrophy (174, 182).  Aside from 
diseased states, pharmacological inhibition of calcineurin results in a failure of myofibres to 
hypertrophy in response to mechanical overload stimulus (155) or insulin-like growth factor 
treatment (156, 169), and also prevents myoblast differentiation during muscle development 
(183).  Altogether, these findings demonstrate the importance of Ca2+ signaling through 
calcineurin in promoting overall muscle health and countering disease pathology.  
Interestingly, SLN has been shown to stimulate calcineurin signaling to enhance oxidative 
capacity and combat obesity (184). 
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This Chapter adds further support of calcineurin’s role in muscle health and SLN’s 
role in stimulating calcineurin by using the PlnOE mouse, two additional models of myopathy 
(tenotomy and mdx), and one model of muscle growth and remodeling (mechanical overload).  
Chapter 4 presents Thesis Study III as the manuscript Sarcolipin is vital for muscle growth 
and remodeling and countering disease pathology written in journal article style and 
currently in submission in Journal of Biological Chemistry.  Included in this Chapter are the 
Overview (Section 4.2), Introduction (Section 4.3), Materials and Methods (Section 4.4), and 
the Results and Discussion (Section 4.5) of the manuscript in the format of this thesis.  
Figures 4.1 to 4.8 and Tables 4.1 and 4.2 are located in order at the end of Section 4.5.        
 
4.2 Overview 
Sarcolipin (SLN) is an important metabolic regulator in muscle that is recruited after 
high-fat feeding to uncouple the sarco(endo)plasmic reticulum Ca2+-ATPase (SERCA) pump, 
increase energy expenditure, and combat obesity.  Similar to high-fat feeding, SLN 
expression in skeletal muscle is also highly upregulated across various myopathic states, 
however to date, the physiological significance of this response remains unknown.  Here, we 
used three different mouse models of disease/damage (centronuclear myopathy, tenotomy, 
and muscular dystrophy), and one mouse model of compensatory hypertrophy (mechanical 
overload), and found that, in the absence of Sln, myofibers were consistently smaller, had a 
faster fiber phenotype, and, in the case of muscular dystrophy, exhibited greater muscle 
degeneration.  Thus, SLN upregulation in muscle not only combats obesity, but also muscle 
disease, and is an adaptive response that is necessary for muscle growth and remodelling and 
may provide a novel therapeutic strategy to counter a number of neuromuscular disorders. 
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4.3 Introduction 
Sarcolipin (SLN) is a small regulator of the sarco(endo)plasmic reticulum Ca2+-
ATPase (SERCA) pump that has garnered a tremendous amount of attention in the field of 
muscle physiology and metabolism for its role in countering obesity (99).  Specifically, we 
and others have found that under conditions of high-fat feeding, SLN expression in skeletal 
muscles increases 3-5-fold (2, 44) and combats obesity by uncoupling SERCA-mediated 
Ca2+ transport from ATP hydrolysis (3).  As a result, scientists are now beginning to examine 
the role of SLN in human obesity (185).  In addition to high-fat feeding, SLN expression is 
highly upregulated across a variety of muscle diseases and conditions (69, 87-89, 91-93, 186), 
however the physiological significance of this change in SLN expression has yet to be 
determined.  Thus, the objective of this study was to determine the role of SLN in muscle 
disease and damage. 
 
4.4 Materials and Methods 
Mice.  The PlnOE and SlnKO mice have been described previously(21, 187) and the mdx mice 
were purchased from The Jackson Laboratory (001801, Maine, USA).  C57BL/6J 
PlnWT/SlnWT, PlnOE/SlnWT, PlnOE/SlnKO mice were generated by backcrossing heterozygous 
male FVB/N PlnOE animals with either C57BL6/J SlnKO or SlnWT littermate females for 6 
generations.  As a result, all Pln overexpressing mice were heterozygous, and the 
PlnWT/SlnWT and PlnOE/SlnWT littermate mice were cousins to the PlnOE/SlnKO mice. To 
generate the mdx/SlnKO and mdx colonies, homozygous mdx females (XmdxXmdx) were crossed 
with homozygous SlnKO males (Sln-/-).  The resulting F1 progeny were hemizygous mdx 
males (XmdxY) and heterozygous mdx females (XmdxX) that were all heterozygous for Sln 
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deletion (Sln-/+).  After crossing the hemizgous mdx females with heterozygous mdx males 
from F1, we selected the founders for the two separate lines used in this study.  First, the 
mdx/SlnKO colony was produced by breeding F2 hemizygous mdx females with F2 
dystrophin-positive males, and both sires and dams were homozygous negative for Sln (Sln-/-).  
Second, the mdx/SlnWT (mdx) colony was produced by breeding F2 hemizygous mdx females 
with F2 dystrophin-positive males, and both sires and dams were homozygous positive for 
Sln (Sln+/+).  As a result, the mdx and mdx/SlnKO mice were cousins at best and were on a 
C57BL6/J:C57BL/10 background.  All animals used in the study were adult mice ranging 
from 3-6 months of age.  Animals were housed in an environmentally controlled room with a 
standard 12:12-hour light-dark cycle and allowed access to food and water ad libitum.  All 
animal procedures were reviewed and approved by the Animal Care Committee of the 
University of Waterloo and are consistent with the guidelines established by the Canadian 
Council on Animal Care.   
 
Simultaneous plantaris mechanical overload and soleus muscle tenotomy. To 
mechanically overload the plantaris muscles, WT and SlnKO mice (3-4 months) were first 
anaesthetized with 2% isofluorane in a precision vaporizer.  Next, the soleus and 
gastrocnemius tendons were transected as previously described(188) and mice were left for 
two weeks in individually housed cages to adapt.  Subsequently, the mice were killed by 
cervical dislocation and the plantaris (sham and overload) and soleus (sham and tenotomized) 
muscles were isolated and either homogenized in homogenizing buffer (250 mM sucrose, 5 
mM HEPES, 0.2 mM PMSF, 0.2% [w/v] NaN3) or embedded in O.C.T. compound (Tissue-
Tek) frozen in liquid nitrogen-cooled isopentane then stored at -80°C until further analysis. 
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Cardiotoxin injury. Acute myotoxic injury was applied to anaesthetized (2% isofluorane in 
a precision vaporizer) WT and SlnKO mice (3-4 months) by injecting 10 µM cardiotoxin 
(Sigma-Aldrich) dissolved in sterile saline into the tibialis anterior (TA) muscles.  At days 7, 
14, or 21 post-injection, animals were killed by cervical dislocation and their TA muscles 
were extracted and either homogenized or embedded in O.C.T. compound frozen in liquid 
nitrogen-cooled isopentane then stored at -80°C until further analysis.   
 
SERCA function. Ca2+-dependent SERCA activity was assessed in soleus homogenates over 
Ca2+ concentrations ranging from pCa 7.2 to 5.4 in the presence of the Ca2+ ionophore 
A23187 (Sigma C7522) using a spectrophotometric plate reader assay as previously 
described(137).  Maximal SERCA activity was taken from the raw data and SERCA activity-
pCa curves were generated with GraphPad PrismTM by non-linear regression curve fitting 
using an equation for a general cooperative model for substrate activation.  Ca2+ uptake was 
measured at a free [Ca2+] of 1500 nM in soleus homogenates in the presence of precipitating 
anion, oxalate, using the fluorescent dye Indo-1 and a spectrofluorometer equipped with 
dual-emission monochromators(138). 
 
Daily food intake and activity. Daily food consumption (g/day) and cage activity were 
measured using a comprehensive laboratory animal monitoring system (CLAMS; Oxymax 
series; Columbus Instruments, Columbus, OH, USA) as previously described(2).  This 
system is equipped with a feed scale for monitoring mass of food consumed, as well as X- 
and Z-axes infrared photocell detectors that allow for monitoring ambulatory activity (when 2 
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adjacent x-axis beams were broken in succession) and total cage activity.  Mice were placed 
in the CLAMS for a 3-day period for 3 separate trials and had free access to food and water. 
 
Antibodies. Primary antibodies against PLN (2D12), phosphorylated-NFAT (PA5-38301), 
and total NFAT (MA3-024) were obtained from Pierce Antibodies.  The primary antibody 
directed against SLN was generated by Lampire Biological Laboratories(20).  The utrophin 
(610896) antibody was purchased from BD Biosciences.  LC3B (2775) and p62 (GP62-C) 
antibodies were obtained from Cell Signaling Technology and Progen Biotechnik, 
respectively.  The primary antibody against actin (A2066) was obtained from Sigma Aldrich. 
The primary antibodies against MHCI (BA-F8), MHCIIa (SC-71), and MHCIIb (BF-F3) 
were obtained from Developmental Studies Hybridoma Bank.  Secondary antibodies for 
western blotting, goat anti-mouse IgG (peroxidase conjugated) and goat anti-rabbit IgG 
(peroxidase conjugated) were obtained from Santa Cruz Biotechnology.  Secondary 
antibodies for immunofluorescence staining, Alexa Fluor 350 anti-mouse IgG2b, Alexa Fluor 
488 anti-mouse IgG1, and Alexa Fluor 555 anti-mouse IgM, were obtained from Molecular 
Probes. 
 
Western blotting. Western blotting was performed to determine expression levels of SLN, 
PLN, phosphorylated-NFAT, total NFAT, utrophin, LC3, and p62.  Solubilized proteins from 
tissue homogenates, were separated using tricine based SDS-PAGE (13% total acrylamide 
for PLN and SLN) or standard SDS-PAGE (6% total acrylamide for utrophin; 7.5% total 
acrylamide for phosphorylated-NFAT, total NFAT; 12% total acrylamide for p62 and LC3).  
Separated proteins were then transferred onto 0.2 µm PVDF membranes for all analyses 
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except for SLN, which utilized nitrocellulose membranes.  Membranes were then 
immunoprobed with their corresponding primary antibodies and subsequently immunoprobed 
with horseradish peroxidase-conjugated secondary antibodies.  Antigen-antibody complexes 
were detected by SuperSignal West FemtoTM substrate (Pierce, Thermo Fisher Scientific 
Inc.) for SLN, utrophin, and phosphorylated NFAT; Luminata ForteTM for and PLN; and 
ECL Western Blot Substrate for total NFAT, LC3 and p62. Quantification of optical 
densities was performed using GeneTools (Syngene, MD, USA) and values were normalized 
to total protein after ponceau staining or actin. 
 
Histological, histochemical, and immunofluorescent staining. Soleus, plantaris, and 
diaphragm muscles embedded in O.C.T. compound were cut into 10 µm thick cryosections 
with a cryostat (Thermo Electronic) maintained at -20°C.  Histological staining included 
H&E and Van Gieson and histochemical staining included succinate dehydrogenase (SDH) 
activity.  Images were acquired with a brightfield Nikon microscope linked to a PixeLink 
digital camera and quantified with ImageJ software.  Immunofluorescence analysis of MHC 
expression was previously described(96) and performed with primary antibodies against 
MHCI, MHCIIa, and MHCIIb.  Slides were visualized with an Axio Observer Z1 fluorescent 
microscope equipped with standard red, green, blue filters, an AxioCam HRm camera, and 
AxioVision software (Carl Ziess).  Quantification of fiber distribution and cross-sectional 
area (CSA) was performed using imageJ software.  The minimal Feret’s diameter, which is 
the minimum distance of parallel tangents at opposing borders of the muscle fiber(189), was 
quantified using H&E-stained sections with imageJ software.   
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Proteolytic activity. Caspase-3 and cathepsin-B/L activity were determined in soleus muscle 
homogenates using the substrates Ac-DEVD-AMC (Alexis Biochemicals) and z-FR-AFC 
(Enzo Life Sciences), respectively, whereas calpain and 20S proteasome activity were 
determined using Suc-LLVY-AMC (Enzo-Life Sciences)(187). These fluorogenic substrates 
are weakly fluorescent but yield highly fluorescent products following proteolytic cleavage 
by their respective proteases.  Fluorescence was measured using a SPECTRAmax Gemini 
XS microplate spectrofluorometer (Molecular Devices, Sunnyvale, CA) with excitation and 
emission wavelengths of 360 nm and 440 nm (caspase-3), 380 nm and 460 nm (calpain and 
20S proteasome), or 400 nm and 505 nm (cathepsin), respectively. To distinguish between 
calpain and 20S proteasome activity, the specific inhibitors Z-Leu-Leu-CHO (calpain; Enzo-
Life Sciences) and epoxomicin (20S proteasome; Cayman Chemical) were incubated and the 
difference in fluorescence from homogenates incubated with and without the respective 
inhibitors was measured. All proteolytic activities were normalized to total protein content 
and expressed as fluorescence intensity in arbitrary units per mg of protein. 
 
Serum creatine kinase analysis. mdx and mdx/SlnKO mice were anesthetized using somnotol 
(0.65 mg/kg body weight) and blood from the left ventricle was drawn into a syringe. Blood 
was centrifuged at 5,000 g for 8 min and the serum was decanted and stored at -80°C until 
analysis. CK activity was measured using a kinetic fluorometric assay as previously 
described (145).  
 
Electrical stimulation and muscle contractility measurements. PlnWT/SlnWT, PlnOE/SlnWT, 
and PlnOE/SlnKO mice were killed by cervical dislocation, and the intact soleus muscles were 
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removed and placed into a bath with oxygenated Tyrode solution (95% O2, 5% CO2) 
containing 121 mM NaCl2, 5 mM KCl, 24 mM NaHCO3, 1.8 mM CaCl2, 0.4 mM NaH2PO4, 
5.5 mM glucose, 0.1 mM EDTA, and 0.5 mM MgCl2, pH 7.3(146), and was maintained at 
25°C.  Muscles were situated between two platinum electrodes and force was electrically 
evoked and assessed across a range of stimulation frequencies from 1 to 100 Hz using a 
biphasic stimulator (Model 710B, Aurora Scientific, Inc.).  Peak isometric force amplitude 
(mN) was analyzed using Dynamic Muscle Control Data Acquisition software (Aurora 
Scientific, Inc) and then normalized to muscle weight (mN/g). 
 
Electron Microscopy. To examine the triad structures in the soleus muscles of PlnWT/SlnWT, 
PlnOE/SlnWT, and PlnOE/SlnKO mice we performed transmission electron microscopy (TEM).  
Briefly, muscle samples (1 cubic mm each) were fixed immediately, in 2.5% glutaraldehyde 
(EM grade) in 0.2M phosphate buffer (pH 7.4) overnight at 4°C.  Subsequently, samples 
were postfixed in 1% osmium tetraoxide in the same buffer, dehydrated in a graded acetone 
series, and embedded in an epon-aldarite resin.  Semithin sections (0.74 µm) were stained 
with toluidine blue and placed on a hot plate for 30 seconds to determine orientation of 
samples.  Ultrathin longitudinal sections (90 nm) were cut on a Leica Reichart Ultracut E 
microtome, double contrasted with uranyl acetate (50% in methanol) and lead citrate (0.4% 
w/v in boiled H2O), and viewed in a CM 10 Philips TEM.  Sarcoplasmic reticulum areas 
were quantified using imageJ. 
 
Statistics. All values are presented as means ± standard error (SEM).  Statistical significance 
was set to P < 0.05.  Comparisons between PlnWT/SlnWT, PlnOE/SlnWT, and PlnOE/SlnKO mice 
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were performed using a one-way ANOVA with a Tukey’s post-hoc test; however a two-way 
repeated ANOVA with a Tukey’s post-hoc test was used for force-frequency analysis.  For 
mechanical overload and tenotomy experiments, we examined the effects of overload and 
tenotomy (vs. sham) separately in WT mice and SlnKO mice.  These planned comparisons on 
stratified datasets were executed using a two-way repeated measures ANOVA for myofiber 
CSA, a non-parametric two-sample Kolmogorov-Smirnov test for fiber CSA frequency 
distribution, and paired t-tests (one-tailed) for fiber type distribution and p-NFAT/NFAT.  
Comparisons between mdx and mdx/SlnKO mice were performed using either a Student’s t-
test or two-way ANOVA.  Finally, comparisons between cardiotoxin-injured WT and SlnKO 
mice at days 7, 14, and 21 were performed using a Student’s t-test at each day.  Any 
significant differences in standard deviations amongst our datasets were adjusted for using 
Welch’s corrections. 
 
4.5 Results and Discussion 
Phospholamban (PLN) is a well-known inhibitor of SERCA pumps and its 
overexpression in mouse slow-twitch type I skeletal muscle fibers (PlnOE) causes impaired 
SERCA function, soleus muscle atrophy, centronuclear myopathy (CNM)-like phenotype, 
and a 7-9-fold upregulation of SLN protein (187).  To examine the role of SLN in muscle 
myopathy, we first crossed PlnOE mice with SlnKO mice.  Since forced over-expression of 
SLN in skeletal muscle represses SR Ca2+ uptake and impairs contractile function (49), we 
hypothesized that removing Sln would improve SERCA function (26) and alleviate the 
muscle weakness and myopathy observed in the PlnOE mice.  Contrary to our hypothesis, and 
despite 8-fold higher SLN in PlnOE/SlnWT compared with PlnWT/SlnWT mice (P = 0.005, Fig. 
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4.1A), rates of Ca2+ uptake (-18-20%) and SERCA’s apparent affinity for Ca2+ (KCa) were 
similarly reduced in the PlnOE/SlnWT and PlnOE/SlnKO mice compared with PlnWT/SlnWT mice, 
and there were no differences in maximal SERCA activity (Vmax) (Fig. 4.1B-C and Table 4.1). 
Corresponding with the lack of improvement in SERCA function, Sln deletion did not 
mitigate CNM pathology since the three typical hallmarks (central nuclei, type I fiber 
predominance and hypotrophy, and central aggregation of oxidative activity) (64) and 
additional ultrastructural/histopathological features of triad disruption (111, 128), endomysial 
fibrosis and core-like aspects (187) were found to a similar degree and, perhaps, even greater 
in PlnOE/SlnKO mice compared with PlnOE/SlnWT (Fig. 4.1D-L).  Indeed, we found evidence 
that Sln deletion worsened the PlnOE-induced myopathy by exacerbating soleus muscle 
atrophy and weakness, revealed by significant reductions in the soleus:body weight ratio and 
mass-specific force at submaximal and maximal frequencies (50-100 Hz) (Fig. 4.2).  The 
soleus muscle atrophy in PlnOE/SlnKO mice could not be explained by differences in body 
weight, daily ambulation, daily food intake (Table 4.2), or increases in either proteolytic 
enzyme activities or autophagic signaling compared with PlnOE/SlnWT (Fig. 4.3).   
In response to the type I fiber hypotrophy induced by Pln overexpression, the type II 
fibers of the soleus muscles experience greater and longer load-bearing activities causing 
them to hypertrophy and undergo a fast-to-slow fiber type transition (Ref (187) and Fig. 1G 
and H). Strikingly, the type II fibers from the PlnOE/SlnKO soleus failed to hypertrophy (Fig. 
4.1H), therefore accounting, at least in part, for the exacerbated soleus muscle atrophy and 
weakness.  In addition, the fast-to-slow fiber type conversion in the PlnOE/SlnKO soleus was 
less prominent as the percent of type IIA fibers remained high (~36%) and was not different 
from the PlnWT/SlnWT soleus (Fig. 4.1G).  Similar to that with Pln overexpression, the type II 
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fibers from mechanically overloaded plantaris muscles also display myofiber hypertrophy 
and a fast-to-slow fiber type shift as a result of synergist ablation of soleus and 
gastrocnemius muscles (155).  Therefore, we questioned whether Sln deletion would also 
impair the muscle growth and remodelling in this model.  To this end, we mechanically 
overloaded plantaris muscles for 2 weeks by performing soleus and gastrocnemius tenotomy 
(surgical transection of the tendon) (188), which in the WT mice induced ectopic expression 
of SLN (Fig. 4.4A).  Interestingly, we detected a significant main effect of surgery in the WT 
mice indicating myofiber hypertrophy ranging from +22% to +48% (Fig. 4.4B); however, 
there were no significant differences in myofiber CSA between sham and overloaded 
muscles in SlnKO mice (Fig. 4B).  Furthermore, fiber size distribution indicates that the 
overloaded SlnKO plantaris is characterized by an increase in smaller fibers (<2,400 µm2) and 
a reduction in larger fibers (>3,600 µm2) compared with WT (Fig. 4.4C).  With respect to the 
expected fast-to-slow fiber type transition, we found a significant increase in type I and IIA 
fiber percentage in the WT mice, but not in SlnKO mice (Fig. 4.4D).  Thus, the plantaris 
myofibers from SlnKO mice failed to hypertrophy and transition towards a slow-oxidative 
fiber phenotype after overload stimulus similar to that seen in PlnOE/SlnKO mice.   
To explain the attenuation in both type II fiber hypertrophy and fiber type 
conversions in the absence of Sln, we focused on calcineurin, the Ca2+-calmodulin dependent 
serine/threonine phosphatase known to regulate these cellular adaptations (154, 155, 169) 
and, perhaps more importantly, shown to be responsive to SLN (184).  Specifically, in a 
previous study using Sln overexpressing mice, calcineurin phosphatase activity was increased 
25% and led to a significant dephosphorylation of the calcineurin substrate NFAT in skeletal 
muscle (184).  Here, in response to mechanical overload, we found a significant decrease in 
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phosphorylation of NFAT (-61%) in WT mice, which was blunted in SlnKO mice (-22%) (Fig. 
4.5A).  Similarly, we found that PlnOE/SlnKO soleus had more phosphorylated NFAT 
compared with PlnOE/SlnWT (Fig. 4.5B), which altogether suggests lowered calcineurin 
signaling in these muscles that lack SLN.  These results are in agreement with previous 
findings (184) and show that SLN upregulation may trigger calcineurin-mediated muscle 
growth and remodelling that, in the case of PlnOE mice, combats muscle atrophy and 
weakness.   
To further characterize SLN’s role in muscle myopathy, we also examined the 
tenotomized soleus, which is a model of hindlimb unloading, that unlike mechanical overload, 
causes muscle degeneration and a slow-to-fast fiber type shift (190, 191).  Here, we show 
that tenotomy increased SLN in soleus muscles 14-fold (P = 0.004, Fig. 4.6A), and, similar 
to PlnOE/SlnKO mice, led to a more severe soleus muscle atrophy in the absence of Sln (Fig. 
4.6B).  As expected, a significant main effect of tenotomy in WT mice was detected 
indicating a 29% to 38% reduction in average myofiber CSA (Fig. 4.6C).  Interestingly, 
SlnKO mice also exhibited significant myofiber atrophy, although with a slightly higher 
percent reduction (33% to 42%) in average myofiber CSA (Fig. 4.6C).  Moreover, the SlnKO 
tenotomized soleus is characterized by an increase in small myofibers with a CSA <1,500 
µm2 and a decrease in large myofibers (>2,250 µm2) (Fig. 4.6D). With respect to the 
expected slow-to-fast fiber type transition, WT tenotomized soleus muscles exhibited a 
partial slow-to-fast fiber type transition with a significant decrease and trending increase in 
type IIA and type IIX fiber percent, respectively (Fig. 4.6E).  Strikingly, the SlnKO 
tenotomized soleus displayed an accelerated slow-to-fast fiber type transition with a 
significant decrease and increase in type I and type IIX fiber percent, respectively (Fig. 4.6E).  
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The percent of type IIA fibers from tenotomized SlnKO soleus muscles also exhibited a 
trending decrease compared with sham.  Calcineurin normally stabilizes/counteracts the 
effects of reduced mechanical loading (192), and consistent with SLN’s putative role in 
stimulating calcineurin (184), we found a significant decrease in phosphorylation of NFAT in 
WT (-57%), which was blunted in SlnKO mice (-32%) (Fig. 4.6F).  Thus, combined with the 
experiments with mechanical overload and PlnOE mice, these results suggest that SLN 
recruitment is required to potentiate muscle growth and slow muscle atrophy, possibly by 
amplifying calcineurin activation.  
Lastly, we examined the dystrophic mdx mouse model, where SLN upregulation in a 
variety of muscle types has been observed (88), by generating mdx/SlnKO mice (Fig. 4.7A).  
Consistent with the results throughout this study, our findings with mdx/SlnKO mice show 
reduced myofiber area with significant main effects of Sln deletion in the soleus and 
diaphragm muscles (Fig. 4.7B).  Furthermore, Sln deletion caused a slow-to-fast fiber type 
transition in soleus and diaphragm muscles relative to mdx (Fig. 4.7C), which may be 
maladaptive since promoting a slow-oxidative fiber phenotype is considered an attractive 
therapeutic strategy to increase expression of the dystrophin homolog, utrophin, that provides 
compensatory membrane stability (175).  Calcineurin controls utrophin expression (176, 177), 
and lower utrophin levels in the mdx/SlnKO muscles (Fig. 4.7D) further supports SLN’s 
putative role in calcineurin activation and accounts for the enhanced myofiber breakdown 
revealed with higher serum CK (Fig. 4.7E).  In addition, mdx/SlnKO mice had greater 
heterogeneity in myofiber size, indicated by the minimal Feret’s diameter coefficient of 
variation (Fig. 4.7F and G) which is a sensitive and reliable measure of muscular dystrophy 
(189).  The combined effects of greater muscle breakdown, lowered myofiber CSA, and 
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impaired muscle regeneration revealed with lower central nuclei (Fig. 4.7H) as a result of Sln 
deletion, likely accounts for the greater variation in the minimal Feret’s diameter, and 
demonstrates clearly that Sln deletion worsens mdx pathology.  Furthermore, the impaired 
regenerative capacity was supported with cardiotoxin experiments, whereby in response to 
acute muscle injury, the TA muscles from SlnKO mice exhibited a delay in muscle 
regeneration (Fig. 4.8).  Specifically we found ectopic expression of SLN by day 21 post-
injury, and removal of this adaptive response led to a failed clearing of central nuclei and 
smaller CSAs of regenerating fibers at that time point.  In the context of muscular dystrophy, 
where constant degeneration and regeneration cycling occurs, these results suggest that in the 
absence of SLN, this balance may shift toward greater muscle degeneration, which could also 
account for the greater serum CK and variability in the minimal Feret’s diameter observed in 
mdx/SlnKO mice  (Fig. 4.7E and G).    
In summary, our study has addressed the long-unanswered question pertaining to 
SLN’s upregulation across many skeletal muscle diseases.  Here, we have demonstrated a 
novel role for SLN in countering disease by regulating muscle growth and remodelling, and 
future studies should determine whether increasing SLN in diseased or damaged states 
represents a viable therapeutic strategy.  Indeed, high-fat feeding upregulates SLN (2, 44) 
and has been shown to benefit muscle structure and function in mdx mice (193).  Furthermore, 
our results provide another way in which SLN can offset obesity since promoting skeletal 
muscle growth can reduce/attenuate adiposity and improve glucose metabolism (194-196).    
Thus, in conclusion, our results demonstrate further the importance of SLN in overall muscle 
health, and we propose that increasing SLN in muscle not only counters obesity, but also 
muscle disease, and could potentially prevent the muscle wasting that occurs during aging 
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and cachexia (197, 198).  We anticipate that future studies examining the underlying 
mechanisms responsible for SLN’s effects on muscle growth and remodelling will lead to the 
generation of novel therapeutic strategies. 
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TABLE 4.1.  SERCA activity in mouse soleus muscles from PlnWT/SlnWT, PlnOE/SlnWT, and 
PlnOE/SlnKO mice.  
 PlnWT/SlnWT PlnOE/SlnWT PlnOE/SlnKO 
SERCA activity    
Vmax 390.1 ± 8.9 392.7 ± 21.5 379.9 ± 12.2 
KCa 6.34 ± 0.02 6.27 ± 0.01* 6.24 ± 0.02* 
ΔKCa - 0.07 0.10 
Soleus muscle homogenates were isolated from PlnWT/SlnWT (n = 7), PlnOE/SlnWT (n = 6), and 
PlnOE/SlnKO mice (n = 6) and were analyzed for Ca2+-ATPase activity over Ca2+ concentrations 
ranging from pCa 7.2 to pCa 5.4 to obtain KCa.  KCa is the Ca2+ concentration required to attain the 
half-maximal Ca2+-ATPase activity rate and is expressed in pCa units. *Significantly different from  
PlnWT/SlnWT using a one-way ANOVA with a Tukey’s post hoc test, P < 0.05. Values are means ± 
SEM.   
 
 
 
TABLE 4.2.  Body weight, daily activity and daily food intake measures from PlnWT/SlnWT, 
PlnOE/SlnWT, and PlnOE/SlnKO mice. 
Parameter PlnWT/SlnWT PlnOE/SlnWT PlnOE/SlnKO 
Body weight 35.9 ± 0.8 37.5 ± 0.8 36.0 ± 1.1 
Food intake (g/d) 4.9 ± 0.5 5.2 ± 0.3 4.7 ± 0.4 
Total activity (counts/d) 15,354 ± 1,073 11,070 ± 1,690 12,072 ± 1,468 
Ambulatory activity 
(counts/d) 
 
5,435 ± 680 
 
3,665 ± 681 
 
3,950 ± 641 
Values are means ± SEM (n = 18-23, for the average body weight of PlnWT/SlnWT, PlnOE/SlnWT, and 
PlnOE/SlnKO mice; n = 6 per genotype for daily food consumption, ambulation, and total activity).  
Ambulatory activity counts were when the mouse crossed 2 adjacent x-axis infrared beams in 
succession.  One-way ANOVA revealed no significant effect of genotype for body weight (P = 0.37), 
food intake (P = 0.48), total activity (P  = 0.12), or dual beam activity (P = 0.17). 
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Figure 4.1.  Sln deletion does not rescue SERCA function or the CNM-like phenotype in PlnOE mice.  (A) 
Representative Western blot image of SLN in soleus muscles across genotypes.  Ponceau was used as a loading 
control.  Rates of Ca2+ uptake (B) and SERCA activity-pCa curves (C) measured from soleus homogenates (n = 
6-7).  Representative H&E-stained sections (D) revealing greater central nuclei (E) in PlnOE/SlnKO and 
PlnOE/SlnWT soleus.  Representative immunofluorescent fiber-type staining (F) showing type I fiber 
predominance (G) and hypotrophy (H) in PlnOE/SlnWT and PlnOE/SlnKO mice.  Type I (blue), -IIA (green), -IIB 
(red), and -IIX (unstained); type IIB fibers were only found in WT (5.9 ± 1.6%). Representative SDH-stained 
sections (I) illustrating central aggregation of oxidative activity (yellow arrowheads) in PlnOE/SlnKO and 
PlnOE/SlnWT soleus.  (J) Representative Van Gieson-stained soleus sections displaying enhanced endomysial 
fibrosis quantified (K) using imageJ software. (L) Representative SDH-stained and H&E-stained sections 
displaying core-like aspects in PlnOE/SlnWT and PlnOE/SlnKO soleus muscles that cannot be explained by the 
presence of an artifact or vacuole. Arrows point to the core-like aspect and asterisks depict the same fiber within 
serial sections. (M) Transmission electron micrographs illustrating triad disruptions with swollen sarcoplasmic 
reticulum in both PlnOE/SlnWT and PlnOE/SlnKO soleus muscles. Arrowheads point to the swollen sarcoplasmic 
reticulum with corresponding area.  For (B, E, G, H, and K), * significantly different from PlnWT/SlnWT using a 
one-way ANOVA with a Tukey’s post-hoc test, P < 0.05.  All values are means ± SEM.  CSA, cross-secitonal 
area. All scale bars are set to 50 µm except for (M) where scale bars are set to 100 nm. 
 
 
	  94 
 
 
Figure 4.2.  Sln deletion worsens muscle atrophy and weakness in PlnOE mice.  (A) Soleus:body weight (mg/g) 
ratio (n = 18-22).  (B) Force-frequency curve analysis in isolated soleus muscles (n = 6-7).  Representative 
twitch (C) and tetanic (D, 100 Hz) force tracings from PlnWT/SlnWT,  PlnOE/SlnWT,  PlnOE/SlnKO soleus muscles.  
For (A), * significantly different from PlnWT/SlnWT, and †significantly different from PlnOE/SlnWT using a one-
way ANOVA with a Tukey’s post-hoc test, P < 0.05.  For (B), *PlnWT/SlnWT vs. PlnOE/SlnKO, P < 0.05; 
†PlnWT/SlnWT vs PlnOE/SlnWT, P < 0.05 with a two-way repeated measures ANOVA and a Tukey’s post-hoc test.  
All values are means ± SEM. 
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Figure 4.3 Sln deletion does not augment proteolytic activity and autophagic signaling in response to Pln 
overexpression.  Calpain (A), caspase-3 (B), and 20S proteasome activity assays (C).  Enhanced autophagy 
revealed by increased cathepsin activity (D), decreased p62 levels (E) and increased LC3-II/I content (F) in 
PlnOE/SlnWT mice is attenuated in PlnOE/SlnKO mice. *Significantly different from PlnWT/SlnWT, †significantly 
different from PlnOE/SlnWT using a one-way ANOVA and a Tukey’s post-hoc test, P < 0.05.  For proteolytic 
measures, n = 6-7; for p62, LC3-I and –II content, n = 11-12 and optical densities were normalized to actin.  All 
values are means ± SEM. 
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Figure 4.4 Sln deletion blunts myofiber hypertrophy and fast-to-slow fiber type transitions during mechanical 
overload of the plantaris muscles.  (A) Western blot image illustrating ectopic expression of SLN in the 
overloaded (OV) plantaris. NS, non-specific bands were included to show that protein was loaded in all lanes 
and ponceau stain demonstrates equal loading (75 µg of plantaris homogenate protein loaded).  (B) Fiber type 
cross-sectional area (CSA) and fiber size frequency histograms (C) quantified using imageJ after performing 
immunofluorescent staining (n = 3-4 per group).  (D) Fiber type changes in response to mechanical overload in 
WT and SlnKO mice. For (B), *denotes a main effect of mechanical overload using a two-way repeated measures 
ANOVA, P < 0.05; for (D), *significantly different from sham using a paired t-test (one tailed) within a 
genotype, P < 0.05. All values are means ± SEM except for (C) where a two-sample Kolmogorov-Smirnov test 
was used to compare frequency distributions (WT n = 271 fibres from 3 animals, SlnKO n = 278 fibres from 4 
animals).  CSA, cross-secitonal area.  
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Figure 4.5.  Phosphorylated NFAT as a marker of calcineurin signaling in mechanical overload experiments 
and in the PlnOE/SlnWT and PlnOE/SlnKO soleus muscles.  (A) Phosphorylation status of NFAT in the sham and 
OV plantaris muscles from WT and SlnKO mice (7.5 µg of plantaris homogenate protein was loaded, n = 4-6 per 
group, expressed relative to sham). (B) Phosphorylation status of NFAT in soleus muscles from PlnOE/SlnWT and 
PlnOE/SlnKO mice (n = 7–11 per group, expressed relative to PlnOE/SlnWT).  For (A), *significantly different from 
sham using a paired t-test (one tailed) within a genotype, P < 0.05; for (B), *significantly different from 
PlnOE/SlnWT using a Student’s t-test, P < 0.05. All values are means ± SEM.   
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Figure 4.6. Sln deletion exacerbates soleus muscle atrophy and slow-to-fast fiber type conversions in response 
to tenotomy.  (A) Western blot image depicting SLN content in WT sham and tenotomized (Tny) soleus 
muscles (n = 5).  25 µg of soleus homogenate protein was loaded for each lane and equal loading was ensured 
with ponceau stain.  (B) Percent reduction in soleus muscle mass after Tny expressed relative to body weight 
(bw).  (C) Fiber type cross-sectional area (CSA) and fiber size frequency histograms (D) quantified using 
imageJ after performing immunofluorescent staining (n = 3-4 per group).  (E) Fiber type changes in response to 
tenotomy in WT and SlnKO mice. (F) Calcineurin activation as measured through the phosphorylation status of 
NFAT in the sham and Tny soleus muscles from WT and SlnKO mice (7.5 µg of soleus homogenate protein was 
loaded, n = 5-6 per group, expressed relative to sham. For (B), *significantly different from WT using a 
Student’s t-test, P < 0.05; for (C), *denotes a significant main effect of tenotomy using a two-way repeated 
measures ANOVA, P < 0.05; for (E and F), *significantly different from sham using a paired t-test (one tailed) 
within a genotype, P < 0.05.  All values are means ± SEM except for (D) where a two-sample Kolmogorov-
Smirnov test was used to compare frequency distributions (WT n = 260 fibres from 3 animals, SlnKO n = 331 
fibres from 4 animals).            
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Figure 4.7.  Sln deletion (-/-) promotes a slow-to-fast fiber type shift, reduces utrophin expression, and worsens 
dystrophic pathology in mdx mice.  (A) Representative Western blot image of SLN in mdx soleus and 
diaphragm muscles.  Equal loading was ensured with ponceau stain (12.5 µg of homogenate protein).  (B) Fiber 
type cross-sectional area (CSA) and distribution (C) in soleus and diaphragm muscles from mdx and mdx/SlnKO 
mice quantified using imageJ after immunofluorescent staining (n = 3-4 per genotype).  (D) Western blot 
quantification of utrophin in soleus and diaphragm muscles from mdx and mdx/SlnKO mice (n = 3-4 per 
genotype, 30 µg of homogenate protein). Equal loading was ensured with ponceau stain.  (E) Serum creatine 
kinase (CK) levels in mdx and mdx/SlnKO mice (n = 3-4 per genotype).  (F) Representative H&E-stained 
sections of soleus and diaphragm muscles illustrating worsened pathology and greater fiber heterogeneity in the 
mdx/SlnKO mice.  (G) Minimal Feret’s diameter coefficient of variation (CV) calculated from H&E-stained 
sections.  CV = (standard deviation /mean of the minimal Feret’s diameter) x 1000; n = 3-4 per genotype; 50 
fibers analyzed per section.  (H) Impaired regenerative capacity in mdx/SlnKO mice revealed by lower central 
nuclei (%) upon H&E staining (n = 3-4 per genotype). For (B, D, G and H), *denotes a significant main effect 
of Sln deletion using a two-way ANOVA, P < 0.05; for (C and E), *significantly different from mdx using 
Student’s t-test, P < 0.05. All scale bars are set to 100 µm.  All values are means ± SEM.    
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Figure 4.8.  SlnKO mice exhibit delayed muscle regeneration after acute cardiotoxin injury.  (A) Ectopic 
expression of SLN in tibialis anterior muscles only by day 21 post-injury suggests a role for SLN in the later 
stages of muscle regeneration.  †The inset below clearly reveals SLN expression by day 21 after adjusting for 
brightness and contrast; NS, non-specific bands were included to show that protein was loaded in all lanes (75 
µg of TA homogenate protein loaded). (B) Fibers with central nuclei, normalized to area of regeneration, remain 
elevated in SlnKO mice at day 21 post-injury, and the average cross-sectional area (CSA, C) of regenerating 
fibers at day 21 post-injury is smaller in SlnKO mice indicating a delay in the later stages of muscle regeneration. 
*Significantly different from WT, using a Student’s t-test at each day, P < 0.05.  All values are means ± SEM. 
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Chapter 5 
Summary, Perspectives, and Future Directions 
 
5.1 Summary 
This thesis began with two main objectives: 1) characterize and diagnose the 
myopathy observed in the PlnOE mouse and 2) determine the role for SLN upregulation.  
Initially, it was hypothesized that PLN overexpression would lead to a dystrophic myopathy 
(Chapter 2); however, the myopathy found in the PlnOE soleus and gluteus minimus muscles 
more closely resembled CNM.  This finding led to the study described in Chapter 3, which 
focused on the diaphragm muscles as studies assessing diaphragm and respiratory function in 
animal models of CNM, at the time, were limited (147).  In this chapter, it was hypothesized 
that the diaphragm muscles would also display muscle weakness and exhibit a CNM-like 
phenotype; however the PlnOE diaphragm did not exhibit CNM and showed no impairments 
in force production.  The relatively small impairments in SERCA function and SLN 
upregulation (2.5-fold) in the PlnOE diaphragm muscles, amongst other findings from current 
literature, led to the hypothesis that Sln deletion would improve SERCA function and 
alleviate the CNM phenotype observed in the PlnOE soleus muscles (Chapter 4).  In contrast, 
genetic deletion of Sln worsened the PlnOE-induced myopathy and had similar effects on two 
other models of damage/disease (tenotomy and mdx).  Experiments with mechanical overload 
surgery, and results for NFAT phosphorylation and utrophin expression suggest that 
sarcolipin counters disease pathology by activating calcineurin.  In conclusion, the studies 
presented in this thesis provide a better understanding of the role of PLN and SLN in skeletal 
muscle disease and are summarized below in table format with respect to their key findings, 
conclusions, and novel/important contributions.    
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Table 5.1.1.  Summary of Chapter 2 - Thesis Study I: Phospholamban overexpression in 
mice causes a centronuclear myopathy-like phenotype. 
Key findings  § Type I fibre-specific PLN overexpression reduces maximal 
SERCA activity, rates of Ca2+ uptake, and SERCA’s apparent 
affinity for Ca2+ assessed in soleus and gluteus minimus muscle 
homogenates. 
§ SLN was upregulated 7- and 9-fold, respectively in soleus and 
gluteus minimus muscles from PlnOE mice. 
§ Soleus muscles from PlnOE mice exhibited progressive muscle 
atrophy and displayed severe muscle weakness in vitro by 4-6 
months of age. 
§ Unlike the original report by Song et al., (2004), the soleus and 
gluteus minimus muscles exhibited signs of myopathy that 
phenotypically recapitulated human CNM (central nuclei, type I 
fibre predominance and hypotrophy, and central aggregation of 
oxidative activity) with additional endomysial fibrosis and core-
like lesions. 
§ The CNM phenotype in PlnOE mice resembles the autosomal 
dominant form of CNM as well as RYR-related and TTN-related 
CNM. 
§ Analyses of three muscle biopsies from genetically unrelated 
CNM patients show significant reductions in maximal SERCA 
activity and a trending increase in PLN expression compared with 
healthy controls. 
§ Consistent with other mouse models of CNM, increased levels of 
dynamin-2 were observed in the PlnOE soleus and gluteus minimus 
muscles; however, a significant reduction in dynamin-2 from 
muscle biopsies from CNM patients compared with healthy 
controls was detected. 
Conclusion § PLN overexpression in mice can lead to a CNM phenotype, and 
the trending increase in PLN expression in human CNM, suggests 
that PLN may play a pathological role in this disease.  
Novel/important 
contributions 
§ The physiological role of PLN in cardiac muscle is well known 
with a variety of genetic mutations leading to cardiomyopathy; 
however the role of PLN in skeletal muscle disease remained 
largely overlooked.  This study, for the first time, demonstrates the 
importance of PLN in murine and human CNM pathology. 
§ 20-30% of CNM cases remain genetically unresolved and 
scientists may now view PLN as a novel gene candidate. 
§ To date, there is no cure for CNM and it is possible that targeting 
PLN may represent a viable therapeutic strategy. 
§ The PlnOE mouse is a commercially available animal model that 
faithfully captures all CNM histopathological features and can be 
used to study the underlying mechanisms leading to these lesions 
as well as testing novel therapeutic strategies. 
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Table 5.1.2.  Summary of Chapter 3 - Thesis Study II: Diaphragm assessment in mice 
overexpressing phospholamban in slow-twitch type I muscle fibres. 
Key findings  § SERCA’s apparent affinity for Ca2+ was lower in PlnOE diaphragm 
compared with WT; however, neither maximal SERCA activity 
nor rates of Ca2+ uptake were significantly different. 
§ SLN expression was upregulated; but only 2.5 fold. 
§ Isolated diaphragm strips from PlnOE mice did not display muscle 
weakness or slowing in twitch kinetics.  
§ Unlike the PlnOE soleus and gluteus minimus muscles, the 
diaphragm muscles did not display all histopathological features 
associated with CNM and only exhibited type I fibre hypotrophy. 
§ Consistent with the lack in CNM phenotype, levels of dynamin 2 
were unaltered between PlnOE and WT diaphragm muscles.  
§ There was a greater proportion of the type II fibres that also 
exhibited significant myofibre hypertrophy in the PlnOE 
diaphragm. 
Conclusion § Diaphragm muscles from PlnOE mice conferred resistance to 
PlnOE-induced CNM and were not weaker than their WT 
littermates. 
Novel/important 
contributions 
§ This study demonstrates that the diaphragm muscles from PlnOE 
mice do not display CNM, which is consistent with the very little 
respiratory complications found in patients with autosomal 
dominant CNM. 
§ Understanding the underlying mechanisms that allow the 
diaphragm to resist the PlnOE-induced CNM may lead to the 
development of novel therapeutic strategies.  This study highlights 
two possibilities: 
• SLN expression appeared to follow disease severity in PlnOE 
mice; therefore SLN’s role in myopathy should be investigated 
in the future. 
• Type I fibres are those primarily affected in the congenital 
myopathies (CNM and CCD), therefore reducing their 
proportions in skeletal muscles, similar to that seen in the 
PlnOE diaphragm muscles, may represent a viable therapeutic 
strategy. 
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Table 5.1.3.  Summary of Chapter 4 - Thesis Study III: Sarcolipin is vital for muscle growth 
and remodeling and counters disease pathology. 
Key findings  § PlnOE/SlnKO soleus muscles did not show improved SERCA 
function or mitigation of the CNM phenotype. 
§ PlnOE/SlnKO soleus muscles had pronounced force reduction and 
exacerbated muscle atrophy, which could not be explained by 
differences in body weight, food intake, daily activity, or muscle 
proteolysis. 
§ PlnOE/SlnKO soleus muscles did not display any compensatory type 
II fibre hypertrophy and showed a delayed transition toward a type 
I fibre population. 
§ The failure to hypertrophy and transition toward a type I fibre 
population upon greater load bearing stimulus, was repeated in the 
mechanically overloaded SlnKO plantaris muscles, and could be 
explained by attenuated calcineurin signaling. 
§ Soleus muscle atrophy and slow-to-fast fibre type transitions 
typically observed after tenotomy were accelerated in SlnKO mice 
and can be explained by attenuated calcineurin signaling.   
§ Muscles from mdx/SlnKO mice had smaller myofibre size, a slow-
to-fast fibre type transition, greater degeneration as revealed by 
serum creatine kinase concentrations, and greater variability in 
myofibre size indicated by a larger minimal Feret’s diameter CV. 
§ Lowered utrophin expression in muscles from mdx/SlnKO mice 
suggest that calcineurin signaling is impaired. 
§ The larger variability in minimal Feret’s diameter in the mdx/SlnKO 
mice likely represents a combined effect of enhanced muscle 
degeneration, reduced myofibre size, and impaired muscle 
regeneration as shown with central nuclei counts in the mdx/SlnKO 
muscles and in acute cardiotoxin injury experiments in SlnKO mice.   
Conclusion § SLN plays a vital role in countering muscle disease by promoting 
muscle growth and remodeling by stimulating calcineurin 
signaling.  
Novel/important 
contributions 
§ This study answered a question that has remained elusive for many 
years: what is the role of SLN upregulation in skeletal muscle 
disease?  The results from this study are the first to show the 
importance of SLN in mediating an adaptive response necessary in 
combatting a widespread of muscle diseases/conditions.   
§ The role of SLN in stimulating muscle growth shown in this study 
could account, in part, for the increased adiposity and impaired 
glucose metabolism seen in high-fat fed SlnKO mice.  
§ The role of SLN in stimulating muscle growth shown in this study 
may also lead to novel therapeutic regiments against muscle 
wasting in aging and cachexia. 
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5.2 Perspectives and future directions 
PLN and CNM: mechanistic insight 
 The results from this thesis clearly demonstrate that PLN overexpression causes a 
CNM-like phenotype in mice; however the exact mechanisms leading to greater central 
nuclei, type I fibre predominance and hypotrophy, and central aggregation of oxidative 
activity in the muscles from PlnOE mice and in all other forms/models of CNM remain 
unknown.  However, recently, there is gaining interest with triad structural anomalies being 
thought to have a key role in the pathogenesis of CNM (111, 128, 129, 199, 200), which is 
supported by the presence of swollen SR membranes in PlnOE mice (Figure C2).  Dynamin 2 
is a GTPase critical for both membrane fission and tubulation with the speed of GTPase 
activity dictating either membrane fission (fast GTP hydrolysis) or membrane tubulation 
(slow GTP hydrolysis) (201).  In CNM, it is posed that speeding up dynamin 2’s GTPase 
activity either through Dnm2 mutations or increased expression of dynamin 2 can cause triad 
abnormalities (SR and t-tubule swelling/vacuolization) (90, 130, 200, 202, 203).  Therefore, 
it is possible that the increase in dynamin 2 in the PlnOE soleus and gluteus minimus muscles 
could contribute to the defects in triad structure and CNM pathology in these mice.  Although 
the exact mechanisms linking PLN overexpression to dynamin 2 upregulation is unknown, 
SABiosciences mining tool for discovering relevant transcription factors regulating murine 
Dnm2 suggests that sterol regulatory binding protein 1 (SREBP-1) may be involved (Figure 
5.2.1).  Interestingly, SREBP-1 can be activated by calpains and could therefore provide a 
link for PLN overexpression and dynamin 2 upregulation; however future studies are 
required to substantiate this speculation (204).    
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Figure 5.2.1.  Transcription factors predicted to regulate murine Dnm2 expression using 
SABiosciences’ Text Mining Application and the UCSC Genome Browser. 
http://www.sabiosciences.com/chipqpcrsearch.php?species_id=1&factor=Over+200+TF&ge
ne=DNM2&nfactor=n&ninfo=n&ngene=n&B2=Search  
 
Of note, while dynamin 2 may have a role in PlnOE-induced CNM and other mouse 
models (90, 203), its role in human CNM is still in question given the results from Chapter 2 
(Figure A6).  Specifically, a significant reduction in dynamin 2 expression in muscle biopsies 
from CNM patients was observed despite having a trending increase in PLN content (Figure 
A5).  Although purely speculative, increased PLN expression could also lead to triad defects 
by altering levels of phosphoinositide-3 phosphate (PIP3), since the kinase responsible for its 
synthesis, phosphoinositide-3 kinase (PI3K), can be activated by Ca2+ (205).  In myotubular 
myopathy, the most severe form of CNM, mutations in MTM1 lead to reduced myotubularin 
protein, which is a 3-phosphoinositide phosphatase.  Moreover, it is thought that the 
concomitant rise in PIP3 levels results in defective membrane trafficking, triad structural 
defects, muscle weakness, and CNM (199, 200).  Thus, it is possible that PLN 
overexpression and SERCA dysfunction may enhance the activity of PI3K and cause a CNM 
phenotype by raising PIP3 levels much like that seen in animal models (mtm1-/y) and human 
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patients with this X-linked form of CNM.   Furthermore, it is possible that PLN could 
contribute to the dysregulated PIP3 levels found in patients and animal models of myotubular 
myopathy, and this should be investigated with future studies.  
Finally, it has also been proposed that impaired autophagy can be a pathogenic 
mechanism leading to CNM (67, 206, 207); but exactly how this occurs is still unknown.  
Interestingly, in a recent study, it was shown that autophagy specifically targets PLN for 
degradation (208), therefore raising the possibility that impairments in autophagy can cause 
CNM, at least partly, through elevated PLN protein.  Impaired autophagy does not seem to be 
a causal factor in the PlnOE-induced CNM since autophagic signaling appeared elevated with 
PLN overexpression (Figure C4); nevertheless, it would be interesting to determine whether 
enhancing autophagy either genetically, pharmacologically (ie. metformin), or through other 
means (caloric restriction) could rescue the CNM phenotype found in PlnOE mice by 
targeting PLN for degradation. 
 
MEF2 and SLN expression: a positive feedback mechanism 
 To date, the factors controlling Sln expression remain largely undetermined and only 
one study provides a potential candidate (209).  In this study by Zhao and colleagues (2002), 
the Sln noncoding region was found to have a highly conserved binding sequence for the 
myocyte enhancer factor 2 (MEF2) transcription factor.  In support of a role for MEF2 in the 
control of Sln expression, both Mef2 and Sln are greatly expressed in the atria compared to 
the ventricles in mouse (209).  In skeletal muscle, protein levels of MEF2 are similar in slow 
and fast mouse muscles, however its primary inhibitors, histone deacetylase (HDAC) -4, -5, 
and -7 are expressed in far lower quantities in mouse soleus compared to EDL (210).  
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Correspondingly, tests from our laboratory have only detected SLN in mouse soleus, gluteus 
minimus, diaphragm and atrial muscles (Figures 2.1, A3, and 3.1, and reference (20)), and to 
date, we have not detected SLN in mouse WT chow-fed EDL muscles. 
Interestingly, calcineurin also stimulates the activity of MEF2 by enhancing its DNA 
binding through dephosphorylation of MEF2, and it’s the synergist action between MEF2 
and NFAT that is thought to control muscle growth and remodeling (154, 211-214).  
Therefore, if MEF2 controls Sln expression, then SLN’s regulation of calcineurin signaling, 
as shown in Chapter 4, points to the existence of a positive feedback mechanism where 
calcineurin signaling increases SLN expression to further amplify calcineurin activity (Figure 
5.2.2).  In addition to calcineurin, members of the CAMK family (I, II and IV) also stimulate 
MEF2 transcriptional activity by phosphorylating HDACs leading to their extrusion from the 
nucleus (214, 215).  Therefore, CAMKs may also stimulate SLN expression, and similar to 
calcineurin, SLN may further amplify CAMKs signaling through its action on the SERCA 
pump.  Future studies should investigate the role of MEF2 in regulating Sln expression and to 
determine the feasibility of this positive feedback mechanism, and could benefit from the use 
of Mef2 knockout mice (216). 
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Figure 5.2.2.  Speculated positive feedback mechanism for Ca2+-dependent Sln expression. 
(1) Rise in [Ca2+]i activates calcineurin (2) and mediates dephosphorylation of NFAT (3a) for 
nuclear localization, and MEF2 (3b) to enhance DNA binding. (4) Members of the CAMK 
family (I, II, and IV) are also activated and phosphorylates HDAC (5) resulting in nuclear 
extrusion and stimulating MEF2 activity. (6) Synergist action of MEF2 and NFAT promotes 
Sln transcription and SLN protein interacts with SERCA and inhibits its function (7) 
contributing to the rise in [Ca2+]i. 
 
If correct, the Ca2+-dependent Sln expression system proposed in Figure 5.2.2 could 
explain why our laboratory has only detected SLN in the soleus, gluteus minimus, diaphragm, 
and atrial muscles of mice, as these muscles exhibit the tonic activity patterns and, thus the 
sustained elevations in [Ca2+]i required for calcineurin signaling (8, 152, 154, 160, 168).  
Indeed, a previous study has shown that soleus muscles fibres contain a high amount of 
nuclear NFATc1 (66%) compared with TA muscles (14%) in the basal state suggestive of 
greater calcineurin signaling (161).  Moreover, Tothova et al. (2006) showed that TA 
muscles subjected to electrical stimulation mimicking slow-motor unit activity patterns (20 
Hz for 10 s, every 30 s, for 60 min) exhibited calcineurin-dependent NFATc1 nuclear 
shuttling, which could not be observed with a faster, less frequent stimulation pattern (100 
Hz for 0.6 s, every 60 s, for 60 min).  Thus, calcineurin-NFAT signaling is dependent on 
nerve activation and favours repetitive low-frequency long duration activity patterns, and 
therefore could explain why SLN was only found in the overloaded plantaris muscles and not 
sham, since soleus and gastrocnemius tenotomy cause plantaris muscles to take on a postural 
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role with a tonic activity pattern (Figure 4.2).  The fact that Sln deletion prevented the 
overload-induced myofibre growth and fast-to-slow fibre type transition indicates that SLN 
plays a critical role in maintaining [Ca2+]i required for calcineurin and potentially CAMK 
signaling, and provides evidence for this positive feedback loop.   
The Ca2+-dependent Sln expression pathway acting through MEF2 shown in Figure 
5.2.2 could also explain why SLN is commonly upregulated in muscle disease, since Ca2+ 
dysregulation and impaired SERCA function are often found (reviewed in Chapter 1).  In 
addition, inflammation may also stimulate Sln expression, as pro-inflammatory cytokines can 
augment the activity of the mitogen activated protein kinase p38α (217), which can then 
increase MEF2’s transcriptional activity by enhancing its DNA binding capacity (218).  Thus, 
both elevated [Ca2+]i and inflammation in diseased states may enhance SLN expression 
through MEF2 and warrants further investigation, especially if increasing SLN content 
represents a viable therapeutic strategy. 
The proposed Ca2+-dependent Sln expression pathway and positive feedback loop 
also highlights an important experimental limitation in this thesis - the lack of [Ca2+]i 
measures.  These types of experiments could provide strong evidence for SLN’s role in 
sustaining the [Ca2+]i required for calcineurin signaling seen in PlnOE mice, mechanical 
overload, soleus tenotomy and mdx mice (Thesis Study III).  In addition, the fact that SERCA 
function was not improved in PlnOE/SlnKO mice (Figure 4.1b and c) may suggest that SLN 
could not have enhanced calcineurin signaling by sustaining the elevations in [Ca2+]i. 
Alternatively, this can be explained by the sheer overexpression of PLN occurring in the type 
I fibres, thereby masking any improvement in SERCA function expected in the type II fibres 
that eventually led to their failure to hypertrophy and transition towards a slow-oxidative 
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phenotype.  Thus, [Ca2+]i measures or assessment of SERCA function at the single fibre level 
would prove useful in determining how SLN activates calcineurin and could possibly explain 
the discrepant results found in the PlnOE/SlnKO mice. 
 
SLN and regulation of muscle mass 
It is well understood that SLN expression is greater in skeletal muscles from larger 
mammals compared to smaller ones (22, 24).  Results from our laboratory support this notion 
since SLN can easily be found in single fibres (20) and in as much as 2 µg of human vastus 
lateralis homogenate (Figure A5).  In contrast, in WT mice, SLN cannot be detected in single 
fibres, and 25 µg of homogenate protein are typically required for detection in soleus muscles.  
Furthermore, in rat soleus muscles, where myofibres are ~3-4x larger than those from mice 
(96), SLN can be detected in single fibres (Figure 5.2.3) and with only 20 µg of homogenate 
protein (219).  To date, the reason for this pattern of expression across mammalian species is 
unknown; however, the findings presented in Chapter 4 of this thesis indicating a role for 
SLN in regulating muscle mass poses an interesting question: can differences in SLN 
expression contribute to differences in muscle size across species?  Even within species it 
would also be interesting to determine if changes in SLN expression could contribute to 
various conditions of muscle wasting such as aging and cachexia.  With respect to aging, 
previous studies have shown an inability of plantaris muscles from aged mice to hypertrophy 
in response to mechanical overload (220, 221).  Therefore, future studies could determine: 1) 
whether reductions in SLN content in aged skeletal muscles could account for the age-related 
muscle loss, and 2) whether a failure to recruit SLN during mechanical overload can account 
for the aged plantaris’ inability to adapt to the overload stimulus (220, 221).    
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Figure 5.2.3.  Single fibre Western blot image demonstrating SLN expression from rat soleus 
muscles.  All fibres were type I fibres that were positive for myosin heavy chain I, and both 
SERCA1a and SERCA2a were detected in every single fibre.     
 
 Importantly, this thesis did not examine the exact mechanisms leading to calcineurin-
mediated myofibre hypertrophy.  However, it is known that existing myofibres can grow in 
size through fusion with additional myoblasts (222, 223).  Indeed, satellite cells are critical in 
skeletal muscle growth induced by growth hormones (214) and during mechanical overload 
(224, 225).  Interestingly, NFATc2, another calcineurin-responsive NFAT isoform (150), has 
been implicated in skeletal muscle growth through its stimulatory action on myoblast to 
myotube/myofibre fusion (223, 226).  In fact, it has been previously shown that myotubes 
deficient in NFATc2 fail to hypertrophy upon treatment with growth hormone (227).  
Moreover, regenerating myofibres from Nfatc2-null mice were significantly smaller than 
their WT counterparts, specifically during the later stages of muscle regeneration (226).  Of 
interest, this finding is similar to the cardiotoxin injury experiments reported in Study III, 
whereby SlnKO mice exhibited a failure to hypertrophy at 21 days post-cardiotoxin injury 
(Figure C4).  Although the exact mechanism leading to NFATc2-induced muscle growth and 
myoblast fusion is unknown, it is thought that NFATc2 controls the expression of various 
cell-cell interaction factors and/or proteins secreted for recruitment of myoblasts (226).  
Nevertheless, SLN’s role in activating calcineurin shown here (Study III) and by Maurya et 
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al., (2015) suggests that SLN may activate NFATc2, and future studies could determine 
whether SLN is involved in muscle growth via effects on myoblast fusion.  In addition, 
during mechanical overload, calcineurin has been shown to repress the expression of 
myostatin (151), a potent negative regulator of skeletal muscle growth (228).  Therefore, one 
additional way in which SLN could induce muscle growth is by potentially attenuating the 
expression of myostatin and this should be examined with future studies.  
 
PLN and SLN divergence: additional support  
The results from this thesis provide additional insight into the divergence between 
PLN and SLN.  Specifically, the findings show that PLN overexpression can cause CNM, 
muscle atrophy, and weakness, whereas an increase in SLN expression is required to 
maintain muscle mass, stimulate muscle growth/remodeling, and counter disease pathology.  
Recent findings from M. Periasamy’s laboratory support the beneficial effects of increased 
SLN expression, as Sln overexpressing (SlnOE) mice exhibited enhanced contractility and 
reduced susceptibility to fatigue (229).  Interestingly, the enhanced contractility in the face of 
SLN overexpression is inconsistent with a previous study in which forced overexpression of 
SLN drastically impaired contractility (49).  This discrepancy may be explained by 
experimental design whereby the findings from Tupling et al. (2002) represent the acute 
effects of SLN overexpression, and those from Sopariwala et al. (2015) represent the effects 
of chronic SLN overexpression where certain cellular adaptations can thrive.  For example, 
the results from this thesis indicating SLN’s role in myofibre size suggest that perhaps an 
increase in myofibre CSA in SlnOE mice could explain the enhanced contractility; however 
this was not measured (229).  Moreover, SLN’s activation of calcineurin signaling shown in 
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study III and in SlnOE mice (184) can enhance oxidative capacity and increase fatigue 
resistance.  Thus, it is clear that increasing SLN over a long period can provide multiple 
benefits in muscle metabolism, structure, and function, which again are in contrast to PLN, 
where its overexpression causes detrimental effects such as weakness and atrophy.  Future 
studies should investigate the reasons why PLN and SLN have distinct effects on muscle 
structure and function. 
 The notion that PLN and SLN may have different roles in muscle physiology and 
cellular signaling in response to certain stressors is difficult to comprehend given that both of 
these proteins are viewed as inhibitors of the SERCA pump.  However, it is interesting to 
note the differences in the pattern of expression in response to these various stressors.  With 
respect to mechanical overload experiments, the plantaris muscles already expressed PLN in 
the sham condition, and were not different from the overloaded condition (Figure 5.2.4).  
Furthermore, PLN expression in soleus muscles was found to be significantly reduced in mdx 
muscles compared with WT, as well in response to high fat feeding (Figure 5.2.5), whereas, 
PLN content was significantly elevated in the tenotomized soleus (Figure 5.2.6).  Altogether, 
these data suggest that, unlike SLN which is consistently upregulated across these models, 
PLN’s response is variable, and this may precede their different roles in muscle physiology.   
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Figure 5.2.4.  PLN expression is unaltered in plantaris muscles in response to mechanical 
overload (OV).  Ponceau was used as a loading control and all data are expressed relative to 
sham (n = 6 per genotype). 
 
 
 
 
 
 
Figure 5.2.5.  PLN expression is reduced in soleus muscles from mdx mice (A) and mice fed 
a high-fat diet (HFD) (B).  Ponceau was used as a loading control and all data are expressed 
relative to WT or chow. n = 5 per genotype for (A) and 8 per dietary group for (B).  
*Significantly different from WT (A) or chow (B) using a Student’s t-test, P < 0.05. For (B), 
mice were fed a high-fat diet (42% kcal) for 8 weeks. 
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Figure 5.2.6.  PLN expression is upregulated in soleus muscles in response to tenotomy 
(Tny).  Ponceau was used as a loading control and all data are expressed relative to sham (n = 
6 per genotype).  * Significantly different from sham using a paired (two-tailed) t-test, P < 
0.05. 
 
 
 
Nonetheless, the question of whether SERCA inhibition induced by PLN can promote 
muscle growth and remodeling and calcineurin activation similar to SLN irrespective of the 
differences in their protein expression remains.  Although, it would be possible for PLN to 
stimulate calcineurin signaling likely through SERCA inhibition, differences in its regulation 
of SERCA may suggest that its capacity to enhance [Ca2+]i suitable for calcineurin activation 
may be lower than SLN.  In particular, PLN is thought to dissociate from SERCA upon Ca2+ 
binding and may only bind to SERCA in its E2 Ca2+ unbound state, whereas SLN can bind to 
SERCA throughout its catalytic cycle despite the presence of Ca2+ (30).  This would suggest 
that while PLN can prevent Ca2+ from binding to SERCA and thus elevate the [Ca2+]i 
required for calcineurin activation, perhaps the concomitant rise in [Ca2+]i within that specific 
microdomain may also cause an appreciable dissociation of PLN from SERCA. Therefore, 
PLN may not amplify calcineurin as well as SLN that is able to maintain its physical 
interaction with SERCA.   
In the context of the PlnOE model, the sheer overexpression of PLN may be able to 
circumvent the competitive displacement that occurs with Ca2+ and may allow for the 
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calcineurin signaling that presumably leads to the type I fibre predominance.  Nevertheless, 
the fast-to-slow fibre type shift was blunted when Sln was genetically removed from the 
PlnOE mice thereby highlighting the importance of SLN upregulation.  In addition, although 
PLN was upregulated in soleus tenotomy and could also potentially circumvent the 
competitive displacement that occurs with Ca2+ and allow for greater calcineurin signaling in 
that particular model, it is important to note the consistent association between muscle 
atrophy and PLN expression.  In the PlnOE soleus and tenotomized soleus muscles from this 
thesis, and in the denervated EDL and soleus muscles from a recent study (manuscript 
currently in submission in collaboration with Dr. Jerome Frennette; see reference (230)), 
PLN expression was significantly upregulated.  Thus, future experiments in PlnKO mice using 
soleus tenotomy or sciatic nerve denervation should be done to determine whether the 
upregulation in PLN causes muscle atrophy similar to that seen in the PlnOE mice.  Lastly, the 
fact that PLN was not upregulated (ie. unaltered or reduced) in the mechanical overload and 
mdx mouse models, may mean that PLN would likely have a smaller role in amplifying 
calcineurin signaling compared with SLN that was found to upregulated and can remain 
bound to SERCA during conditions of elevated [Ca2+]i.  
Future experiments using primary cell cultures from both SlnKO and PlnKO myofibres 
may directly assess whether PLN and SLN stimulates calcineurin signaling and to what 
extent.  For example, primary myoblasts/myotubes from PlnKO and SlnKO muscles could be 
treated with ionomycin, a Ca2+ mobilizing agent often used in these types of experiments, to 
determine whether NFAT nuclear localization occurs differently in the absence of PLN or 
SLN compared with WT (226, 231).  Alternatively, stimulating muscles with a repetitive 
tonic low frequency pattern (20 Hz, for 10 s every 30 seconds) causes rapid NFATc1 nuclear 
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localization in adult TA muscles (161), and could potentially be used in the investigation of 
whether or not PLN and SLN directly activates calcineurin and NFAT localization.  However, 
since SLN was only found in the overloaded TA muscle (Figure 4.4), experiments on the 
overloaded condition would be most appropriate. 
Current ongoing experiments within our laboratory will also provide further 
indication of whether or not PLN and SLN have similar roles in muscle physiology and 
calcineurin signaling. With respect to muscle metabolism and obesity, it is now thought that 
SLN’s activation of calcineurin, and thus, oxidative capacity, plays a vital role in combatting 
the effects of high-fat feeding (184, 232).  Preliminary data from our laboratory suggests that 
the PlnKO mice respond differently to a high-fat diet compared with SlnKO mice and may 
ultimately suggest that PLN may not have a role in stimulating calcineurin.  With respect to 
mdx, we have generated the mdx/PlnKO mice in similar fashion to the mdx/SlnKO mice, and 
future experiments on muscle fibre type, size, and integrity will provide further indication of 
whether PLN can stimulate calcineurin signaling, given calcineurin’s importance in dictating 
fibre type specialization, size, and muscle regeneration (150, 151, 178-180, 226, 233, 234).  
If PLN does not stimulate calcineurin at least to the capacity of which SLN can, then 
although purely speculative, the data presented in this thesis and found within the current 
literature may suggest that PLN in skeletal muscle offers dynamic control of Ca2+ handling, 
similar to that in cardiac tissue, whereas SLN in skeletal muscle may be utilized and recruited 
more for cellular signaling processes.  Essentially, SLN’s ability to inhibit SERCA in the 
face of greater [Ca2+]i may make SLN more suitable for cellular signaling and mediating 
necessary adaptations, and may explain why it is consistently elevated across many skeletal 
muscle diseases and also during muscle growth and development (24).  Future experiments 
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with other models of skeletal muscle disease, damage and aging, will provide further 
evidence for the role of SLN in countering pathology.  In contrast, the dissociation of PLN 
from SERCA under conditions of elevated [Ca2+]i may allow for greater SERCA mediated 
Ca2+ uptake and may elicit similar chronotropic and inotropic effects normally found in 
cardiac muscle (97).  Perhaps it is of no coincidence that PLN is found primarily in type I 
fibres (20) that have greater β-adrenergic receptors compared with type II (235), as this 
would also provide further dynamic control of Ca2+ handling and muscle contractility via 
PLN phosphorylation.  In the context of disease, it is possible that PLN overexpression and 
the potential concomitant loss in this dynamic control of Ca2+, as result of a failure of Ca2+ to 
displace PLN from SERCA, may also have a role in CNM pathology and muscle atrophy.  
Indeed, there are loss-of-function PLN mutations that do not inhibit SERCA, yet cause 
cardiomyopathy, as a result of a failure to phosphorylate normal PLN molecules and to 
promote the dynamic control of Ca2+ (98).  Future experiments, knocking in these various 
loss-of-function Pln mutants in the skeletal muscles of mice to determine whether they also 
cause atrophy and CNM muscle pathology would be of interest, as it would provide further 
insight on PLN’s role in muscle pathology and could potentially explain the divergence 
between PLN and SLN reported in this thesis.     
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Figure A1. PLN is overexpressed in type I fibres from soleus muscles.  PLN expression in single fibres from 
WT mice was modestly detected in some type I and type IIA fibres and is clearly overexpressed in type I fibres 
from PlnOE mice.  MHCI was used to identify type I fibres.  After detection of MHCI, membranes were stripped 
and re-probed with MHCIIa to identify type IIA fibres.  Residual signals from MHCI were still present after the 
stripping and re-probing protocol.  PLN (p), PLN pentamer; PLN (m), PLN monomer.  
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Figure A2.	  Embryonic MHC in soleus muscles of PlnOE mice. Centrally-located nuclei depicted through H&E 
staining cannot be fully explained by muscle regeneration as myosin heavy chain immunofluorescent stained 
sections of the soleus muscles show only minimal fibres positive for embryonic myosin heavy chain (eMHC, 
green). Cross sections were stained with dystrophin (red) to mark the sarcolemmal membrane of the fibre.  
Fibre-type analysis indicates that centrally-located nuclei are predominantly found in type I fibres (MHC I, 
blue) but can also be seen in some type IIA fibres (MHC IIa, green). Scale bars are set to 100 µm. White 
asterisks represent the same fibre in serial cross-sections. 
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Figure A3. Impaired SERCA function and CNM in gluteus minimus muscles from PlnOE mice. (A) Western 
blotting for PLN in WT and PlnOE mice from gluteus minimus homogenates.  For WT mice, 25 µg of total 
protein was loaded whereas only 2.5 µg was required for PlnOE mice to detect PLN protein.  (B) Ca2+-ATPase 
activity-pCa curves in WT (n = 7) and PlnOE mice (n = 6) in the presence of the Ca2+ ionophore .  (C)  Ca2+ 
uptake assessed in soleus and gluteus minimus muscles from WT (n = 6) and PlnOE mice (n = 6). Western 
blotting for SERCA1a (D), SERCA2a (E), and sarcolipin (SLN; F) in soleus from WT and PlnOE mice (n = 6 
per genotype).  Actin was used as a loading control and all values are expressed relative to WT.  Representative 
gluteus minimus cross sections after H&E (G), Van Gieson (H), SDH (I), and immunofluorescent (J) staining. 
Cross sections were stained with MHC antibodies to identify type I (blue), type IIA (green), type IIB (red), and 
type IIX (unstained).  Yellow dashed lines in (J) indicate the area that likely represents the gluteus medius and 
not the gluteus minimus.  (K) Percent of fibres containing central nuclei in the gluteus minimus at 4-6 months 
(n = 4 per genotype at each age with 300-600 fibres counted per mouse).  (L) Quantitation of fibrotic area in the 
soleus at 4-6 months of age (n = 4 per genotype).  ImageJ software was used to quantify fibrotic area. 
*Significantly different from WT using Student’s t-test, P < 0.05.  All values are presented as mean ± standard 
error. Scale bars in (G)- (J) are set to 50 µm.       
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Figure A4. Muscle function in PlnOE mice.  (A) Soleus isometric twitch force normalized to mass in 4-6 month 
old mice (WT n = 17, PlnOE = 6). (B) Maximum rates of isometric twitch force development in soleus muscles 
from 4-6 month old mice (WT n = 17, PlnOE = 6).  (C) Maximum rates of isometric twitch force relaxation in 
soleus muscles from 4-6 month old mice (WT n = 17, PlnOE = 6).  (D) Force-frequency analysis in soleus 
muscles from 4-6 month old mice (WT n = 17, PlnOE = 6).  (E) Treadmill exercise performance of 4-6 month 
old mice measured as time (min) to exhaustion. * Significantly different from WT, P < 0.05.  All values are 
presented as mean ± standard error.   
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Figure A5.  Ca2+-ATPase activity and protein expression in muscle biopsies from three patients with 
centronuclear myopathy (CNM).  (A) Maximal rates of SERCA ATPase activity in biopsies from patients with 
CNM and healthy controls.  Western blotting for PLN (B), MHC I (C), SERCA2a (D), SERCA1a (E), and SLN 
(F) in biopsies from patients with CNM and healthy controls.  Actin was used as a loading control. 
*Significantly different from healthy using Student’s t-test, P < 0.05.  All values are presented as mean ± 
standard error. PLN (m), monomeric PLN; PLN (p) pentameric PLN; PLN (t), total boiled PLN. For PLN, 
MHCI, and SERCA2a 1 µg of total protein was loaded.  For SERCA1a 0.5 µg of total protein was loaded. For 
SLN 2 µg of total protein was loaded.  CNM (R369W), DNM2-CNM patient.    
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Figure A6.  Dynamin 2 protein content in the PlnOE soleus (A) and PlnOE gluteus minimus (B) muscles, and in 
muscle biopsies from three CNM patients compared to five healthy controls (C). For mouse soleus and gluteus 
minimus muscles, 7.5 µg of total protein were loaded, and 2 µg were loaded for human vastus lateralis. Actin 
was used as a loading control. *Significantly different from WT or healthy, using Student’s t-test, P < 0.05.  All 
values are presented as mean ± standard error. CNM (R369W), DNM2-CNM patient. 
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Table A1.  Body weight, soleus weight, and soleus:body weight ratios in WT and PlnOE mice 
at 1 month, 4-6 months, and 10-12 months of age. 
 1 month 4-6 months 10-12 months 
Body weight    
   WT 22.9 ± 0.7  30.8 ± 0.8 33.1 ± 1.1 
   PlnOE 22.4 ± 0.5 29.2 ± 0.5 33.7 ± 0.5 
Soleus weight    
   WT 4.5 ± 0.4 6.5 ± 0.4 5.8 ± 0.4 
   PlnOE 3.3 ± 0.3   3.6 ± 0.3*   4.0 ± 0.1* 
Soleus:body weight    
   WT 0.19 ± 0.01 0.21 ± 0.01 0.17 ± 0.01 
   PlnOE 0.15 ± 0.01   0.12 ± 0.01*   0.10 ± 0.01* 
Values are means ± standard error.  1 month (WT, n = 8; PlnOE, n = 8); 4-6 months (WT, n = 
15; PlnOE, n = 15); 10-12 months (WT, n = 8; PlnOE, n = 6).  *Significantly different from 
WT within the same age group, P < 0.05 using two-way ANOVA including genotype and 
age as factors and a Tukey’s post-hoc test when necessary.   
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Table A2.  SERCA activity in gluteus minimus muscles from WT and PlnOE mice at 4-6 
months of age. 
Values are means ± standard error.  Homogenates were isolated from WT and PlnOE mouse 
gluteus minimus muscles and were analyzed for Ca2+-ATPase activity over Ca2+ 
concentrations ranging from pCa 7 to pCa 4.5 to obtain KCa.  KCa is the Ca2+ concentration 
required to attain the half-maximal Ca2+-ATPase activity rate and is expressed in pCa units.  
*Significantly different from WT using Student’s t-test, P <0.05.  A trend was observed for 
the KCa in the gluteus minimus muscles from WT and PlnOE mice (P = 0.10). 
  
Genotype Vmax KCa ΔpCa50 
WT 558.5 ± 29.1 5.99 ± 0.02 - 
PlnOE   477.1 ± 24.5* 5.96 ± 0.01 0.03 
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Table A3.  Quantitative analysis of fibre type distribution and cross-sectional area (CSA) in 
gluteus minimus muscles from WT and PlnOE mice at 4-6 months of age. 
Values are means ± standard error (n = 5-6 per genotype).  *Significantly different from WT 
within the same age; P < 0.05 using Student’s t-test.  
  
 Fibre distribution (%) Fibre CSA (µm2) 
 Type I    
   WT 26.9 ± 0.5 2713 ± 102 
   PlnOE   47.7 ± 2.4*   1009 ± 180* 
 Type IIA   
   WT 50.4 ± 1.7 2177 ± 110 
   PlnOE   31.9 ± 2.9* 3026 ± 461 
 Type IIX   
   WT 10.2 ± 1.0 2401 ± 118 
   PlnOE   8.7 ± 0.7   3913 ± 406* 
 Type IIB   
   WT 7.2 ± 0.7 4388 ± 189 
   PlnOE 9.4 ± 0.3   5465 ± 267* 
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Figure B1.  Lifespan of PlnOE (n = 23) and WT (n = 17) mice.  *Significantly different from WT, using 
Student’s t-test, P < 0.05.   
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Figure B2.  Ca2+ uptake assays in the soleus (A) and gluteus minimus (B) muscles from PlnOE and WT mice.  
Ca2+ uptake assays were assessed at a pCa of 6.0. *Significantly different from WT, using Student’s t-test, P < 
0.05.  WT, soleus n = 4, gluteus minimus n =6; PlnOE, soleus n = 4, gluteus minimus n = 6. 
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Figure B3.  Calcineurin (CnA) and nuclear factor of activated T-cell (NFAT) nuclear content in soleus (A, D), 
gluteus minimus (B, E) and diaphragm (C, F) muscles from PlnOE and WT mice.  (G) Nuclear cell fraction 
purity demonstrated through Western blots from tibialis anterior muscles using Histone H2B and CuZnSOD as 
nuclear and cytosolic markers, respectively. Two tailed Student’s t-tests were used to assess statistical 
significance for CnA expression across skeletal muscles (n = 6 per genotype). Based on those results, one tail 
Student’s t-tests were used for NFAT content analysis (n = 4 per genotype). *P < 0.05. 
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Appendix C 
Note on on total fibre count  
  
The total fibre count is a useful measure in determining whether changes in muscle 
mass is due to hyper- or hypoplasia.  In addition, changes in the fibre type distribution in the 
absence of changes in total fibre count, may also suggest that a ‘true’ shift in fibre type is 
more likely occuring.  In the PlnOE mouse model reported in Study I of this thesis, there was 
a significant main effect of age (P = 0.05) and genotype (P = 0.03) when assessing the total 
fibre count Figure C1.  The main effect of age suggests that as animals aged there was a 
reduction in total fibre count, which corresponds well with sarcopenia that occurs with aging.  
The main effect of genotype suggests that there were an increase number of fibres in the 
PlnOE mice, which is inconsistent with the muscle atrophy that occurs in the soleus muscles 
of these fibres.  This could potentially be explained by the splitting of the type I fibres into 
smaller caliber myofibres as a result of the selective PLN overexpression and may also 
contribute to the greater proportion of type I fibres found in these muscles.   
 
 
Figure C1.  Total fibre count in PlnOE and WT soleus muscles at 1 month, 4-6 months, and 
10-12 months of age.  Two-way ANOVA detected a significant main effect of age and 
genotype, but no interaction, P < 0.05. 
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In the diaphragm muscles assessed in Study II of this thesis, there was a trending 
decrease in the total fibre counts found in response to PlnOE (P = 0.06) which may 
correspond well with the selective loss of type I fibres and thus increase in type II fibre 
proportion (Figure C2).  However, caution should be taken when interpreting total fibre 
counts from the diaphragm, as the total number would be highly dependent on the size of the 
diaphragm strip extracted for fibre type analyses.  
 
 
Figure C2.  Total fibre count in PlnOE and WT diaphragm strips 4-6 months of age.  
Student’s t-test detected a trend, P = 0.06. 
 
 The total fibre count analyses in all models of Study III were also performed.  
Interestingly, hypoplasia was found in the PlnOE/SlnKO muscles, which could also contribute 
to the exacerbated soleus muscle atrophy found in these mice (Figure C3A).  
Correspondingly, deletion of Sln removed the expected myofibre hyperplasia (236) in 
response to mechanical overload (Figure C3B), which would suggest that SLN may have a 
role in maintaining total fibre counts.  However, there were no differences in total fibre count 
in tenotomy experiments or mdx soleus muscles in the absence of SLN (Figure C3C and D). 
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Figure C3.  Total fibre count in PlnWT/SlnWT, PlnOE/SlnWT, and PlnOE/SlnKO soleus muscles 
(A), sham and mechanically overloaded WT and SlnKO plantaris muscles (B), sham and 
tenotomized WT and SlnKO muscles (C), and mdx and mdx/SlnKO soleus muscles.  For (A), 
*significantly different from PlnWT/SlnWT, † significantly different from PlnOE/SlnWT using a 
one-way ANOVA with a Tukey’s post hoc test, P < 0.05.  For (B) and (C), *significantly 
different from sham within a specific genotype using a paired (one-tailed) t-test, P < 0.05. 
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Appendix D 
Protocols for genotyping mice 
 To genotype the PlnOE, SlnWT and SlnKO mice, all mice were ear notched and tagged 
at 3-4 weeks of age.  The DNA was then extracted from ear notches using a pureLink 
Genomic DNA mini kit (Invitrogen, Carslbad, CA).  PCR was then performed to amplify the 
DNA of interest.  Briefly, approximately 50 ng of DNA was added to a Taq DNA 
polymerase mix (EP0402, Thermo Scientific Fermentas, Canada) containing Taq Buffer with 
(NH4)2S04 buffer (diluted to 1X), 4 mM MgCl2, 200 µM dNTP (R0192, Thermo Scientific 
Fermetas), 0.625 units of Taq DNA polymerase, and 0.4 µM of the appropriate forward and 
reverse primers (Table D1).  Samples were then placed in a thermal cycler (MJ MINI, Bio-
Rad Canada) and underwent their respective PCR reactions (Table D2).  The amplified 
products were then separated on a 1% agarose gel (in 1X TBE) containing 0.01% ethidium 
bromide (Bioshop, Canada) for 40 min at 80V in 1xTBE buffer, and identified using a bio-
imaging system (Syngene, Frederick, MD). 
 
Table D1.  Forward and reverse primers used to detect PlnOE, SlnWT, and SlnKO mice. 
Mouse Sequence 
PlnOE  
   forward, SK-1 5’-AAG GGG CGG GAA GGC ATA TAG-3’ 
   reverse, PLB-RC 5’-GAT TCT GAC GTG CTT GCT GAGG-3’   
SlnWT  
   forward  5’-TGT CCT CAT CAC CGT TCT CCT-3’ 
   reverse 5’-GCT GGA GCA TCT TGG CTA ATC-3’ 
SlnKO  
   forward 5’-GTG GCC AGA GCT TTC CCA TA-3’ 
   reverse 5’-CAA AAC CAA ATT AAG GGC CA-3’ 
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Table D2.  PCR cycles for PlnOE SlnWT, and SlnKO mice. 
Mouse Temperature (°C) Time Number of cycles 
PlnOE    
   1. Denaturation 95 3 min 1 
   2. Denaturation 94 30 s  
34 cycles (ie. go to 
2 34 times) 
   3. Annealing 70 30 s 
   4. Extension 72 1 min 
   5. Final Extension 72 10 min 1 
   6. Hold 4 - can hold here until 
ready to perform 
electrophoresis. 
    
PlnOE    
   1. Denaturation 94 3 min 1 
   2. Denaturation 94 30 s  
30 cycles (ie. go to 
2 34 times) 
   3. Annealing 51 30 s 
   4. Extension 72 1 min 
   5. Final Extension 72 7 min 1 
   6. Hold 4 - can hold here until 
ready to perform 
electrophoresis. 
 
 
 To genotype the mdx mice, at 3-4 weeks of age all mice were ear notched and tagged. 
The DNA was then extracted using a high-purity/high-yield DNA extraction protocol (see 
below).  Following this, 40 ng of DNA was added to a Taq DNA polymerase mix (EP0402, 
Thermo Scientific Fermentas, Canada) containing Taq Buffer with (NH4)2S04 buffer (diluted 
to 1X), 4 mM MgCl2, 200 µM dNTP (R0192, Thermo Scientific Fermetas), 0.6 units of Taq 
DNA polymerase, and 0.66 µM of the appropriate forward and reverse primers (Table D3).  
The primers used in this assay were based from a competitive PCR reaction that uses a 
common forward primer, mdx reverse primer, and a WT reverse primer (237).  The PCR 
reaction is detailed in Table D4.  The amplified products were then separated on a 3% 
agarose gel (in 1x TBE) containing 0.01% ethidium bromide (Bioshop, Canada) for 80 min at 
100V in 1xTBE buffer, and identified using a bio-imaging system (Syngene, Frederick, MD). 
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High DNA Extraction Protocol 
 
Buffers: 
 
Mouse Ear-notch/Tail DNA Isolation Buffer 
0.5% SDS 
0.1M NaCl 
0.05M Tris base (pH 8.0) 
2-4mM EDTA 
Set final pH to 8.0.  
 
8M Potassium Acetate 
4g in 200mL dH20 (autoclaved water) 
 
 
1. Add Proteinase K from pureLink Genomic DNA mini kit (Invitrogen, Carslbad, CA) 
to mouse ear-notch/tail DNA Isolation Buffer (see recipe below) at a concentration of 
1.0 mg/ml and mix. 
2. Add 400ul of solution to each Eppendorf tube with sample (ear notch/tail clip). Place 
tubes in a conical tube. 
3. Immediately place tubes in a water bath set to 63°C. Let tissue digest overnight. 
NOTE: The digests are freezable after. 
4. Add 75ul of 8M potassium acetate to each tube.  
5. Add 500ul of chloroform to each tube. Vortex for 5-10 mins. Sample can be frozen 
overnight if needed. 
6. Spin 5-8mins at 9,000 g. 
7. Pipetter aqueous top layer in a new Eppendorf tube. There should be approximately 
400ul. 
8. Add 2 volumes (if you get 400ul from step 7 then you add 800ul) of 100% ethanol at 
room temperature. Mix by inverting.  
9. Spin at 14000 rpm for 20min at 4°C. 
10. Remove the supernatant and air dry for 2-3 mins.  
11. Add 30 ul of Autoclaved Water. 
12. Dilute to desired concentration with autoclaved water after determining concentration 
in a Nanodropper 2000 (for mdx genotyping protocol dilute to 20ng/ul). 
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Table D3.  Forward and reverse primers used to detect mdx mice. 
Primer name Sequence 
Common forward 
(DL1577) 
5’GCG CGA AAC TCA AAT ATG CGT GTT AGT GT-3’ 
WT forward 
(DL1509) 134 bp 
5’-GAT ACG CTG CTT TAA TGC CTT TAG TCA CTC AGA 
TAG TTG AAG CCA TTT TG-3’ 
mdx reverse 
(DL1573) 117 bp 
5’-CGG CCT GTC ACT CAG ATA GTT GAA GCC ATT TTA-3’ 
 
Table D3.  PCR cycle for mdx mice. 
 Temperature (°C) Time Number of cycles 
mdx    
   1. Denaturation 94 5 min 1 
   2. Denaturation 94 30 s  
34 cycles (ie. go to 
2 34 times) 
   3. Annealing 60 30 s 
   4. Extension 72 30 s 
   5. Final Extension 72 3 min 1 
   6. Hold 4 - can hold here until 
ready to perform 
electrophoresis. 
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Appendix E 
Breeding strategies for transgenic mice 
PlnOE/SlnKO (PlnOE/Sln-/-) and PlnOE/SlnWT (PlnOE/Sln+/+) Breeding Strategy 
 
F1 - PlnOE mice (AUPP 10-11) were mated with Sln-/- mice (11-03).  As PlnOE mice are 
heterozygous for the transgene F1 offspring are 50% PlnOE and 50% without the transgene.  
Since PlnOE mice are homozygous for Sln-positive (Sln+/+) the F1 offspring will be 100% 
heterozygous for Sln ablation (Sln-/+).  At this point F1 progeny are 50:50 for 
FVB/N:C57BL/6J. 
F2 - Progeny from F1 will be used to generate F2 progeny. Specifically, from here we 
decided to generate two subset colonies: 1) PlnOESln-/- and 2) PlnOESln+/+.  To do this, 
PlnOESln+/- F1 progeny were crossed with either the Sln-/-or the Sln+/+ mice from AUPP 11-03.  
From this cross, we were able to generate the PlnOESln-/- and the PlnOESln+/+ mice that were 
then used for the F3 cross. At this point F2 progeny are 25:75 for FVB/N:C57BL/6J. 
F3 - The PlnOESln-/- and the PlnOESln+/+ mice were then mated with Sln-/- and the Sln+/+ mice, 
respectively.  Again we were able to generate the PlnOESln-/- and the PlnOESln+/+ mice that 
were then used for the F4 cross.  At this point F3 progeny are 12.5:87.5 for 
FVB/N:C57BL/6J. 
F1 
PlnOE (FVB/N)    x    Sln-/- (C57BL/6J) 
•  50% PlnOE Sln+/- (FVB/N / C57BL/6J) 
•  50% Sln+/- (FVB/N / C57BL/6J) 
PlnOE Sln-negative (PlnOE Sln-/-)  PlnOE Sln-positive (PlnOE Sln+/+)  
F2 PlnOE Sln+/- (FVB/N / C57BL/6J)   x   Sln-/- (C57BL/6J) PlnOE Sln+/- (FVB/N / C57BL/6J)   x   Sln+/+ (C57BL/6J) 
•  25% PlnOE Sln-/- (FVB/N / C57BL/6J) 
•  25% PlnOE Sln+/- (FVB/N / C57BL/6J) 
•  25% Sln+/- (FVB/N / C57BL/6J) 
•  25% Sln-/- (FVB/N / C57BL/6J) 
•  25% PlnOE Sln+/+ (FVB/N / C57BL/6J) 
•  25% PlnOE Sln+/- (FVB/N / C57BL/6J) 
•  25% Sln+/- (FVB/N / C57BL/6J) 
•  25% Sln-+/+ (FVB/N / C57BL/6J) 
F3 PlnOE Sln-/- (FVB/N / C57BL/6J)   x   Sln-/- (C57BL/6J) PlnOE Sln+/+ (FVB/N / C57BL/6J)   x   Sln+/+ (C57BL/6J) 
•  50% PlnOE Sln-/- (FVB/N / C57BL/6J) 
•  50% Sln-/- (FVB/N / C57BL/6J) 
•  50% PlnOE Sln+/+ (FVB/N / C57BL/6J) 
•  50% Sln+/+ (FVB/N / C57BL/6J) 
F4, F5, F6 repeat F3 crosses with Sln-/- or Sln+/+ until F6 to be considered 100% C57BL/6J 
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F4 – Repeat of F3 cross.  Again we were able to generate the PlnOESln-/- and the PlnOESln+/+ 
mice that were then used for the F4 cross.  At this point F4 progeny are 6.25:93.75 for 
FVB/N:C57BL/6J.  These mice were used for initial experiments under AUPP 13-01. 
F5 – Repeat of F4 cross.  Again we were able to generate the PlnOESln-/- and the PlnOESln+/+ 
mice that were then used for the F6 cross.  At this point F5 progeny are 3.125:96.875 for 
FVB/N:C57BL/6J.  These mice will be used for experiments under AUPP 13-01. 
F6 – Repeat of F5 cross.  We will generate the PlnOESln-/- and the PlnOESln+/+. At this point 
F6 progeny are 1.56:98.43 for FVB/N:C57BL/6J.  Typically, this enough for these mice to be 
considered 100% C57BL/6J.  These mice will be used for experiments under AUPP 13-01. 
Since these mice are considered 100% C57BL/6J after F6 we will no longer need to 
backcross onto the Sln-/- or Sln+/+ mice from AUPP 11-03.  Instead, we can maintain these 
colonies by breeding the Sln-/- or Sln+/+ mice generated from the F6 and future F generations.  
However, it is probably better practice to keep breeding to the Sln-/- or Sln+/+ mice from 
AUPP 11-03, as this will completely eliminate the chances of getting a homozygous PlnOE 
mouse (ie. the Sln-/- or Sln+/+ mice from AUPP 11-03 never overexpressed PLN). 
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Mdx/SlnKO mice 
To generate our research animals for our mdx/SlnKO and mdx/SlnWT (mdx) colonies we first 
crossed homozygous female mdx animals with a male homozygous SlnKO mouse. 
 
 
From this cross we obtained F1 offspring that are either female hemizgous mdx or male 
heterozygous mdx.  All F1 offspring were heterozygous for Sln.  Next, we crossed F1 
offspring male and females together (from a separate breeding pair so that it is not inbred).  
 
The resulting F2 offspring will be a variety of genotypes including our experimental animals, 
mdx and mdx/SlnKO.  To improve the odds at which we generate the experimental animals, 
we generated two subset colonies that independently gave rise to mdx mice and mdx/SlnKO 
mice. 
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mdx/SlnKO: For this subset colony dystrophin positive male mice from F2 were bred with 
heterozygous mdx females from F2, and both sires and dams were homozygous for SlnKO. 
 
 
mdx: For this subset colony dystrophin positive male mice from F2 were bred with 
heterozygous mdx females from F2, and both sires and dams were homozygous for SlnWT. 
 
 
Note: Because crosses were bred from previous generations, the strain is a 50:50 mix of 
C57BL/10Scn:C57BL6/J).  To prevent genetic drift, the mdx and mdx/SlnKO subset colonies 
should be limited to 3 additional generations. 
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Appendix F 
Protocol for SERCA activity assay  
As per Duhamel et al. (137). 
Buffers 
Muscle Homogenizing Buffer 
500 mM HEPES pH7.5 
200 mM PMSF 
 
SR Homogenate Ca2+-ATPase buffer 
      For 1L  For 200 ml 
200 mM KCL     14.91 g 2.982 g 
20 mM HEPES    4.766 g 953.2 mg 
10 mM NaN3     650 mg 130.02 mg 
1 mM EGTA     380.4 mg 76.08 mg 
15 mM MgCl2     1.428 g 285.62 mg 
5 mM ATP     3.026 g 605.2 mg 
10 mM Phosphoenolpyruvate (PEP)   4.688 g 930.6 mg 
 
Heat to 37°C and then pH to 7.0 with 2N KOH 
Store at -20°C 
 
Isolation Ca2+-ATPase buffer 
      For 1L  For 200 ml 
100 mM KCL     7.45 g  1.491 g 
20 mM HEPES    4.766 g 953.2 mg 
10 mM NaN3     650 mg 130.02 mg 
1 mM EGTA     380.4 mg 76.08 mg 
10 mM MgCl2     952 mg 190.4 mg 
5 mM ATP     3.026 g 605.2 mg 
10 mM Phosphoenolpyruvate (PEP)   4.688 g 930.6 mg 
 
Heat to 37°C and then pH to 7.0 with 2N KOH 
Store at -20°C 
 
Enzymes and reagents 
 
18 Uml-1 pyruvate kinase (PK, 10-128-163-001, Roche) 
 
18 Uml-1 lactate dehydrogenase (LDH, L2625-25 KU, Sigma) 
 
1 mgml-1 Calcium Ionophore (A23187, C-7522 Sigma; 10 mg in 10 ml of HPLC grade 
ethanol) 
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1.9 % (w/v) NADH (Divide mass by 19 to get volume of water needed) only good for 6 
hours. (13348539, Roche) 
 
10 mM CaCl2 
 
40 mM cyclopiazonic acid (CPA, 111258-00-5, Sigma) (50 mg in 3.71 ml chloroform) 
 
Protocol 
 
1. Pipette Ca2+ from 10 mM CaCl2 stock into eppendorf tubes to get 16 different 
calcium concentrations. This will vary depending on muscle type and species. 
 
Example: Add to 16 different tubes: 
1. 12 µl 
2. 15 µl 
3. 18 µl 
4. 19.5 µl 
5. 21 µl 
6. 22 µl 
7. 23 µl 
8. 24 µl 
9. 25 µl 
10. 26 µl 
11. 27 µl 
12. 28 µl 
13. 29 µl 
14. 30 µl 
15. 31 µl 
16. 31 µl + 1 µl CPA (measure background ATPase) 
 
2. Make reaction master mix: 
  5 ml of ATPase Buffer 
13.5 µl LDH 
18 µl PK 
10.5 µl Ionophore 
20 µl of SR vesicles or homogenate  
3. Transfer 300 µl of master mix to each of the 16 Eppendorf tubes. Transfer 4 at a time 
then vortex before the next 4 tubes and so on. 
4. Vortex Eppendorf tubes and pipette 100 µl in duplicate to a clear 96 well-plate 
5. Add 2 µl of NADH to each well immediately prior to reading the plate. 
6. Place loaded plate into Spec Plate reader and complete a Path length correction read. 
This corrects the path length to 1/3 of a cm. 
7. Then read plate on Spec Plate reader for kinetic assay 
Temp = 37°C 
Time = 30 min 
Wavelength = 340 nm 
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 All data are then plotted against a negative logarithm of [Ca2+]f (pCa) using 
GraphpadTM Prism statistical software to determine KCa, which is the concentration required 
to elicit half-maximal SERCA activity reported in pCa units (ie. pCa50).  Specifically, KCa 
was determined by non-linear regression curve fitting using the sigmoidal dose response 
equation: 
  
Y = Ybot + (Ytop – Ybot)/(1 +(LogCa50- x) * nH) 
 
where Ybot is the bottom of the plateau, Ytop is the top of the plateau, Log Ca50 is the 
logarithm of pCa50 and nH is the hill coefficient.   Note that the maximal SERCA activity is 
taken from the raw data and not the plateau estimated from Graphpad.    
 The accurate measurement of [Ca2+]f used for the ATPase activity assay was 
measured using the Ca2+ fluorophore, indo-1 on a spectrophotometric plate reader 
(SPECTRAmax Gemini SX; Molecular Devices, Toronto, ON).  The 16 different Ca2+ 
additions along with a zero Ca2+ and max Ca2+ (10 mM) were measured in triplicate as 
described below. 
1. Pipette Ca2+ from 10 mM CaCl2 stock into eppendorf tubes to get 17 different 
calcium concentrations. You will have to multiply the original additions for the assay 
by 4/3 to adjust for triplicate rather than duplicate (ie. working with 400 µl of reaction 
mix per tube rather than 300 µl). 
 
Example: Add to 16 different tubes: 
17. 12 µl x 4/3 = 16 µl 
18. 15 µl x 4/3 = 20 µl 
19. 18 µl x 4/3 = 24 µl 
20. 19.5 µl x 4/3 = 25.9 µl  
21. 21 µl x 4/3 = 27.9 µl 
22. 22 µl x 4/3 = 29.3 µl 
23. 23 µl x 4/3 = 30.6 µl 
24. 24 µl x 4/3 = 31.9 µl 
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25. 25 µl x 4/3 = 33.3 µl 
26. 26 µl x 4/3 = 34.6 µl 
27. 27 µl x 4/3 = 35.9 µl 
28. 28 µl x 4/3 = 37.2 µl 
29. 29 µl x 4/3 = 38.6 µl 
30. 30 µl x 4/3 = 40 µl 
31. 31 µl x 4/3 = 41.2 µl 
32. 0 Ca2+ 
33. max Ca2+: 41.2 µl of 10 mM CaCl2 
 
2. Make reaction master mix: 
  7 ml of ATPase Buffer 
18.9 µl LDH 
25.2 µl PK 
14.7 µl Ionophore 
8 µl INDO-1 (in the dark) 
3. Transfer 400 µl of master mix into each of the Ca2+ addition tubes. Transfer 4 at a 
time then vortex before the next 4 tubes and so on. 
4. Vortex Eppendorf tubes and load 100µl in triplicate onto black 96 well plate (Costar, 
Corning Incorporated, NY). 
5. Read black plate on Fluor Plate reader (SPECTRAmax Gemini XS; Molecular 
Devices, Toronto, ON) for an end point assay. 
Temp = 37°C 
Excitation wavelength = 355 nm 
Emission wavelength Ca2+ bound indo-1 = 405 nm 
Emission wavelength Ca2+ free indo-1 = 485 nm 
Ratio = 405/485 
6. Read plate for first reading, then wait 15 minutes to warm the plate at 37°C, then re-
read the plate. Temperature does affect pCa values so this step is required. 
7. Calculate using equation for INDO-1 
 
[Ca2+]f = Kd * (GmaxGmin) * (R-Rmin)/(Rmax-R) 
   
 where Kd is the equilibrium constant for the interaction between Ca2+ and indo-1, Rmin  
is the minimum value of R with zero Ca2+, Gmax is the maximum value of G with zero  
Ca22+, Rmax is the maximum value of R at max Ca2+ (10 mM) and Gmin is the 
minimum value of G at max Ca2+ (10 mM).  The Kd value of indo-1 Ca2+ dye 
complex is 250 for muscle homogenates (238). 
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 Appendix G 
Protocol for Ca2+ uptake assay  
 
This uptake assay was initially described by Tupling et al., 2002 (138).  The indo-1 
Ca2+ fluorophore is used to determine Ca2+ uptake in muscle homogenates and SR vesicles.  
Fluorescence signals produced by Indo-1 are collected on a dual emission wavelength 
spectrofluorometer (RatiomasterTM system, Photon Technology International, Birmingham, 
NJ).  Measurements are based on the difference in Ca2+ bound Indo-1 and Ca2+ free Indo-1 
complexes which have emission wavelengths of 405 and 485 nm upon excitation with a 355 
nm wavelength, respectively.  As Ca2+ uptake occurs, the [Ca2+]f decreases which therefore 
increases the Ca2+ free Indo-1 causing the ratio between free/bound Indo-1 (R) to decrease.  
Measurements can be done with or without the Ca2+ precipitation anion, oxalate.  Oxalate 
and phosphate can increase rates of Ca2+ uptake by precipitating calcium in the lumen of the 
SR, which prevents an excessive rise in lumenal Ca2+ and preventing back-inhibition (239). 
Buffers and reagents 
Uptake buffer 
      For 200 ml 
200 mM KCl     2.982 g 
20 mM HEPES    953.2 mg 
10 mM NaN3     130.02 mg 
5 µM TPEN     0.424 g 
5 mM Oxalate     0.18 g 
15 mM MgCl2     0.29 g 
 
Add reagents to 150 ml of water.  Heat to 37°C and then pH to 7.0 with 2N KOH and then 
bring to a final volume of 200 ml.  Store at -20°C 
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Other reagents 
250 mM ATP 
Stock EGTA: 50 mM EGTA, pH 7.0 
Stock Ca2+: 100 mM Ca2+ solution 
2 mM Indo-1 in 50 mM glycine, pH 11 
Protocol 
1. Turn on water bath and make sure it is set to 42°C. Ensure that there is good flow in 
tubing to heat the jacket around the cuvette. The temperature in the cuvette should be 
at 37°C after ~1hr. If the temperature is failing to reach 37°C clean the jacket and 
don’t jack up the temperature setting above 42°C.  
2. Turn on a second water bath to about 40-42°C. This will heat up the Ca2+ uptake 
buffer and is higher than 37°C because when pipetting and transferring buffer to the 
cuvette it will cool down naturally. 
3. Turn on Arc lamp. Then ignite by pressing start. Ensure that it is set at greater than 65. 
4. Get an aliquot of 250 mM ATP, pH 7.0. This must be fresh and not freeze-thawed 
more than once. 
5. Place INDO-1 and ATP on ice. 
6. Prepare EGTA.  
• Stock EGTA: 50 mM EGTA, pH 7.0 
• Dilute 10x to 5 mM 
• 200 µl stock + 1800 µl dH2O 
7. Prepare low and high Ca2+ 
• High 100 mM stock in fridge. Pipette 1 ml into Eppendorf tube. 
• Low 10 mM (10x dilution of stock: 100 µl stock + 900 µl water) 
8. Turn on power of Motor-Driver MD-5020  
9. Turn on power of BryteBox 
10. Open Felix32 program on computer. 
11. Check photomultipliers (Left – 909, Right – 1000) 
12. Calibration 
• Click configure 
Ø Hardware configuration 
Ø Open digital file (only file listed) 
Ø Initialize (lightning bolt) 
Ø Go around to the others side and note the number on the dial. 
Ø Place value into monochromater  
Ø OK 
Ø Save 
13. Acquisition 
• Open acquisition 
Ø Click uptake 
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Ø Set duration 
Ø Set view window  
Ø Check excitation 355 
Ø Check emission 1 405 
Ø Check emission 2 485 
14. Display 
• Clear background * Only when using a new batch of buffer 
15. Acquire prep 
• Go around to ensure that the number is 355. If not then re-calibrate by 
pressing abort on acquisition.  
 
16. Measure background fluorescence 
• In cuvette place stir bar 
• 1960 µl of buffer 
• 40 µl of ATP 
• 2 µl low calcium 
• 1 µl INDO-1 
Ø Start. Wait 1s then click Stop. 
17. Click Math 
• Average 
• Select tool | | and highlight the whole area. 
• Note the average for D1 and D2. 
18. Click Display 
• Type in background values (D1 & D2) 
• Click OK 
• Save on acquisition. 
Now ready for data collection. 
Replace with new cuvette. Working solution is always 2 ml and this solution contains: 
1. Uptake buffer.  Subtract sum of: sample volume + ATP volume + INDO-1 volume + 
low Ca2+ volume from 2000 to get buffer volume. 
2. Sample (volume depends on sample type).  Soleus is 80 µl and plantaris is 30 µl. 
3. 40 µl ATP 
4. Low Ca2+ volume (depends on sample – try 2 µl first) 
5. 1 µl INDO-1 
Order of pipetting: 
1. Pipette buffer then place cuvette into jacket to stay warm. 
2. Add sample with a positive displacement pipette. 
3. Add low Ca2+ 
4. Add INDO-1 
5. Click start on acquisition  
6. Add ATP through hole on the top of the box (or open and close the lid quickly) into 
the cuvette.  This starts the reaction. 
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7. Wait for curves to plateau. 
8. Add 145 µl EGTA (for min). 
9. Wait 10s. 
10. Add 30 µl high Ca2+ (for max). 
11. Clean stir bar before next sample. 
Data acquisition 
1. Click transform 
Ø Concentration Map 
Ø Highlight Ratio on left 
Ø Equation 
Ø Edit/select 
2. Zoom into EGTA and high Ca2+ part of the curves 
3. Select the flat part of the EGTA  
Ø Capture Rmin 
4. Select the flat part of the high Ca2+ 
Ø Capture Rmax 
5. Select the flat part of the high Ca2+ 
Ø Highlight D2 on left 
Ø Capture Sb2 
6. Select the flat part of the EGTA 
Ø Highlight D2 on left 
Ø Capture Sf 
7. Click on Ratio-2 then click execute on transform box. 
8. Highlight Ratio-2 
Ø Click Math 
Ø Click Smooth 
Ø Buffer size set to 21 points 
Ø Execute  
Ø Close 
Check the curve for the ratio by zooming out. Click Axes and select fixed. Set min 0 and max 
to 5000. Counts should be between 3000-4000 at the start. 
Analysis 
 The generate curve ([Ca2+]f versus time) is then smoothed over 21 points using the 
Savitsky-Golay algorithm.  The instantaneous tangents/slopes are then determined at 500 nM, 
1000 nM, and 1500 nM to determine the rate of calcium uptake, which is then normalized to 
total protein content and expressed as µmoles/g protein/min.  Note that to determine rates of 
Ca2+ at a higher free [Ca2+]f  a modified Indo-1 that is not easily saturated at high Ca2+ 
concentrations could be used. 
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Appendix H 
 
Protocol for simultaneous mechanical overload 
and soleus tenotomy  
 
 This protocol, approved by the University of Waterloo’s Animal Care Committee, 
described the procedure to mechanically overload plantaris muscles by performing soleus 
and gastrocnemius tenotomy.  Since, soleus muscles are left intact in the muscle, the soleus 
muscle can then be analyzed as well, as a model of unloading and muscle degeneration. 
 
UNIVERSITY OF WATERLOO 
OFFICE OF RESEARCH ETHICS 
 
STANDARD OPERATING PROCEDURES 
 
SOP CAF MED 083: Synergistic ablation in rodents 
 
 
Purpose:    This SOP discusses the materials required and the method used to perform 
synergistic ablation of the soleus and gastrocnemius muscles in the rodent.  This 
procedure is to be done in a surgery room and not in an animal room.  This is a 
survival procedure. 
 
Responsibility:  Animal Health Technicians, Researchers 
 
1.0 Material Required Before Starting Procedure 
 
- Forceps 
- Surgical scissors 
- Betadine solution 
- alcohol swabs 
- 7-0 silk suture (CDMV: 104965) 
- gauze 
- Bead sterilizer 
 
2.0 Anaesthesia and Analgesia 
 
2.1 General anaesthesia (GA) is required for the synergistic ablation of the soleus 
and gastrocnemius muscles from rodents.  Isofluorane can be used as an 
anesthetic agent with the anaesthesia machine (refer to SOP CAF MED 030: 
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Use of Rodent Anaesthesia Machine).   
 
2.2 Meloxicam will be administered subcutaneously shortly after GA induction 
(rats and mice 1.0 mg/kg; refer to SOP CAF MED 059: Meloxicam use in 
Rodents). 
 
3.0  Surgical Protocol: General 
 
 3.1  Place animal on top of a covered heating pad to prevent hypothermia in the  
  animal (refer to SOP CAF MED 061: Preventing Hypothermia During  
  Surgery and Recovery from Anaesthesia). 
 
 3.2  Apply Tear Gel to the eyes. Shave the hindlimbs. Wipe the incision site with  
  the alcohol swab. Follow with a wipe of Betadine solution.  
 
 3.3. Extend the hindlimb and pinch the foot to ensure that the mouse is under full  
  anaesthesia. A brief midline incision will be made in the skin on the hindlimbs  
  (2013 Ito et al., 2013. Nature Medicine. 19(1): 101-106).   
 
 3.4  Perform blunt dissection (open and close forceps inside the incision) to expose  
  the muscle and tendons.  
 
 3.5 Invert the foot (ie. facing towards the body).  By doing this it will be easier to  
  perform step 3.4. 
 
 3.6 Locate and transect the distal tendons of both the gastrocnemius and soleus  
  muscles. 
 
 
 
   
  
 
 
 
 
 
 
 
  Figure H1.  Photo illustrating the tendons involved in mechanically 
  overloading the plantaris muscle and tenotomising the soleus.  The soleus and  
  gastrocnemius tendons from a mouse hind-limb are transected while the  
  plantaris tendon is left intact.  In the image is a right-hind limb with the foot  
  inverted. 
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 3.7  Close the incision/wound with a 7-0 silk suture. 
 
 3.8 The hindlimb from the other leg will serve as a sham control.  Shave the hair  
  from the incision site and wipe with alcohol followed by Betadine solution.   
  Make a small incision and then close the wound with a 7-0 silk suture. 
 
 3.9 The animal will be returned to a recovery cage post-op and monitored.   
  Following recovery, animal will be individually housed. 
 
 3.10 Meloxicam should be given up to 3 days post-operatively. 
 
 3.11 The animal should be carefully monitored for self injury to the hind limb or  
  the removal of sutures. 
 
 3.12 If the animal will be kept for longer than 2 weeks post-surgery, then an  
  absorbable suture should be considered. 
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Appendix I 
Protocol for transmission electron microscopy  
Fixing skeletal muscle for TEM analysis 
 
Materials & Solutions  
 
50% Glutaraldehyde solution (Electron Microscopy grade) 
Reagent grade acetone 
HPLC grade acetone 
1 drum vials with black caps (4 mL vials) 
BEEM capsules 
Dissecting pins 
Dissecting microscope with reticle 
Blade  
 
0.2 M Phosphate buffer pH 7.4 
• Na2HPO4   10.9g 
• NaH2PO4  3.2g 
• Distilled water 400 mL 
• pH to 7.4 with NaOH then top up to 500 mL 
 
1% Osmium tetraoxide (OsO4) in 0.2 M phosphate buffer 
• 2 mL ampule of 4% OsO4 
o Open very carefully in fumehood.   
• Poor 2 mL of 4% OsO4 into 6 mL of 0.2 M phosphate buffer 
• Discard the ampule and any pipette into an appropriately labeled waste bucket. 
 
Epon-Aldarite plastic resin 
1. Weigh in a weigh boat the following chemicals and slowly pour into a plastic urine 
specimen bottle with lid  
• 30g dodecenylsuccinic anhydride (Canemco #031) 
• 11.1g of araldite 502 (Canemco #CA062) 
• 15.5g of TAAB 812 embedding resin (Canemco #CE001-3; previously called 
epon812) 
2. Cover and stir well on a stir plate for 15-20 min 
3. In the fumehood, add in 1.4 g of DMP-30 (2,4,6-tri-(dimethylaminoethyl)phenol) 
(Canemco #033) 
4. Cover and stir well on a stir plate for 15-20 min 
5. Degas for approx. 1 hr until bubbles subside.  Put the solution (uncovered) inside a 
desiccator with side arm and attach to vacuum pump to degas.  Line the bottom of the 
desiccator in case it bubbles over. 
6. Get 2 new 30 mL syringes with a slip-tip and without the rubber gasket (NORM 
JECT eccentric lure slip Fisher #14-817034) 
7. Attach approx. 2 inches of tygon tubing and clamp and label syringes. 
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8. Remove the syringe plungers and prop the syringes vertically. 
9. After degassing, pour carefully to avoid further air introduction and pour the entire 
solution into the 2 syringes. 
10. Remove the tube clamp and carefully put the plunger back into the syringes. 
11. Re-attach clamps and freeze at -20 degrees for up to approx. 3 weeks. 
12. Remove syringe from freezer approx. 1hr. before use.  Can re-freeze unused portions. 
 
 
Protocol 
 
Day 1 
1. Isolate mouse soleus tissue 
2. Cut muscle tissue into 1 mm cubes using a dissecting scope with a reticle and a 
blade.  Four or five of them to begin with. 
3. Fix in 2.5% glutaraldehyde in 0.2 M phosphate buffer pH 7.4 overnight 4 deg in a 1-
drum vial (200 uL of 50% glutaraldehyde in 3800 ul of 0.2 M phosphate buffer). 
 
Day 2 
1. Carefully pipette out 2.5% glutaraldehyde solution.  Do not pipette out muscle cubes. 
2. Wash in 0.2 M phosphate buffer for 20 min. 
3. Discard and re-wash in new phosphate buffer for 20 min. 
4. Discard and re-wash in new phosphate buffer for 20 min. 
5. Fix in 250 ul of 1% OsO4 in phosphate buffer for 1 hr at room temperature in a 
fumehood.  Sample should go black. 
6. Replace OsO4 with water 2x (15 min each). 
7. Dehydrate with 20% acetone (400 ul acetone + 1600 ul water; 10 min) 
8. Dehydrate with 50% acetone (1000 ul acetone + 1000 ul water; 10 min) 
9. Dehydrate with 70% acetone (1400 ul acetone + 600 ul water; 10 min) 
10. Dehydrate with 70% acetone (1400 ul acetone + 600 ul water; 10 min) 
11. Dehydrate with 90% acetone (1800 ul acetone + 200 ul water; 10 min) 
12. Dehydrate with 90% acetone (1800 ul acetone + 200 ul water; 10 min) 
13. Dehydrate with pure anhydrous acetone (100% acetone, HPLC grade) (10 min) 
14. Dehydrate with pure anhydrous acetone (100% acetone, HPLC grade) (overnight 
room temperature) 
 
Day 3 
1. Thaw E/A plastics 1 hr RT. 
2. With a sharpie and a ruler mark 4 obvious sections in the lower 2/3 of the vial. 
3. Embed in 75% acetone + 25% E/A - rotate 1 hr room temperature (3 vols 100% 
acetone + 1 vol of E/A) 
4. Embed in 50% E/A + 50% acetone - rotate 1 hr room temperature 
5. 100% E/A rotate 1 hr room temperature 
6. Fresh 100% E/A rotate overnight at room temperature 
 
Day 4 
1. Take syringe of E/A out of the freezer and warm to room temperature for 1 hr. 
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2. Place BEEM capsules in the special white tray in the storeroom on the shelves above 
the student lab dispenser pumps. 
3. Use tiny font on the computer, make tiny labels on regular printer paper and cut them 
so that they are tall enough to go from the bottom of the tube to the top and wide 
enough so they don’t interfere with the sample. 
4. Put fresh E/A into each BEEM capsule to fill. 
5. Aspirate the E/A from vials and turn vials upside down on individual pieces of foil to 
drain.  Use dissection pins to get tissue into the BEEMS.  Very carefully use the 
needle to poke the tissue all the way to the very bottom of the tube - TRAPPING NO 
AIR BUBBLES.  The entire piece of tissue must be used for each BEEM capsule.  Do 
not cut tissue down in size at this point or it won’t be properly fixed. 
6. Polymerize in 60deg oven 24-48 hrs or indefinitely. 
 
Sectioning the Embedded Fixed Muscle 
 
Materials & Equipment  
 
Glass cutter 
A strip of glass 
Foil tape 
Nail polish 
Microtome 
Blade 
Xylene + wooden skewer stick 
Distilled water 
Tweezers 
Copper mesh grids with 100 squares 
Whatman filter paper (cut into small wedges) 
Toludine blue 
Microscope slides (#2) 
Light microscope 
 
 
Making the glass knife 
These knives need to be made the day of sectioning as the moisture from the air can dull 
them. 
1. Wash glass strip with soap and water.  Then dry. 
2. Place the rough edge against the white holder. 
3. Push the glass through till it touches the silver bump. 
4. Turn lever on the left towards you until the glass is clamped down.  If the glass is not 
clamped down it will not cut properly, so clamp and unclamp until it is. 
5. When the glass is sufficiently clamped ensure that the diamond cutter is set to the dial 
with ‘two’ lines. 
6. Pull the knob for the diamond cutter towards you in a single smooth motion.  
7. Turn the black knob on the bottom right clockwise to the silver line.  This will break 
the glass where the diamond cutter made the score.   
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8. After the cut, turn the black knob back to its starting position.  Release the clamp and 
push the diamond cutter back to its original position. 
9. Remove the excess piece of glass and only work with the square. 
10. Carefully turn the square into a diamond that fits the groove on the horizontal clamps.  
Pull the handle on the left to bring the clamps together. 
11. Clamp the diamond down with the lever on the left, again keeping in mind that it has 
to be sufficiently clamped. 
12. Using the diamond cutter, turn the dial to the ‘diamond’ 25.  Then in a single smooth 
motion score the glass. 
13. Turn the black knob on the bottom right to break the square into two triangles. 
14. Turn each triangle so that the sharpest edge (1 and 2) are facing upwards. 
15. Cut two pieces of foil tape, each approximately 2 inches long.  Tape the foil tape at 
the top of the knife on one end and wrap it around to the other end leaving a gap to 
make a boat with the blade.  This is important, as it will be filled with water so that 
when the blade cuts sections it falls into and floats atop the water. 
16. Seal the edges of the tape with nail polish.  Pay careful attention to the front; there 
should be not gap between the tape and the glass as will not serve well as a reservoir 
for water.  Seal with thick nail polish. 
 
 
 
This figure shows the cutline of the square (diamond).  The number 1 refers to that side 
being the primary blade (sharpest) and 2 being the secondary blade. 
 
 
Sectioning the muscle sample into large trapezoids 
 
1. Carefully remove your sample from the BEEM capsule using a blade to cut two strips 
along the edge. 
2. Take the E/A embedded sample and place into vertical plane sample holder making 
sure that the sample is facing upwards.  
3. Under the microscope and with a blade cut your sample into a small trapezoid.  On 
the highest magnification it will be square wide at the top and 1.5-3 squares wide at 
the bottom.  Always cut down on an angle. 
4. Under the microscope, with an intermediate magnification, and with a blade cut your 
sample into a large trapezoid (ie. 3 squares on the top and 4 on the bottom). Always 
cut down on an angle. 
5. Once the trapezoid is cut remove the sample from the vertical plane holder and place 
onto horizontal plane holder. 
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6. Place fresh glass knife into its holder and situate the knife close to the sample using 
the microscope for reference. 
7. Fill the reservoir with distilled water until it gets a shiny silver metal car colour look. 
8. Set the microtome to 0.74 um and a speed of 0.9.   
9. Pull the lever down to start the microtome. 
10. When sections become full trapezoids stop the microtome (only when the light green 
– never stop when it is red). 
11. Collect a large trapezoid and place onto a drop of water on a microscope slide. 
12. Place the slide on a block heater to dry. 
13. Then add a few drops of toluidine blue while on the block heater. 
14. Then rinse with water. 
15. Under a light microscope check to see that the section is in the right orientation and 
which area you’d like to cut the small trapezoid for TEM. 
 
Sectioning the muscle sample into small trapezoids 
 
1. When you’ve decided which area of the sample to cut a small trapezoid place the 
sample back on the vertical plane holder. 
2. Using a blade, cut the sample into a small trapezoid under the microscope at the 
highest magnification (1 square on top to 1.5-3 squares on the bottom). 
3. Once the trapezoid is cut remove the sample from the vertical plane holder and place 
onto horizontal plane holder. 
4. Place fresh glass knife into its holder and situate the knife close to the sample using 
the microscope for reference. 
5. Fill the reservoir with distilled water until it gets a shiny silver metal car colour look. 
6. Set the microtome to 90 nm and a speed of 0.9.   
7. Pull the lever down to start the microtome. 
8. When sections become full trapezoids stop the microtome (only when the light green 
– never stop when it is red). 
9. Waft xylene over the reservoir with a skewer stick soaked in xylene with 3 passes.   
10. Then using tweezers grab a copper mesh grid with the shiny side down and place it 
onto the trapezoid sections (ideally 6 per grid with 2 columns of 3). 
11. The trapezoids should stick onto the grid.  Place onto a wedge of Whatman paper to 
dry.  Once dried place into a grid holder. 
12. Repeat for 10-15 times per sample. 
 
Staining the muscle sample with Lead Citrate (Pb Citrate) and Uranyl Acetate 
 
Since the contrast in the electron microscope depends primarily on the differences in the 
electron density of the organic molecules in the cell, the efficiency of a stain is determined by 
the atomic weight of the stain attached to the biological structures.  Consequently, the most 
widely used stains in electron microscopy are the heavy metals uranium and lead.  Although 
the use of one of these stains alone could be quite practical for routine purposes, the highest 
contrast is obtained when both of these stains are used in sequences, “double contrasting”, 
with uranyl acetate and lead citrate. 
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Uranyl acetate (negative stain) 
The uranyl acetate (UA) enhances the contrast by interaction with lipids and proteins.  
The uranyl ions bind to proteins and lipids with sialic acid carboxyl groups such as 
glycoproteins and ganglioside and to nucleic acid phosphate groups of DNA and RNA.  
Gangliosides are glycolipids and are concentrated on cell surfaces.  Glycoproteins are 
abundant in all membranes and part of the glycocalyx.  Therefore UA delivers good 
contrasting results of membranes, nucleic acids and nucleic acids containing protein 
complexes such as ribosomes.  UA is sensitive to light, especially UV and will precipitate if 
exposed.  It also precipitates when ageing so all UA is made fresh and only used for ½ 
hour.  In addition, UA is both radioactive and toxic (0.37-0.51 uCi/g). This is a very mild 
level of radioactivity and is not sufficient to be harmful while the material remains 
external to the body. 
 
For this protocol, we use alcoholic uranyl acetate, which has the advantage of penetrating 
more easily into the plastic embedded tissue and thus give a high contrast requiring only a 
short staining time (10 min). 
 
Lead citrate 
Lead citrate enhances the contrasting effect for a wide range of cellular structures such as 
ribosomes, lipid membranes, cytoskeleton and other compartments of the cytoplasm. The 
enhancement of the contrasting effect depends on the interaction with reduced osmium, since 
it allows the attachment of lead ions to the polar groups of molecules.  Osmium, as in our 
protocol, is used routinely as a fixative.  Lead citrate also interacts, to a weaker extent, with 
UA and therefore lead citrate staining is employed after UA staining.  Lead citrate 
precipitates easily in the presence of carbon dioxide, either in air or in the water used for 
preparing the stain for rinsing.  Lead carbonate is a water insoluble toxic white precipitate 
and accordingly will not dissolve in rinsing water.  In general, all lead salts such as lead 
citrate are extremely toxic. 
 
The staining effect of lead solutions is highly dependent on the pH of the solution. Unlike 
uranyl acetate, it is possible to use lead based staining solutions at very high pH values (>12 
pH).  All alkaline lead stains can be considered to be stabilized solutions.  Therefore, those 
solutions are suitable for commercial handling, provided they are made under conditions, 
which eliminate the formation of lead carbonate. 
 
http://www.leica-microsystems.com/science-lab/brief-introduction-to-contrasting-for-em-
sample-preparation/ 
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Staining Protocol 
Equipment and materials 
Glass vials 
Petri dishes 
Parafilm 
Filter paper 
Syringe filters and small syringes (5cc) 
Forceps 
 
Pb Citrate 
Uranyl Acetate 
10N NaOH 
 
Steps 
1. Boil H2O for 5 min (to release CO2 from it) and cool the H2O in a beaker covered 
with tin foil to room temp. 
2. Make fresh 50% methanol (100 ml 50:50 with boiled water). 
3. Dissolve a few crystals of uranyl acetate in 50% methanol.  It takes about 10 min to 
get it into a bright yellow solution.  This is light sensitive so cover in tin foil. 
4. Using a small syringe with a syringe filter, place a few drops of uranyl acetate 
solution onto a piece of parafilm inside a petri dish. 
5. With sections side up, place a TEM grid into a drop of uranyl acetate in the petri dish 
for 10 min. 
6. Wash excess uranyl acetate with 50% methanol. 
7. Place grid in a separate holding petri dish. 
8. Weigh out 0.04 g of Pb citrate and put into 10 ml of boiled water.  To get this into 
solution at 100 µl of 10 N NaOH.  Close lid tightly and shake vigorously until Pb 
citrate is fully dissolved. 
9. Using a small syringe with a syringe filter, place a few drops of Pb citrate solution 
onto another piece of parafilm inside a separate petri dish. 
10. With sections side up, place a TEM grid into a drop of uranyl acetate in the petri dish 
for 10 min. 
11. Wash excess uranyl acetate with boiled water. 
12. Grids are now ready to be visualized using a Transmission Electron Microscope. 
 
Note: You need fresh Pb citrate and uranyl acetate droplets for every time a new grid is 
stained. 
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